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Abstract
The objective of this doctoral research was two-fold: 1) to estimate inequalities with regard to a)
social determinants of health (SDoH) and health-related quality of life, and b) substance use
between women living with HIV and the general population of women in Canada; and 2) to
assess the impact of the SDoH clusters/classes on a) illicit drug use and b) heavy alcohol
drinking among women living with HIV. For the first objective, prevalences of social
determinants, self-rated health status, and substance use were estimated from 1,422 women with
HIV aged 16+ in the 2013-2015 Canadian HIV Women’s Sexual and Reproductive Health
Cohort Study (CHIWOS, time-point 1), and then compared with their counterparts estimated in
46,831 general population women in the 2013-2014 Canadian Community Health Survey
(CCHS), standardized to the age/ethnoracial group distribution of women with HIV. For the
second objective, we used longitudinal data from the 2013-2017 CHIWOS at time-point 1
(N=1,422) and time-point 2 (N=1,252). Findings showed that compared to general population
women, a higher proportion of women with HIV reported a) adversities regarding the social
determinants (e.g., poverty, food insecurity, poor social support), poor/fair self-rated health
status [manuscript 1], and b) greater cigarette smoking and illicit drug use, but similar to lower
likelihood of binge drinking [manuscript 2]. Latent class analysis was used to determine the
clustering of SDoH. We identified four distinct classes: no/least SDoH adversities,
discrimination/stigma, economic hardship, and most SDoH adversities. Inverse-probability
weighted regression models showed a substantial difference in a) illicit drug use [manuscript 3],
and b) heavy alcohol drinking [manuscript 4] between no/least SDoH class and other SDoH
classes. These findings underscore the need for novel approaches to address socio-structural
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adversities and substance use among women with HIV. We also discuss additional implications
and future research directions.
Keywords: Social determinants of health; Substance use; Disparities; Women; HIV; Canada
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Summary for lay audience
People with HIV now live longer. This is due to advances in HIV care and treatment services.
But, these people continue to face challenges in their life. The two most important challenges are
substance use and social adversities. In this study, we compared several social factors between
women with and without HIV. We also compared the patterns of substance use between these
two populations. We used two data sets: 1) 1,422 women with HIV and 2) 46,851 women
without HIV. We showed that a higher proportion of women with HIV reported living with low
income (70.3% versus 28.1%). Severe food insecurity was more common among women with
HIV (54.1% versus 10.2%). Poor social support, gender discrimination, and race discrimination
were also more common among women with HIV. Poor/fair health status was more frequent
among women with HIV. Except for alcohol, the use of other substances was more prevalent
among women with HIV. As shown, a higher proportion of women reported living with these
challenges. In the next step, we examined whether social factors tend to co-occur among women
with HIV. To do this, we used data of 12 social factors. Using statistical models, we identified
four unique groups: a) no social adversities (group 1; 6.6%), b) mainly stigma and discrimination
(group 2; 18.0%), c) mainly economic difficulties (group 3; 30.2%), and d) most social
adversities (group 4; 45.2%). We finally examined the association of these groups with substance
use. We found that illicit drug use was significantly lower among women in group 1 versus the
other three groups. The same findings were observed for heavy alcohol use. Social
vulnerabilities were shown to be significantly associated with a greater risk of substance use. To
reduce harms due to substance use, social adversities are required to be addressed.
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1.

Chapter 1: Objectives, introduction, and literature review

1.1. Thesis Objectives
The overall objective of this doctoral research work was to study the inequalities with regard to
social determinants of health (SDoH) and the impact of the clusters of SDoH on substance use
among women living with HIV in Canada. Specifically, this thesis had two main objectives:
Objective 1: To explore the inequalities associated with SDoH and substance use among women
living with HIV comparing with women in the general population in Canada. To this end, we
used data from the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study
(CHIWOS, at baseline 2013/15) and comparable information from the Canadian Community
Health Survey (CCHS, 2013/14). This objective had 2 sub-objectives:
1a. To compare age- and ethnoracial-standardized prevalence of SDoH and self-rated
quality of life between women living with HIV and the general population of women.
1b. To compare age- and ethnoracial-standardized prevalence of substance use between
women living with HIV and the general population of women.
Objective 2: To investigate the clustered impact of SDoH on substance use among women living
with HIV in Canada. To do this objective, we used data from CHIWOS for two time-points
(Wave 1 in 2013/15 and Wave 2 in 2015/17) to explore the clustered impact of 12 SDoH on
substance use. Specifically, this objective had two sub-objectives:
2a. To investigate the impact of the clusters of SDoH on drug use (opioid/stimulant use)
among women living with HIV in Canada.
2b. To investigate the impact of the clusters of SDoH on heavy alcohol consumption
among women living with HIV in Canada.

1

1.2. Thesis organization
Chapter 1: This chapter consists of a comprehensive review of the literature in line with the main
objectives of this thesis.
Chapter 2: This chapter addresses Objective 1a: comparing SDoH between women living with
HIV and the general population of women. A version of this chapter has been published in PloS
One (Manuscript 1).
Chapter 3: This chapter addresses Objective 1b: comparing substance use between women living
with HIV and the general population of women. A version of this chapter has been published in
Drug and Alcohol Dependence (Manuscript 2).
Chapter 4: This chapter addresses Objective 2a: The clustered impact of SDoH on drug use
among women living with HIV. A version of this chapter has been published in Addiction
(Manuscript 3).
Chapter 5: This chapter addresses Objective 2b: The clustered impact of SDoH on heavy
drinking among women living with HIV. A version of this chapter has been published in AIDS
and Behavior (Manuscript 4).
Chapter 6: This chapter provides an integrated discussion, conclusions, and future directions.
Appendices: This section consists of questionnaires, and data sharing agreements.
1.3. Introduction

1.3.1 HIV profile, a global perspective
The human immunodeficiency virus (HIV) infection continues to be a major public health
problem worldwide.1 Since the beginning of the HIV epidemic, more than 77 million individuals
have become infected with HIV and more than 35 million people have died from AIDS/HIVrelated illnesses globally. Estimates from the Joint United Nations Programme on HIV/AIDS
2

(UNAIDS) in 2017 showed that approximately 36.9 million people were living with HIV
globally, with 1.8 million people newly infected with HIV.2 Women constitute approximately
half of all people living with HIV globally; with 18.2 million women living with HIV in 2017. In
2017, approximately one million people died from AIDS-related illnesses, which was half of the
estimate since the epidemic’s peak in 2004 (i.e., 1.9 million).3 The advent of combined
antiretroviral treatment (cART) has been considered as the key reason for the significant
reduction in HIV-related deaths worldwide.4
Since its introduction in 1996, treatment with cART has significantly improved such that
cART regimens have become more effective, less toxic, and simpler with regard to pill burden
and frequency; consequently, adherence to HIV treatment regimens has also been enhanced.5-7
Both observational research5 and randomized trials6 have supported the improved treatment
adherence due to advances in treatment regimens. The availability of cART has brought about
sustained virologic (i.e., referring to viral load suppression) and immunological (i.e., mainly
referring to CD4 cell count) responses.4,8,9 Research shows that cART effectively reduces the
plasma HIV-1 viral load to its undetectable level (i.e., HIV RNA < 50 copies/mL or less; a limit
of detection of the most sensitive available clinical tests), leading to a significant immunological
recovery through an increase in circulating CD4+ T-lymphocytes.10,11 Viral load and CD4 cell
counts are the two common clinical measures of HIV progression. Viral load refers the amount
or concentration of HIV virus in the blood, with a level less than 50 copies/mL indicating
undetectable/suppressed viral load (this limit may differ by clinical assays/tests, but 50
copies/mL is the most common limit used in the literature). CD4 cell count assesses the function
of the immune system, with a CD4 count below 500 cells per mm3 indicating increased
vulnerabilities to immune suppression and associated opportunistic infections and diseases.
3

However, treatment adherence – typically defined as the extent to which individuals take their
medication as prescribed12,13 – is an important measure in determining undetectable HIV viral
load,14 with taking ≥ 95% of the medications defined as optimal adherence.12
Progress in viral load suppression and immunological function reconstitution have
translated into significant improvements in life expectancy (as an important population health
indicator) of people living with HIV,4,7,15-18 particularly in high-income nations where
individuals living with HIV have access to health care and cART.4,19-23 For example,
Teeraananchai et al. (2017) in a meta-analysis using data from eight cohort studies of individuals
on cART aged ≥ 14 years found that the overall life expectancy in high-income countries was an
additional 43.3 years and 32.2 years at ages 20 and 35 years, respectively, versus 28.3 and 25.6
additional years, respectively, in low/middle-income countries.24 Research has also documented
that life expectancy among individuals on cART is approaching that in the general
population.19,20 For example, a study in Switzerland showed that life expectancy at age 20 years
increased from 11.8 years in the monotherapy era (1988–1991, where combination therapy was
not yet introduced) to 54.9 years in the most recent cART era of the study (2006–2013),
compared with 62.3 to 63.0 years, respectively, in the general population.20
While advances in HIV treatment have substantially improved the life expectancy,
individuals with HIV are still experiencing lower quality of life. A study in the United Kingdom
assessing health-related quality of life among individuals with HIV aged ≥ 18 years who were
mostly virologically and immunologically stable found a lower level of quality of life for people
with HIV compared with the general population; it has been hypothesized that a substantial part
of this gap might be due to the higher levels of psychiatric symptoms such as anxiety and
depression in people with HIV.25This hypothesis is consistent with evidence from studies
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conducted in the United States (US) indicating that people living with HIV are approximately
three times more likely to experience depression than do individuals without HIV.26
In general, existing evidence indicates that despite the notable improvements in their life
expectancy, people living with HIV still experience greater morbidity and mortality in
comparison to the general population.27 In addition to the role of HIV itself and aging-associated
conditions, behavioural or lifestyle factors such as substance use27-29 and socio-structural
conditions27,30-36 (e.g., socioeconomic status, social support, employment status, and HIV stigma)
have been introduced as the key contributing factors that negatively affect health-related quality
of life of individuals with HIV, either independently or in combination.27

1.3.2 Global strategies to end the HIV/AIDS epidemic
To end the HIV/AIDS epidemic by 2030, UNAIDS and partners in 2014 launched three
ambitious goals/targets that called on countries to reach by 2020:37 i) to diagnose 90% of all HIV
cases, ii) to provide cART for 90% of all persons diagnosed with HIV, and iii) to achieve viral
suppression for 90% of people with HIV on cART. The UNAIDS 90-90-90 targets are a
commitment to increase access to cART treatment, prevent AIDS-related deaths, prevent HIV
transmission, and meet the goals in line with human rights. The end target is to achieve an
undetectable viral load in 73% of people with HIV.37-39 While this strategy is a crucial step in
eliminating the HIV epidemic, reports from the global HIV programmes indicate that greater
efforts are required to help end the epidemic by 2030.39 Actions should particularly focus on the
challenges that individuals typically face along with all stages of the HIV treatment (i.e., the HIV
care cascade). Recent updates show that out of an estimated 36.9 million living with HIV
globally, only 75% were aware of their HIV status, 59% were on cART, and 47% were virally
suppressed,40 with the highest rates in resource-rich nations.41 These estimates imply that while
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enormous efforts have been made to control HIV/AIDS, national programs are still far from
meeting the global targets.
To achieve the UNAIDS targets, evidence suggests that an effective HIV medical care
program such as the “HIV care cascade” (or “HIV treatment continuum”), an internationallyrecognized framework, is required. This framework forms the basis of the UNAIDS 90-90-90
targets. While various steps (stages) can be reported, this framework primarily focuses on the
modeling of five main successive dynamic steps of HIV care, including HIV diagnosis, linkage
to care, retention in care, adherence to cART, and viral load suppression.42-45 Such a sequence of
HIV medical care and delivery is commonly used to gauge the effectiveness of cART.44 The
success of this framework in preventing new HIV cases, HIV complications and HIV/AIDSrelated morbidity and mortality rely on addressing each of these steps, from scaling up HIV
testing to diagnose those not yet known to be infected with HIV, to linkage to care and treatment
programmes to achieve viral suppression.46,47 This framework aims to help depict estimates (i.e.,
proportions) for the successive steps from HIV diagnosis through viral suppression.45 While
addressing all steps along the HIV care continuum framework is highly important,44 researchers
have focused on those steps in the middle of this framework (i.e., linkage to and retention in
care, and adherence to treatment), underscoring their significance in optimizing health and
clinical outcomes among diagnosed individuals.42,45,48,49
With remarkable advances in the management of HIV and improved knowledge regarding
the optimized practices for HIV care and treatment, reasons for people with HIV receiving poor
linkage to and retention in care as well as suboptimal treatment adherence are not justifiable.42
Despite the success attributable to the cART expansion and uptake, suboptimal HIV treatment
remains a public health challenge worldwide. The findings of a meta-analysis of studies of
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people with HIV in North America and Africa showed that only 55% and 77%, respectively,
achieved over 80% adherence.50 A global meta-analysis in 2011 among individuals on cART
showed that, on average, 62% of individuals achieved optimal HIV treatment adherence.51 The
fact is that the complexity of the HIV care models as well as multiple social and structural
factors may limit the ability of people with HIV to remain engaged in care, highlighting the need
for a social determinants of health (SDoH) framework when addressing the challenges
attributable to suboptimal treatment outcomes.42,52 Such socio-structural-level barriers along with
individual-level factors such as illicit drug use and heavy alcohol consumption have the potential
to negatively impact coverage of each step along with the HIV care cascade.46 These challenges
and their associated consequences in the context of HIV are discussed in greater detail below.
1.4. Epidemiological profile of HIV in Canada

1.4.1 Prevalence and incidence
The national HIV statistics showed that there were an estimated 63,110 people living with
HIV/AIDS in Canada at the end of 2016, an approximate 5% increase since 2014 (i.e., 2,945 new
HIV infections since 2014).53,54 This estimate corresponds to a prevalence of 173 per 100,000.
Almost half (N = 32,762; 51.9%) of individuals living with HIV in Canada are gay, bisexual and
other men who have sex with men (gbMSM), with a large number of cases (N = 30,980)
attributed to having sex with men and a small number (N = 1,782) through either having sex with
men and/or injection drug use (IDU) (these are based on the reporting categories). Other main
modes of HIV transmission in Canada are: heterosexual sex (N = 20,543, 32.6%), and IDU (N =
10,986 (17.4%)), including 9,204 people whose HIV was attributed to IDU and 1,782 men
whose HIV status could be attributed to either sex with men or IDU. The populations impacted
by HIV infection vary from province to province. For example, based on the available estimates
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in 2011,55 the HIV epidemic is concentrated mainly in gbMSM in British Columbia (45.5% of
people with HIV), and Ontario (56.0%), and Quebec (54.2%). Estimates also show that an
estimated 14,520 females were living with HIV, representing approximately 23% (prevalent
cases) of all individuals living with HIV in Canada.
HIV infection has slightly increased in Canada recently.54-56 Estimates in 2016 showed that
there were 2,165 new HIV infections (incident cases) in Canada, with a slight increase over the
estimated 1,960 new cases in 2014. The national estimates in 2016 indicate that the number of
new HIV cases slightly increased among females since 2014: from 436 new HIV infections
(22.2% of all new cases in 2014) to 507 (23.4% of all new cases in 2016). The HIV incidence
rate was 6.0 per 100,000 population in Canada in 2016, with 3.3 per 100,000 for females (based
on available data in 2014).54,56,57 According to the 2016 national estimates, heterosexual sex and
injection drug use are the main drivers of HIV infection among females, with 78% and 22% of
all new HIV cases among females attributed to heterosexual sex and injection drug use,
respectively. According to the same data from the national estimates in 2016, females aged 20 to
49 (years) comprised almost three-quarters of all new HIV diagnoses among women. Black,
Indigenous and white females (women and girls) constituted 37%, 36% and 21% of all new HIV
diagnoses among women in 2016.

1.4.2 Treatment cascade and targets
In line with global commitments, Canada has made substantial progress in the control of HIV
and AIDS. At the end of 2014, approximately 80% of all estimated 65,040 individuals with HIV
knew their HIV status (i.e., an estimated 52,220 were diagnosed). Of individuals diagnosed with
HIV, 76% were on HIV treatment (i.e., 39,790 individuals with HIV received cART). Of all
individuals on treatment, 89% had achieved viral suppression (i.e., 35,350 individuals on
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treatment were virally suppressed). Reports show that only 61% of all estimated individuals
living with HIV in Canada received appropriate HIV treatment (the global expected percentage
is 81%), and only 54% of all individuals living with HIV were virally suppressed58 (the global
target is 73%).59According to the Public Health Agency of Canada (PHAC),58 achieving the first
90 target (i.e., 90% of all individuals with HIV know their HIV status) necessitates greater
actions to enhance HIV test uptake and diagnosis through identifying and addressing the main
barriers associated with HIV testing (e.g., increasing community knowledge, improving access to
services). The low estimate for the second 90 target (i.e., 90% of all people with diagnosed HIV
receive sustained cART) is assumed to be partly related to the “treat all” recommendation (i.e.,
treat all people with HIV at diagnosis60) being relatively new in 2016 when these targets were
set. In other words, implementing this policy and adjusting to this recommendation may require
more time for both clinicians and individuals with HIV.

1.4.3 Life expectancy
Reports indicate that mortality among Canadian people with HIV has declined considerably.4,22
PHAC in 2016 reported that HIV-related deaths decreased by half between 1997 and 2011, and
5-year survival rates among individuals with AIDS increased from 7% in 1981–1986 to 65% in
1997–2012.61 Notable improvements in life expectancy have also been reported among people
with HIV in Canada. For example, Samji et al. (2013) using data from the United States and
Canada suggested that life expectancy at age 20 increased from approximately 36 years in 20002002 to 51 years in 2006-2007, an estimate that is approaching that of a 20-year-old person in the
general population.22 Patterson et al. (2015), in a study in Canada in 2015, demonstrated a steady
increase in life expectancy at age 20 from the calendar period 2000-2003 to 2008-2012 (31 vs.
54 years).23 Using data from British Columbia, Eyawo et al. (2017)62 found a remarkable
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reduction in all-cause age-standardized mortality rates (ASMR) among individuals with HIV:
approximately 127 per 1000 population in 1996 to 22 per 1000 population in 2011-2012 (83%
decline), compared with 7.9 per 1000 population in 1996 to 6.8 per 1000 population among HIVuninfected individuals (14% decline). These findings indicate that even though mortality rates
have been significantly reduced over time among Canadians with HIV, mortality rates still
remained in excess of that of HIV-uninfected individuals.

1.4.4 Women living with HIV
Globally, the intersection of various factors (e.g., biological, social, structural, and political
factors) that contributes to women’s increased vulnerability to HIV may also contribute to
greater vulnerabilities to worse HIV- and treatment-related outcomes among women with HIV,6365

a phenomenon that is called the “feminization of HIV”.63,66,67 The unique challenges that

women experience with regard to HIV may hamper or disrupt access to care, retention in care,
and service utilization. Such challenges among women oftentimes result from their greater
biological susceptibility to HIV acquisition, increased vulnerability to sexual and physical
violence, and lower socioeconomic participations (e.g., lower educational achievement, lower
participation in paid work, and lower income opportunities).2,68,69 In Canada, the complex
intersection of discrimination based on gender with other dimensions of identity (e.g., racism,
and sexism) can also pose critical challenges to their engagement in HIV care.63,70-72
Consistent with international literature,68,73-79 research in Canada, where individuals have
universal access to health care, has also documented gender inequalities/differences, with women
reporting a lower engagement along the HIV care cascade as well as subsequent poorer HIV
outcomes over time than their male counterparts.64,76,79-81 For example, Carter et al. (2014)
documented gender inequalities in quality of HIV care during the first year after initiation of
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treatment, and found that female gender predicted poorer quality of care (adjusted odds ratio
(aOR) = 1.22†). Among women, the likelihood of poorer quality of care was greater among those
with injection drug use history.79 Based on data from British Columbia, Lourenço et al. (2104)
documented the high levels of heterogeneity in the HIV cascade of care across different
population subgroups, with women having greater attrition at every step of the cascade than
men.80 They found that a lower proportion of women than men achieved virologic suppression
(73% vs. 87%), transitioned from linked to care to retained in care (20% loss vs. 11% loss),
transitioned from retained in care to on cART treatment (15% loss vs. 8% loss), and from on
cART to viral suppression (27% loss vs.13% loss). Puskas et al. (2011) reviewed comparative
data on treatment adherence stratified by gender in developed countries, with eight studies from
Canada, and found that women were less likely to report optimal treatment adherence.76 Using a
population-based HAART Observational Medical Evaluation and Research (HOMER; N =
4,534) cohort in British Columbia,64 Puskas et al. found that a lower proportion of women
reported optimal treatment adherence than men (57.0% vs. 77.1%, respectively). Women were
45% less likely to be optimally adherent to cART treatment in the adjusted analyses (aOR =
0.55). Furthermore, a Canadian longitudinal study of injection drug users living with HIV (N =
545) identified female gender as an independent factor associated with a greater likelihood of
suboptimal treatment adherence (aOR = 0.70).82 Using data from the Canadian Observational
Cohort (CANOC; N = 5442) collaboration, a multisite cohort study of individuals with HIV,
Cescon et al. (2013)81 also documented gender differences in poor clinical outcomes, with
women at heightened vulnerabilities. Using Kaplan-Meier methods, the estimated probability of
virologic suppression by 6 and 12 months post-ART initiation was respectively 38% and 52% for
†

To report the measures of associations such as odds ratio and risk ratio, this rule was followed: aa.a for estimates greater than 10 (e.g., 12.3), a.a
for estimates between 2 and 10 (e.g., 7.4), a.aa for estimates between 1 and 2 (e.g., 1.43), and .aa for estimates less than 1 (e.g., 0.89). For very
small estimates, we followed this rule: a.aaa such as 1.003 and .aaa such as 0.006.
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women, and respectively 47% and 65% for men. Adjusted analyses showed that women were
13% less likely to achieve virologic suppression than men (aHR = 0.87) and were 55% more
likely to have virologic rebound (aHR = 1.55).
Traumatic and stressful events owing to socio-structural conditions have resulted in
substantial inequalities in attrition across the cascade of care among women with HIV in Canada.
For example, Kerkerian et al. using the baseline data of the Canadian HIV Women’s Sexual and
Reproductive Health Cohort Study (CHIWOS; N = 1,424) found that 83% of women were on
cART, of whom 68% were adherent and 72% were virally suppressed, with a considerable
variability among those who experienced greater disadvantages concerning the social and
structural determinants.83 In fact, social determinants were found to be the main factors
associated with attritions from one stage to another. For example, the greatest attrition between
linkage to care and cART initiation occurred among women with unstable housing; and attrition
between cART use and cART adherence happened mostly among women with illicit drug use
and recent incarceration. Household annual income, racial discrimination, and incarceration
history were among the significant contributing factors of attrition at viral suppression stage.
According to the same data from Canadian women with HIV, Kronfli et al. (2017) documented
that unstable housing, history of recreational drug use, and experiences of everyday racism were
the main barriers to access to HIV care.84
Consistent with the evidence from developed countries,4,20 life expectancy among
Canadians living with HIV has also improved as mainly the result of the scale up of cART.
While there are differences, available evidence in Canada indicates that life expectancy of
individuals living with HIV on cART are approaching that of the general population,22 with a
considerable gap between men and women with HIV. Samji et al. in a study involving data from
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the U.S. and Canada found that while life expectancy at age 20 years increased with calendar
time in both men and women with HIV, it was lower among women. Life expectancy among
men with HIV at age 20 years was estimated as 35.9 years in 2000/02 to 53.4 years in 2006/07
vs. women with HIV from 36.6 years in 2002/03 to 47.3 in 2006/07.22 The 2009 estimate of life
expectancy in the general population of Canada at age 20 years was 59.7 years for men and 63.9
years for women, indicating that life expectancy of men and women with HIV lags behind the
life expectancy of men and women in the general population up to 6.3 and 16.6 years,
respectively.22 Other research in Canada using data from the Canadian Observational Cohort
(CANOC) collaboration, including people with HIV aged ≥18 years receiving cART reported a
lower life expectancy at age 20 among women with HIV versus men with HIV (32.4 vs. 39.2
years) and for participants with injection drug use history versus those without injection drug
history (23.9 vs. 52.3 years).23 A global systematic review of the literature in 2016, in which
three studies from Canada were also included, showed that life expectancy among women with
HIV was higher than that among men with HIV in all resource-rich settings, except for Canada.85
Research in Canada has found that women with HIV have a lower life expectancy
compared to men,23,86 a difference that may be due to variations in risk factors for HIV
acquisition rooted in social and structural inequities, resulting in poor or suboptimal HIV-related
health outcomes among women compared with men.64,65 Analyses of data from British Columbia
using a retrospective cohort study (2003-2011) of 3,653 people with HIV on treatment aged ≥ 20
years demonstrated that life expectancy of individuals living with HIV at age 20 years was 34.5
years, and it increased to 48.7 years (41% increase) when researchers considered only those who
were alive after the first year follow-up.86 The overall life expectancy at age 20 years among
females was lower than males with HIV (27.2 vs. 37.5 years). Individuals with HIV were 3.2
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times more likely to die than the general population (mortality rates: 28.8 vs. 8.9 deaths per 1000
person-years), with greater mortality among females with HIV (34.6 vs. 8.6 deaths per 1000
person-years) than males with HIV (27.6 vs. 9.3 deaths per 1,000 person-years). Another study
based on data from British Columbia consisted of electronic health records from 9,310
individuals with HIV and 510,313 adults without HIV (1996-2012) found that health-adjusted
life expectancy (HALE) at age 20 years was approximately 31 and 58 years among men with and
without HIV, respectively.87 Such estimates were approximately 27 and 63 years among women
with and without HIV, respectively. The findings of these studies indicate much shorter overall
life expectancies among women with HIV than among men with HIV, as well as their female
counterparts in the general population.

1.4.5 Contributing factors in gender inequalities
These findings show that despite universal access and availability to cART in the Canadian
context, the fact is that not all individuals with HIV have equally benefited from the available
HIV treatment and care programs. Disparities in care engagement, HIV outcomes, and life
expectancy across background (e.g., sex) and baseline characteristics (e.g., history of drug use)
remain.22 Multiple barriers may negatively impact the degree to which women with HIV remain
engaged in HIV care and treatment services. Canadian research has consistently highlighted the
contribution of social, economic and structural determinants – collectively known as the social
determinants of health (SDoH) – to the poor HIV care and treatment outcomes among women.
Suboptimal health-related outcomes are particularly overrepresented among those who face or
continue to face socio-structural adversities and stressful events in their daily lives (e.g., poverty,
discrimination, HIV-related stigma, violence). In addition to daily living conditions, other
factors, more importantly, substance use (e.g., illicit drug use) and difficulties in accessing HIV
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and support services are amongst significant barriers that may hinder access to HIV care,
initiation or continuation of HIV care and treatment services, and retention in HIV care;
consequently, they may negate the efforts in ending the HIV/AIDS epidemic. Of particular
concern is that marginalized women in Canada are disproportionately infected with HIV, which
underscores the necessity of understanding the social adversities as well as behavioural factors
driving the disproportionate impact of HIV among women in Canada.88
Identification of these adversities that women with HIV may experience in excess of what
their counterparts do in the general population (i.e., those who are or assumed to be without
HIV) is an essential step in dealing with these barriers. PHAC’s HIV strategy states that, “It is
critical to continue to work towards creating supportive environments that address social
determinants, decrease stigma and discrimination, and reduce barriers to prevention, treatment,
care and support.”58 Therefore, it is essential to further investigate the individual/behavioural as
well as socio-structural determinants that continue to negatively affect the health and well-being
of Canadians with HIV, particularly women. The importance of these determinants and their role
in poor HIV-related outcomes are further discussed below.
1.5. Social determinants of health

1.5.1 Definitions and importance
Over the recent decades, growing attention has been paid to understanding and addressing the
social environment factors (e.g., income), physical environment factors (e.g., housing), structural
factors (e.g., stigma), and access to health services, collectively known as the social determinants
of health (SDoH).89-91 These are the social and structural conditions that people typically
experience in their daily life and impact their health and well-being.91 Greater insights into SDoH
have been gained as of 2005 when the Commission on Social Determinants of Health (CSDH)
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was set up by the World Health Organization (WHO) to accumulate the evidence on health
equity and how to promote it.91 WHO provides a holistic SDoH conceptual framework92 in
which the principle of health inequality is explicitly articulated. Under this framework, WHO
defines SDoH as, “The conditions in which an individual is born, grows, works, lives, ages, as
well as the wider set of forces and systems shaping the conditions of daily life”.91 The unequal
distributions of these determinants play a significant role in overall health and give rise to greater
inequalities in the health of individuals. WHO underlines that understanding the social
determinants helps identify the processes interacting to create avoidable inequities in health
outcomes.91 That being said, dealing with the social impacts on health is considered as a way to
reduce health inequalities and improve the health and well-being of individuals and
populations.93
The proposed WHO framework provides two levels of the SDoH, and the link between the
determinants and health status. These two levels are: a) structural mechanisms (determinants),
which stem from the key institutions and processes of the socioeconomic and political context
(e.g., macroeconomic policies, social policies, public policies, and culture and societal values).
As this framework asserts, these structural mechanisms are responsible for stratification and
social class divisions in the society and that define socioeconomic status of individuals within
hierarchies of power, prestige and access to resources. Income, education, occupation, social
class, gender, and ethnoracial identity are among the most important structural stratifiers.
Together, context, structural mechanisms and the resultant socioeconomic status are “structural
determinants”, which are, in fact, referred to as the “social determinants of health inequities.”
These inequities operate through a set of intermediary determinants of health to cause health
outcomes; and b) intermediary determinants: This level directly determines the vulnerability to
16

factors that affect health. These determinants include material circumstances (e.g., housing, food
availability); psychosocial circumstances (e.g., lack of social support); behavioural factors (e.g.,
substance use), biological factors (e.g., genetic factors); and the health system (e.g., access to
healthcare services).
In the Canadian context, the concept of SDoH is seen as the social and economic
circumstances that contribute to the health of individuals, communities, and jurisdictions as a
whole. Dennis Raphael, the author of Social Determinants of Health: Canadian Perspectives,94
provides two definitions for SDoH: i) A narrow definition as, “the primary determinants of
whether individuals stay healthy or become ill”, and ii) A broad definition as, “the extent to
which a person possesses the physical, social, and personal resources to identify and achieve
personal aspirations, satisfy needs, and cope with the environment.” Raphael adds that SDoH
“are about the quantity and quality of a variety of resources that a society makes available to its
members.”94 While a wide range of SDoH have been developed over time, the most important
ones in the Canadian setting, proposed by Dennis Raphael, include: Aboriginal status, gender,
disability, housing, early life, education, income and income distribution, race, employment and
working conditions, social exclusion, food insecurity, social safety net, health services,
unemployment and job security.94,95
A social determinants of health (SDoH) approach is seen as an approach moving beyond a
medical model, in which the body is seen as a mechanism that is either running well or in need of
repair, and a lifestyle approach, in which the causes of diseases are to be found in individuals’
unhealthy choices.94 Said differently, the two approaches of biomedical and behavioural factors
are relatively poor indicators of health status in comparison with a social-determinants approach.
This does not mean that SDoH approach undermines the importance of the medical care models
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that influence health, instead, the SDoH perspective emphasizes that medical care is not the only
influence on health.90,94,96 For example, in 2000, the number of deaths in the US attributable to
three social factors of low education, racial segregation, and low social support was shown to be
comparable with the number of deaths attributable to three medical conditions of myocardial
infarction, cerebrovascular disease, and lung cancer, respectively.97 Additionally, studies in the
United States showed that medical care was responsible for only 10-15% of avoidable deaths.98
Other studies have also consistently shown the leading role of daily living conditions (e.g.,
income, employment) on health-related outcomes.99,100

1.5.2 Social determinants and HIV
Despite substantial advances in HIV prevention and treatment strategies, people continue to be
infected with HIV, and people with HIV continue to experience poor health-related outcomes,
with considerable inequalities across population subgroups. While the reasons for such
inequalities are complex, evidence has documented the interplaying role of the multifaceted
factors impacting the effectiveness of HIV care and treatment programs. A set of social and
structural determinants are among those contributing to health inequalities.101-103
In the context of HIV, the Centers for Disease Control and Prevention’s (CDC’s) National
Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) defines SDoH as,
“the complex, integrated, and overlapping social structures and economic systems that include
the social environment, physical environment, health services and structural and societal
factors.”104 In this definition, structural, cultural, and societal determinants are responsible for
inequalities in health, which in turn influence individuals’ ability to fight against HIV. Morin in
1988 described HIV as three separate but linked epidemics: HIV (viral) epidemic, AIDS
(disease) epidemic as well as a set of epidemics defined as “the social, cultural, economic, and
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political reactions to the HIV and AIDS”.105 The last one – that is termed as SDoH – has played a
significant role in expanding the infection and changing the profile of the infection. Even after
the acquisition of the infection, people with HIV are more likely to experience inequalities with
regard to these determinants. As the effectiveness of HIV treatment is now heavily contingent on
consistent linkage to and retention in care as well as sustained adherence,44,106-108 recognizing
these determinants and their overlapping nature is key to designing effective HIV care and
treatment programs.90,101,109
The connection between SDoH and HIV is complex and multi-directional.110 Despite the
significant role the social determinants of health play in increasing vulnerabilities to HIV
infection, living with HIV can itself elevate vulnerability to experiencing greater inequalities
with regard to these daily life conditions. For example, living with HIV may reduce the incomegenerating opportunities or may exacerbate the extent of the socio-structural adversities through
experiencing the unfair or unjust discriminatory behaviours due to their HIV status (i.e., HIVrelated stigma).110 In Canada, while the individuals most affected by HIV (e.g., men who have
sex with men, heterosexual route, injection drug use) may have different life experiences, they
may, however, share the experience of being socio-economically marginalized and victims of
various forms of stigma and discrimination (e.g., homophobia, racism, and sexism, HIV-related
stigma).110 Inequalities with regard to social determinants not only add an additional burden of
health problems, but they also impact the ability of individuals to seek care, treatment and
support,111 and then restrict individuals from access to resources that have potential to reduce
their HIV-related complications. The negative impacts of socioeconomic and structural
adversities on HIV outcomes are discussed in more detail below
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1.5.3 Socioeconomic marginalization and HIV outcomes
Despite the substantial improvements in the survival and clinical outcomes of individuals living
with HIV since the advent of cART, these individuals continue to experience difficulties in their
livelihood. While consistent linkage in and retention to HIV care and optimal adherence to HIV
treatment are necessary for individuals to gain the maximum benefits from the HIV
programs/intervention, adversities with socioeconomic status are among the central challenges
that individuals with HIV still face in the post-cART era.112 Poverty, income insecurity,
unemployment, and food insecurity are among the significant socioeconomic cofactors that not
only affect the distribution of HIV infection,103,113 but also increase the vulnerabilities to HIVrelated clinical and health outcomes among individuals with HIV. Beyond their influence on a
wide range of health problems, the health problems created by these determinants can result in
conditions that, in turn, deteriorate social determinants as well as other health
determinants.94,114,115 For example, poverty has been linked with increased vulnerabilities to HIV
infection which, in turn, reduces opportunities to engage in a secure employment condition,
thereby exacerbating poverty itself as well as poverty-related outcomes.
The link between socioeconomic status (SES) and health inequalities in HIV infection does
not seem to be similar to other chronic health conditions. While in many chronic conditions there
is an SES-health disparities gradient, HIV infection has predominantly impacted individuals who
face socioeconomic adversity or marginalization;34 this is particularly pronounced for women
with HIV. For example, the US Center for Disease Control reported that HIV infection occurs
mostly among socioeconomically disadvantaged people (i.e., those at or below the poverty
level).116 In Canada, HIV infection occurs predominantly among marginalized subpopulations
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with histories of drug use/injection, sex work involvement, incarceration, and other
socioeconomic adversities.61,63,85,86
Adversity with respect to socioeconomic factors such as low education and unemployment
has contributed to the HIV epidemic and HIV outcomes; for example, a high prevalence of HIV
is seen among those with lower education and/or those without an occupation.116,117 Research has
demonstrated worse HIV related outcomes with lower socioeconomic positions.118-120 Research
examining HIV-related outcomes has found a set of socio-structural determinants that influence
the risk of suboptimal HIV care and treatment outcomes, clinical outcomes, and morbidity and
mortality. Extant research has shown that a large proportion of individuals living with HIV
experience difficulties with achieving economic security or attaining employment as well as the
subsequent suboptimal HIV care and treatment outcomes. In a review study in 2015 aiming at
documenting factors associated with treatment initiation and adherence in Australia, Canada, and
the United Kingdom, the economic factors were found to be the leading but under-reported
barriers of HIV care.121 A meta-analysis including 28 studies published between 1996 and 2014
from 14 countries (N = 8,743) showed a statistically significant association between being
employed and cART adherence (overall pooled odds ratio = 1.27), and the association remained
significant for studies from low-income and high-income countries (subgroup overall OR = 1.85
and 1.33, respectively).122 Income, education, and employment were found to be independently
associated with the level of HIV medication adherence in a systematic review.123 Data from the
Women’s Interagency HIV Study (WIHS; N = 1,481), a multicenter cohort study in the United
States, demonstrated that insured women with higher annual income (i.e., a yearly income of >
$18,000) were 21% less likely to have a detectable viral load than those in the least annual
income category (i.e., < $6000/yr).124 Another study from the same cohort of women with HIV
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(WIHS; N = 1,115) comparing socioeconomic data between women with and without HIV found
that a higher proportion of women with HIV reported a low income level (69% vs. 64%) and not
having an employment (77% vs. 57%).125
Evidence from Canada and internationally has consistently linked the socioeconomic
indicators with HIV clinical indicators, including suboptimal cART treatment, elevated failure in
immunological and virologic responses, and increased mortality rates.118,126-131 For example,
individuals with lower education in comparison with those with higher education reported
experiencing delayed diagnosis (40.5% vs. 22.0%); reported lower immunological (68% vs.
84%) and virologic (76% vs. 86%) responses to HIV treatment; and higher risk of mortality
(adjusted hazard ratio (aHR) = 2.3);126 economically poor individuals had a significantly higher
risk of mortality (aHR = 1.50), and that poverty (aHR = 1.60) and hunger (aHR = 1.70)
continued to predict mortality after excluding the potential mediators;127 individuals with no net
wealth versus individuals with > $50,000 and individuals with an education less than high school
versus those with college degree had greater hazard of mortality (aHR = 1.81, and 1.52,
respectively);128 in comparison with individuals who had tertiary education, the risk of mortality
was significantly higher among those with secondary (aHR = 1.30), primary (aHR = 1.68), and
incomplete primary education (aHR = 1.93), respectively,130 and that the risk of HIV virologic
success was lower among those with primary (aHR = 0.93) and incomplete primary (aHR =
0.80) education.130
Food insecurity is another key SDoH, and is defined as, “limited or uncertain availability
of nutritionally adequate, safe foods or the inability to acquire personally acceptable foods in
socially acceptable ways.”132,133 Food insecurity is prevalent among individuals with HIV,132,134137

and is considered as one of the main barriers to optimal care and treatment outcomes.135
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Research has linked food insecurity with HIV outcomes among individuals with HIV. For
example, in a study of 1,213 men and women with HIV in British Columbia, 48% were
identified as food insecure (i.e., 27% as food insecure without hunger and 21% as food insecure
with hunger), with greater prevalence among women than men.132 Data from the Longitudinal
Investigations into Supportive and Ancillary Health Services (LISA, N = 457) cohort in British
Columbia documented food insecurity among 71% of individuals with HIV.136 Weiser et al.
presented a conceptual framework and theorized that adverse HIV outcomes may be linked with
food insecurity through nutritional, mental health and behavioural pathways.137 Studies among
people with HIV receiving HIV treatment have found that food insecurity is associated with
suboptimal adherence to HIV treatment, and incomplete HIV RNA suppression, and
mortality.134,135,138 Data from British Columbia found a high prevalence (48%) of food insecurity
among 1,119 individuals living with HIV (1998-2007). Adjusted analyses showed that
individuals who were food insecure and underweight were 94% more likely to die than those
who were not food insecure or underweight (adjusted hazard ratio = 1.94).135 Anema et al. in a
study in British Columbia among 254 injection drug users living with HIV who initiated cART
documented a high prevalence of food insecurity (71.3%), and found an independent association
of food insecurity with mortality (aHR = 1.95).134

1.5.4 Stigma and discrimination
While evidence has consistently demonstrated that the advancements in HIV care and treatment
have changed the profile of HIV from an acute to a chronic health condition, many other
challenges such as HIV-related stigma and discrimination continue to exist and have potential to
endanger attempts to manage HIV/AIDS in the post cART-era. Since the beginning of the HIV
epidemic, HIV-related stigma has continued to occur globally, and has been considered as one of
23

the most serious and prevalent challenges for controlling the epidemic.139-141 A systematic review
in 2014 found that the prevalence of the experience of some types of stigma among individuals
with HIV who were on HIV treatment varied from 42% in resource-rich nations to 82% in
resource-limited nations.142
Erving Goffman, a Canadian sociologist, defines the term stigma as the “situation of the
individual who is disqualified from full social acceptance.”143 Goffman further describes stigma
as a term referring to an attribute or a characteristic (e.g., race/ethnicity, gender) that is deeply
discrediting such that reduces a person in our minds “from a whole or usual person to a tainted,
discounted one”.143 In the context of HIV, stigma is defined as discounting, discrediting and
discriminating against individuals who are living with HIV and AIDS. The UNAIDS defines
HIV-related stigma as “the negative beliefs, feelings and attitudes towards people living with
HIV, groups associated with people living with HIV (e.g. the families of people living with HIV)
and other key populations at higher risk of HIV infection, such as people who inject drugs, sex
workers, men who have sex with men and transgender people.”140,144 Peter Piot, the former
Executive Director of UNAIDS, in a viewpoint paper entitled AIDS: from crisis management to
sustained strategic response published in The Lancet in 2006, introduced combating stigma and
discrimination as one of five key imperatives for a sustained response to the HIV/AIDS
epidemic.145 Piot emphasized that wide access to antiretroviral therapy is helpful in combatting
stigma and discrimination, but insufficient. Different types of HIV-related stigma have been
introduced and been associated with worse HIV outcomes. Some of these types include: a)
perceived stigma, which refers to the awareness of individuals with HIV from negative attitudes
of other people in the society, and involves expectations of discrimination and prejudice from
others owing to their HIV status; b) internalized stigma, which refers to negative beliefs, views
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and feelings towards themselves and those with HIV/AIDS; c) enacted stigma, which refers to
acts of discrimination (e.g., violence, exclusion) toward individuals with HIV because they are
infected with HIV, and involves the experience of such discriminative behaviours.141,146-151
HIV-related stigma has been one of the most common barriers to HIV care and treatment
programs. Various observational and review studies have shown the detrimental impact of HIVrelated stigma and discrimination on multiple HIV and health-related outcomes.33,141,142 While
the reduction of HIV-related stigma is a crucial step toward reducing HIV inequalities and health
inequities,152 its complexity has been introduced as one of the main reasons for the insufficient
response to this prevalent phenomenon.141,146 Mahajan et al. believe that lack of a clear
definition, difficulties in measuring the extent of HIV stigma, difficulties in assessing the impact
of stigma on HIV outcomes and the effectiveness of HIV programs, and difficulties in
developing interventions to reduce stigma are amongst those challenges that have hindered
universal efforts to appropriately respond to HIV-related stigma.141 The complexity in defining
this phenomenon may partly originate from its interaction with a range of cross-cultural
differences, socio-structural disparities, discriminative behaviours from health care providers,
and social processes that are not usually measured in common practice.146,153,154 HIV-related
stigma can be particularly complex when compounded by marginalized behaviours (e.g.,
substance use, sex work) and demographic characteristics (e.g., gender and race/ethnicity).141,146
Women with HIV have frequently reported experiencing multiple forms of stigma beyond
those related to their gender and HIV itself;152 for example, stigma due to sexual minority
orientation, transgender identity, substance use, history of sex work involvement, incarceration,
and violence. Logie et al.88 developed an “intersectional model of stigma and discrimination” in
which intersectional stigma refers to mutually constitutive relationships between disadvantaged
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societal attributes and inequities such as HIV-related stigma, discrimination due to gender (i.e.,
sexism), discrimination due to ethno-racial status (i.e., racism), and discrimination due to sexual
orientation or gender minority status (i.e., homo/transphobia). These stigmas have been the key
issues identified in previous research with populations at elevated risk for HIV infection in
Canada.88 While each type of stigma and discrimination can be studied independently,152 they
may also tend to co-occur and create clusters or combinations in which a group of individuals
may follow certain patterns. The identification of the distinct pattern of these stigmas can help
better understand the impact of these societal stigmas. This is a concept similar to what Logie et
al. called “intersectional stigma and discrimination,” referring to the overlapping, multilevel
forms of stigma and discrimination that concomitantly pose barriers to health and wellbeing of
women with HIV.88
Stigma can negatively impact the ability of individuals with HIV to manage their disease
and multiple health and HIV outcomes,33,155-158 ranging from its interfering impact on
engagement in HIV care and treatment to inferior clinical indicators of HIV progression.146,158-160
Previous studies have suggested that individuals who experience high levels of HIV-related
stigma have lower access to, retention in and utilization of medical and HIV care as well as
poorer treatment adherence and HIV clinical indicators. In a systematic review and series of
meta-analyses (64 studies included), Rueda et al. found significant associations between HIVrelated stigma and lower levels of medication adherence, and lower access to and usage of health
and social services.33
The interlinked nature of HIV-related stigma with other social and mental health indictors
in influencing the health and clinical outcomes among people with HIV have been well
documented. For example, using data from a national cohort of women with HIV in Canada
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(CHIWOS; N = 1,425), Logie et al. found a significant direct association between HIV-related
stigma and gender discrimination on mental health-related quality of life (HR-QoL). In addition
to their direct effects, these two indicators indirectly impacted HR-QoL through social support
(acting as mediators) such that low social support accounted for 22.7% of the effect between
HIV-related stigma and mental HR-QoL and 41.4% of the effect between gender discrimination
and mental HR-QoL. For the impact of HIV-related stigma and racial discrimination on physical
HR-QoL, economic insecurity accounted for 14.3% and 42.4% of the effect, respectively.155 In
another study, Logie et al. found that depressive symptoms mediated the association between
personalized stigma and cART adherence as well as the association between negative self-image
and both cART use and adherence.161 Rao et al. in a cross-sectional study of individuals with
HIV (N = 720) found that much of the effect of stigma on HIV treatment adherence was
explained by depressive symptoms, suggesting the mediating role of depressive symptoms on the
association between HIV-related stigma and HIV medication adherence.156 Based on data from
the Women's Interagency HIV Study (WIHS; N = 1168), Turan et al. found that depressive
symptoms and low social support (or loneliness) each separately mediated the association
between internalized stigma and suboptimal HIV treatment adherence;162 meaning that a part of
this association was explained by depressive symptoms and low social support. They also found
that low social support operated through depressive symptoms to explain the indirect association
between internalized HIV stigma and lower HIV adherence. Turan et al.163 in another study in
the same population (N = 1356) found that perceived discrimination in healthcare settings
significantly reduced the likelihood of optimal cART adherence (aOR = 0.81). Through serial
mediation analyses, they documented that internalized HIV-related stigma and depressive
symptoms mediated the perceived discrimination-adherence association, suggesting the indirect
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impact of perceived discrimination in healthcare settings on cART adherence, first through
internalized HIV stigma, and then through depressive symptoms.
1.6. Substance use
Substance use (e.g., illicit drugs, alcohol use) is prevalent among individuals with HIV.
Inequality in substance use between individuals with HIV and their counterparts in the general
population has been documented, suggesting a higher prevalence among individuals with HIV.
Previous research has also estimated the prevalence of use of various substances and examined
their association with multiple HIV and health outcomes as well as mortality.35 Substance use is
not only a common driver of HIV infection, but also is directly and indirectly associated with
suboptimal HIV care and treatment outcomes.
There is limited research focusing on the patterns of substance use specifically in women
with HIV, who appear to be of particular vulnerability to poorer HIV outcomes attributable to
substance use164-166 owing to elevated burdens of psychiatric comorbidity, underdiagnosed
alcohol use disorder, and greater difficulties accessing substance use treatment due to greater
socioeconomic, cultural and structural adversities.166-168 Given such additional burdens of daily
life adversities, women with concomitant HIV infection and substance use are indeed of
particular vulnerability to poorer HIV outcomes.168 In addition to inequalities with regard to
income-producing opportunities, women with HIV experience a greater level of stress and
stressful events such as posttraumatic stress disorder (PTSD) and intimate partner violence
(IPV),169 or are at greater risk for depression in their daily life.169-172 Research suggests that
substance use is one coping strategy through which individuals tend to escape or avoid their
everyday stresses or stressful events.173 Substance use, coupled with socioeconomic
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marginalization and structural adversities, can bring about greater vulnerabilities toward
suboptimal HIV outcomes among women with HIV.
Substance use is, in fact, one of the most frequently studied correlates of HIV treatment
non-adherence.174 Greater focus on substance use in the current era of cART is warranted for
multiple reasons. One of the key reasons is due to the preponderant co-existence of HIV and
substance use.175 Vagenas et al.175 reported that HIV and alcohol use, for example, “are
intricately intertwined and mutually reinforcing epidemics” that have the potential for poor
outcomes. Skalski et al.176 also added other reasons such as: i) the direct and indirect
contributions of substance use to the circulation of HIV infection, ii) their association with
health-seeking behaviours and HIV care and treatment interventions such as non-adherence to
cART treatment, and iii) their interference with virologic and immunologic responses to cART,
and subsequently accelerating disease progression, and mortality. Identifying and remediating
such common barriers to treatment adherence are major priorities of behavioural HIV
research177,178 and of particular importance for people with HIV themselves, as well as those
bodies (e.g., care providers, policy-makers) that are committed to improve treatment outcomes
and the health and well-being of these individuals.175 Evidence suggests that optimal adherence
can be improved via either the facilitation of interventions that improve adherence directly or
through the mitigation of the key challenges at each step along the HIV treatment cascade.179-183
Substance use is one of these challenges that has substantially contributed to suboptimal
engagement of individuals with HIV at each step of the HIV cascade; consequently, it has
negated the efforts in improving HIV treatment programs. Given the modifiable nature of this
behavioural practice, interventions targeting substance use and its predictors can potentially

29

improve the management of HIV and then enhance treatment outcomes. Below, the importance
of these behavioural practices is discussed in detail.

1.6.1 Alcohol consumption
Alcohol consumption, particularly heavy use (or hazardous use), is considered a major public
health challenge among individuals with HIV due to its high prevalence as well as its
contribution to worse HIV outcomes.184-187 The World Health Organization (WHO) defines
heavy/hazardous drinking as, “quantity or pattern of use that places patients at risk for adverse
consequences,” and heavy drinking is defined as, “quantity of pattern of use that exceeds a
defined threshold.”184,188,189 The National Institute on Alcohol Abuse and Alcoholism (NIAAA)
has also provided specific definitions for different measures of heavy/hazardous alcohol use,
specifically, a) Hazardous (or, high-risk) drinking, defined as 7 drinks or more per week for
women.190 While hazardous drinking is not considered as alcohol use disorder (AUD),
individuals who are involved in such hazardous practices are at elevated risk for the worse
outcomes attributed to alcohol use;191 and b) Binge drinking, defined as “a pattern of drinking
that brings blood alcohol concentration levels to 0.08 g/dL,” where typically happens after 4
drinks for women in about 2 hours.192 A woman then can be considered as a binge drinker if she
drinks 4 or more alcoholic drinks on the same occasion on at least 1 day within 30 days.193
Heavy drinking can impact the HIV outcomes through a) behavioural mechanisms: by
diminishing health-seeking behaviours of individuals with HIV and negate retention in care and
treatment adherence (discussed below); and b) biochemical mechanisms: by its potential impact
on the acceleration of disease progression.
Multiple studies have demonstrated the preponderance of heavy/hazardous alcohol
consumption among individuals with HIV. For example, data from a nationally representative
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sample of people with HIV in the United States in 2002 (N = 2,864) estimated that more than
half (53%) of individuals with HIV who were in HIV care reported last-month alcohol
consumption, with 8% of entire sample and 15% among those who reported alcohol drinking
identified as heavy drinkers (defined as the weekly consumption of ≥ 5 drinks/day). No statistical
difference was observed for heavy drinking between men vs. women with HIV (15.0% vs.
15.5%, respectively). Another study in the United States estimated a high prevalence of pastmonth alcohol use (60.6%), with binge drinking reported by 27.2% of the whole sample.194
Studies of women with HIV have also suggested a high prevalence of alcohol consumption; for
example, Cook et al. identified five distinct drinking trajectories among women with HIV:
continued heavy drinking (3%), reduction from heavy to non-heavy drinking (4%), increase from
non-heavy to heavy drinking (8%), continued non-heavy drinking (36%), and continued nondrinking (49%), indicating that almost 15% of the sample were involved in heavy drinking at
some point during the follow-up.195 Cook et al. in an 11 year follow-up study found that
approximately half of women reported drinking alcohol and 14% to 24% reported past-year
hazardous drinking, suggesting that approximately 1 in 5 met criteria for hazardous drinking.185
Cook et al. in a qualitative research identified that women with HIV reported drinking alcohol to
cope with multiple adversities, including biological (e.g., addiction, to manage pain),
psychological (e.g., coping, to escape negative experiences, to feel in control), and social (e.g.,
peer/family pressure, to socialize).196 Studies comparing the patterns of alcohol drinking between
men and women have documented mixed findings. While some epidemiological research197,198
found a higher prevalence among men vs. women, data from other studies199 indicated that a
higher proportion of women who classified as heavy drinkers than men (7% vs. 5%,
respectively).
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Both in vitro and epidemiological studies have shown the negative impact of heavy
drinking on subsequent HIV outcomes. In vitro studies demonstrated that alcohol accelerate HIV
disease progression through impacts on key inflammatory markers (e.g., elevation in plasma
CD4, a marker of monocyte activation),200 or alteration of the virus infectivity, the immune
response of the host, and tissue injury.201 Epidemiological studies have also introduced heavy
drinking as an important barrier to every step of the HIV care cascade.187,202 For example, a
2010-2015 systematic review175 including 53 clinical studies examining the impact of alcohol
use on each step of the HIV treatment cascade found that 77% of the included studies
documented a negative association of alcohol consumption with at least one step of the treatment
cascade. Other observational and review research have shown such negative impact of heavy
alcohol consumption on the HIV care cascade outcomes; for example, retention in HIV care,203
health care utilization,204 and suboptimal adherence to treatment.177,202,204,205 Aside from impacts
on each step at the HIV care cascade, alcohol use has also been associated HIV progression
indicators and mortality; for example, different patterns of heavy alcohol consumption have been
associated with failing to achieve immunological response (i.e., CD4 cell count ≤ 200/mm3)206,207
and virologic failure (i.e., detectable viral load)208-210 as well as a higher risk of hospitalization211
and mortality.186

1.6.2 Cigarette smoking
Cigarette smoking is also prevalent among people with HIV,212,213 with its high prevalence
contributes to a variety of poor outcomes.194,213 For example, Mdodo et al. in a nationally
representative cross-sectional study in the United States in 2009 demonstrated that individuals
with HIV receiving medical care were approximately twice as likely to be current smokers
compared with adults in the general population (37.6% vs. 20.6%), with a higher prevalence
32

among both men and women with HIV (40.9% and 34.6%, respectively) compared to their
counterparts in the general population (23.3% and 18.0%, respectively).213 Other epidemiological
studies, mainly from the United States, have shown the high prevalence of current cigarette
smoking among individuals with HIV.194,214
Cigarette smoking contributes to both HIV-related and non–HIV-related health outcomes
among individuals with HIV.213 Beyond its contribution to the elevated risk of noncommunicable diseases such as chronic obstructive pulmonary disease (COPD),215
cardiovascular disease,215 and cancers,216 cigarette smoking has been also shown to have a
deleterious impact on HIV outcomes, such as health and treatment outcomes as well as mortality
among individuals with HIV. Nicotine, the active ingredient in tobacco, and HIV have
synergistic interaction to negatively regulate the synaptic plasticity gene expression and spine
density which may contribute to the elevated risk of HIV-associated neurocognitive disorder
(HAND),217 as characterized by development of cognitive, behavioural and motor abnormalities,
and reported among almost half of individuals with HIV.218 Epidemiological research indicates
that such lifestyle factors continue to negate advances in HIV outcomes.219 For example,
multiple studies have reported the negative impact of cigarette smoking on outcomes among
individuals with HIV; e.g., suboptimal adherence.220
In addition to its impact on treatment interruption and non-adherence, smoking has also
been associated with worse clinical indicators and increased risk of mortality. Such elevated
vulnerability has been reported to be due mainly to a) biochemical mechanisms through which
smoking can negatively influence immune and virological response, regardless of cART
use,221,222 and b) behavioural mechanisms in which smoking can potentially increase cART nonadherence.223,224 Research shows that individuals with HIV who reported cigarette smoking are
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at a greater vulnerability to poor immunological and virologic responses, as well as greater risk
of developing AIDS and all-cause mortality.214,225-227 Data from individuals with HIV enrolled in
European and North American cohorts (N = 17,995) suggested a high prevalence of smoking
(60%), and that smokers had a higher mortality rate than non-smokers (mortality rate ratio =
1.94; with 1.84 among men and 2.41 among women).227 This study showed that mortality
attributed to smoking is higher than mortality due to HIV itself. Furthermore, a lower level of
quality of life has also been reported among individuals with HIV who were current smokers
versus never smokers.228

1.6.3 Illicit drug use
Illicit drug use is also prevalent among individuals with HIV. Despite its substantial contribution
to driving HIV acquisition and transmission, drug use – both injection and non-injection – has
the potential to threaten the significant clinical benefits obtained in the control of HIV in the
cART era.229,230 Illicit drug use is of particular concern among people with HIV given its high
prevalence and the negative effects on HIV treatment outcomes and morbidity and mortality.
Prior research from different contexts has suggested that a high proportion of individuals
with HIV meet criteria for illicit drug use alone or in combination with other substances, alcohol
use in particular. For example, Pence et al. reported a high prevalence of marijuana (12%) and
crack (5%), with 11% reporting using a non-marijuana drug and 7% reporting polysubstance use
(i.e., multiple substances at one time) at least weekly.198 Gurung et al. reviewed electronic
medical records of 4,965 individuals with HIV in New York City and reported that 12.7% had an
alcohol use diagnosis and 26.4% had a recorded drug use diagnosis, with 8.7% having co-morbid
alcohol and drug-use diagnoses.231 Hartzler et al. using data from the Center for AIDS Research
Network of Integrated Clinical Systems (CNICS; N = 10,652), a multi-regional U.S.-based data,
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estimated the prevalence of any substance use disorders (SUDs) at 48% (50% for men vs. 36%
for women), with 31% marijuana use, 19% alcohol use, 13% methamphetamine use, 11%
cocaine use, and 4% opiate use, and 20% having polysubstance use disorder.232 Of the limited
research among women with HIV, Cook et al. found a high prevalence of illicit drug use among
heavy drinkers: 30.2% cocaine use, 39.5% crack use, 42.1% marijuana use, and 21.5% heroin
use.185 Kuo et al. examined data from the HIV Prevention Trials Network (HPTN 064; analytic
N = 1,882) Study, and found that 76.1% reported using one or more substances or binge drinking
in the past six months (i.e., 37.5% as frequent users [i.e., daily or less than weekly] and 38.6%
infrequent user), with 63.3% reported binge drinking (of them, 54.5% being as frequent users),
followed by 25.0% cocaine use (of them, 29.5% as being frequent users) and 16.5% opioid use
(of them, 54.5% being as frequent users).233
Illicit drug use can also negatively impact the pathobiology of HIV. Xu et al. investigated
in vitro effects of cocaine and found that a direct effect of cocaine on four major immune
competent cells (i.e., T cell function such as helper T cells [CD4], B cell function, natural killer
[NK] cell function, and monocyte-macrophage function).234 In vitro and animal models have
documented that illicit drugs may impact the pathobiology of HIV through altering immune
functions (e.g., NK cells, T cells, neutrophils and macrophages) and the ability of such immune
cells to secrete immunoregulatory cytokines, and also enhancing the infectivity and/or replication
of HIV virus.235,236
Apart from the biochemical mechanisms explaining such heightened risk of HIV
outcomes, drug use negatively impacts on health seeking behaviours, treatment utilization and
adherence, and subsequent outcomes among individuals with HIV.237,238 Sohler et al. examined
patterns of drug use (at baseline only, 6-month follow-up [i.e., starters], both periods [i.e.,
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consistent user], and nonuse) and health care utilization, and found that any drug users were
more likely to miss HIV medical appointments (aOR = 2.2 for starters [who newly started] vs.
nonusers, aOR = 2.9 for consistent users vs. nonusers), more likely to use emergency services
(aOR = 4.9 for starters vs. nonusers, aOR = 2.2 for consistent users vs. nonusers), less likely to
use antiretroviral medication (aOR = 0.23 for starters vs. nonusers, aOR = 0.19 for consistent
users vs. nonusers), and more likely to report unmet support services need (aOR = 1.8 for
consistent users vs. nonusers).239 Individuals who stopped using drugs within the follow-up did
not significantly differ from nonusers with regard to these outcomes. Individuals reporting the
use of hard drugs (i.e., cocaine, amphetamines, or heroin) were more likely to be cART nonadherent (aOR = 2.1), and had higher risk of AIDS progression or death with (aHR = 2.1) or
without (aHR = 2.5) adjusting for non-adherence, suggesting a possible adherence-independent
mechanism of harm associated with illicit drug use.238 Research also showed that concurrent
illicit drug use with other substance, e.g., alcohol use, exacerbated the negative impacts on HIV
treatment outcomes. For example, concurrent hazardous drinking and active drug use was
significantly negatively associated with the lowest odds of cART use (aOR = 0.40), cART
adherence (aOR = 0.32), and viral suppression (aOR = 0.50).240 Limited data on women with
HIV also showed that substance users were 20% more likely to be suboptimal cART adherent
(adjusted prevalence ratio (aPR) = 1.20).241 They found that both marijuana use and nonmarijuana illicit drug use predicted suboptimal adherence.
Epidemiological research showed that the association of illicit drug use with HIV treatment
nonadherence has led to elevated likelihood of failure to achieve viral suppression and reduced
CD4 cell recovery,242 and consequently resulting in greater risk of HIV disease progression,
opportunistic infections, and mortality.243-246 In fact, illicit drug use facilitates HIV progression
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through either curtailing treatment adherence among those receiving cART or independent of
cART use. For example, compared to nonusers, abstinent heroin/cocaine intermittent users (aOR
= 1.4); active intermittent users (aOR = 2.3); and persistent users (aOR = 2.1) were at greater risk
of opportunistic infection. Persistent crack cocaine using women were at greater risk than nonusers to die from AIDS-related causes (aHR = 3.6) and to develop newly acquired AIDSdefining illness (aHR = 1.65).246 Both pattern and type of illicit drug use were associated with
HIV progression and mortality. Kapadia et al. showed an elevated risk of progression to AIDS
among consistent (aHR = 2.5), inconsistent (aHR = 1.63) and former (aHR = 1.56) illicit drug
using women than never users, and an increased risk of progression for stimulant users (aHR =
2.0) and polydrug users (aHR = 1.65) compared with non-users. They also found that consistent
drug users had greater risk of all-cause mortality (aHR = 1.43) and AIDS-related mortality (aHR
= 1.42) than never users.247
1.7. Social determinants and substance use
As made clear above, evidence has well documented that individuals with HIV reported a higher
prevalence of illicit drug use248 than their counterparts in the general population, with mixed
findings for heavy alcohol consumption.249,250 Substance use as a public health problem is of
particular concern among people with HIV due to its direct and indirect impacts.251,252 Substance
use impacts individuals’ cognitive capacity and impairs their decision making and judgment,
resulting in other risky practices.253-255 The co-occurrence of substance use and care and
treatment interruptions attenuates the public health benefits of HIV treatment.256 As noted above,
a large body of evidence has identified strong associations of substance use with HIV outcomes
such as low retention in care, treatment non-adherence, poorer immunological and virologic
responses, and elevated burdens on health systems.28 For example, illicit stimulant drugs (e.g.,
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crack-cocaine use) enhance viral replication, resulting in unsuppressed viral load, and blunt
effector function of cytotoxic T lymphocytes.257 In addition to such direct impacts, individuals
with HIV who use substances have elevated prevalence and frequency of medical, psychiatric,
and substance use disorders. The resulting complications contribute to multiple key challenges in
the provision of HIV care. In addition, drug using individuals under care for HIV and taking
cART have increased age-matched morbidity and mortality than do their counterparts who do
not use substances.258
Few studies have explored the patterns of substance use among women with HIV and little
research has compared such patterns with their counterparts in the general population to explore
the inequalities associated with substance use. Given the fact that an increasing number of
women become infected with HIV, the need to address modifiable barriers that directly or
indirectly accelerate disease progression and negatively impact survival becomes more
essential.185 This is particularly important among women with HIV who are also at greater
vulnerabilities for their daily living conditions. While there have been appreciable progresses in
the understanding of the epidemiology of HIV and risk factors among women over the recent
decade, epidemiological data remain limited with respect to the key modifiable risk factors that
have potential to diminish the efforts made to control and manage the HIV epidemic. Substance
use is one such modifiable risk factor; however, evidence indicates that less attention has been
paid to substance use disorders given the fact that it is an important aspect of HIV care and
treatment.208 While the optimal benefits of HIV treatment are strongly tied to treatment
adherence, substance use has the potential to interfere with treatment through non-adherence and
then lead to poorer subsequent HIV treatment outcomes. In addition to inadequate evidence
concerning substance use among women with HIV, the literature has also inadequately addressed
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the modifiable risk factors associated with substance use, particularly through the SDoH
perspective.
The SDoH perspective highlights the leading role that the social and structural
environments play in determining health outcomes and health status.91,94,114,259 According to this
framework, certain groups are at greater risk for poor health outcomes due mainly to inequitably
experiencing adversities with respect to the social and structural determinants.259 Even though
the contribution of these determinants in the spread of the HIV epidemic has been well
recognized, a relatively small number of studies have demonstrated the role of these
determinants in the initiation or continuation of substance use among women with HIV. While
evidence from different fields of research has suggested that the etiology of substance use is
multifactorial, such that genetic, psychological, and social factors all contribute to substance use,
Galea et al. believe that greater attention needs to be paid to the social aspects of substance
use.260 In addition to the fact that people are biologic and social organisms, these researchers
believe that there are few biologic processes or behaviours that are not mediated through social
context. In the case of substance use behaviour in particular, evidence indicates that the
experiences have consistently been rooted in the social context.260,261 In other words, social
determinants have a direct impact on the patterns of substance use as well as the resultant levels
of harms.262 Marmot and Allen in support of the leading role of social determinants believe that
investigators “need to understand and improve the social determinants of [unhealthy] behaviours
to reduce health inequalities and improve health while simultaneously trying to facilitate and
support better existing behaviours.”263 A better understanding of these key determinants of health
and their association with substance use is imperative for identifying and developing effective
interventions in the course of HIV management among women.262
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Evidence, predominantly US-based research, has linked substance use with social
determinants among individuals with HIV, with a substantial focus on social stratification
characteristics such as gender, race/ethnicity, and socioeconomic status. For example, Chander et
al.191 investigated the contribution of gender, education, and race/ethnicity to both any alcohol
use and hazardous drinking among a sample of individuals with HIV at 14 HIV primary care
sites in the United States. They found the significant contribution of gender (aOR = 1.52 for male
sex) and education (aOR = 1.87 for those with a college education vs. < high school) with any
alcohol use, while no significant difference was observed across race/ethnicity groups. No
significant association was observed between these three determinants and hazardous alcohol
use. Crane et al.264 using a sample of 8,567 people with HIV from seven U.S. sites from 2013–
2015 found a significant contribution of gender (aOR = 0.77 for females vs. males) and
race/ethnicity (e.g., aOR = 0.81 for Black vs. White) to binge drinking, and race/ethnicity to
hazardous drinking (e.g., aOR = 0.74 for Black vs. White). Analyses stratified by sex showed
that certain race/ethnic groups had different risk for heavy/hazardous alcohol consumption
among males and females with HIV. Bilal et al. in a prospective sample of 7,906 people with
HIV receiving care assessed clinical and sociodemographic predictors of alcohol misuse and
alcohol use trajectory separately for men and women.197 The only available SDoH indicator in
their model was race/ethnicity, a non-modifiable SDoH measure. While certain race/ethnic
groups had different risk for alcohol misuse among males, no difference was observed across
race/ethnic groups in the sample of females. Alcohol consumption trajectories were also not
different across race/ethnic groups for males and females. Kelso-Chichetto et al. using data from
two cohorts of men and women with HIV in their model explored the role of only two SDoH
indicators of annual income and race on heavy alcohol use separately for male and female
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samples. Among women, those with lower annual income levels: < $10,000 (aOR = 0.76) and
$10,000-$30,000 (aOR = 0.72) non-significantly had lower risk of heavy drinking vs. those in
the higher income level (≥ $ 30,000), with significant differences observed across racial groups.
Compared with individuals in higher income levels, those with < $10,000 annual income had a
significantly increased risk of heavy drinking (aOR = 1.97).199
Research focusing on data from women living with HIV has also documented the
contribution of a few social determinants to alcohol use. For example, Cook et al. found that
women were significantly less likely to report hazardous drinking if they were employed (aOR =
0.80) and had higher education (aOR = 0.72 for those with more than high school education vs.
those with high school or less), with no significant difference for race groups and marital status
in the adjusted analysis.185 Cook et al. in another study showed that among women without
heavy drinking at baseline, those with more than high school education had a lower risk of heavy
drinking trajectory than those with high school or lower education (aOR = 0.65), with no
difference across racial groups, employment and marital status. Ghebremichael et al.265 found a
higher odds of alcohol use among women with a higher education (aOR = 1.53 for those with
more than high school education vs. high school or less), with no significant difference for those
with different income levels.
The same patterns of association between social determinants and illicit drug use have also
been documented. For example, Pence et al.198 found that women with HIV were less likely to
report frequent non-marijuana drug use (aOR = 0.88) and polysubstance use (aOR = 0.46) than
heterosexual males with HIV. No significant difference was observed for racial groups (minority
vs. majority) and educational levels (beyond high school vs. high school or less). In addition to
these determinants, these authors also assessed the association of other social determinants
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including experienced trauma, stressful life, and social support on illicit drug use. Lifetime
trauma increased the risk (per number of traumatic experiences) of frequent non-marijuana drug
use by 13%, frequent crack use by 9%, and polysubstance use by 30%. In addition, stressful life
events increased the risk of frequent non-marijuana drug use by 38% per event. Higher social
support levels decreased the risk of frequent crack use by 18% and increased the risk of
polysubstance use by 39%, even though these estimates were not statistically significant. Studies
focusing specifically on data from women with HIV and assessing social determinants of illicit
drug use is limited. Carter et al.266 in a Canadian context found six distinct classes of substance
use: abstainers (26.3%), tobacco users (8.8%), alcohol users (31.9%), ‘socially acceptable’ polysubstance users (13.9%), illicit polysubstance users (9.8%) and illicit poly-substance users of all
types (9.3%). They also found a complex pattern for women with an annual household income <
$20,000 vs. those with ≥ $20,000: women were significantly more likely to be illicit polysubstance users of all types (aOR = 2.8) while less likely to be alcohol users (aOR = 0.59).
Violence as a key social determinant also significantly increased the odds of substance use.
These studies have also found that recent experience of violence was independently associated
with all classes of substance use, e.g., alcohol use (aOR = 2.6), illicit polysubstance use (aOR =
7.3), illicit poly-substance users of all types (aOR = 9.4). The contribution of social determinants
to illicit drug use is even stronger among other subgroups living with HIV. For example, a crosssectional sample of 2,216 youth (ages 12-26) living with HIV found that individuals with
lifetime unstable housing reported a higher odds of non-marijuana illicit drug use (aOR = 2.2).267
As noted, research has generally focused on non-modifiable social stratification
characteristics/positions such as ethnoracial identity in assessing the role of social and structural
determinants and their inequalities on substance use. This might be since that disparity in the
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United States is often referred to racial/ethnic differences in health, while this concept
(commonly termed inequality) in the United Kingdom and European countries has referred to
differences in health across individuals with different socioeconomic classes.263 Undoubtedly,
these groups of social determinants can highlight the significance of the social context of
substance use; however, these do not provide enough help in recognizing the specific patterns of
social determinants in relation to substance use. Therefore, to better address substance use and its
associated harms, greater actions are required. Beyond the role of the social stratification
characteristics, there is also a need for research on identifying the comprehensive social
determinants that substantially influence and shape the behaviours of individuals with HIV. This
is particularly important in the current context of HIV where effective care and treatment are
available and accessible, and treatment has brought about significant advances in the life of
individuals with HIV.263 From the social determinants of health perspective, there is indeed a
need to address larger environmental and social factors – also called the upstream level268 – that
influence individuals’ behaviours.268,269 The extent to which substance use is influenced by a
comprehensive set of social and structural factors warrants additional study, particularly among
women with HIV. Studying socio-structural factors and assessing their role in substance use have
implications for HIV care and treatment.270
1.8. The current research
The current research was informed by the social determinants of health (SDoH) framework, a
conceptual framework around the social and structural context of health. We aimed to document
inequalities in daily life conditions and lifestyle factors among women with HIV in comparison
to the general population. Informed by a social determinants of health framework, we first
examined how social determinants of health may cluster together, and then how the identified
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clusters of social determinants may have the differential influence on illicit drug use and
heavy/hazardous drinking among women with HIV in Canada. In fact, this framework was used
to help explain how substance use, that itself substantially contributes to poor HIV treatment
outcomes, are patterned by social and structural environments. We hypothesized that the choices
women with HIV make (here, substance use) are shaped by the choices they have (here, daily
living conditions), which are themselves shaped by structural policies and processes. Growing
interest in the socio-structural determinants of health has led to an increasing emphasis on
understanding these fundamental causes (or upstream factors) and their contributions to health
inequities.271 Exploring a broad range of social, economic and structural determinants can help
understand how these determinants play a fundamental role in lifestyle-related outcomes,
substance use in particular in the present research, among women with HIV. There is a lack of
research among women with HIV analyzing these determinants and exploring their contribution
to substance use, as key lifestyle or individual-level factors that have the potential to negate the
HIV treatment outcomes and mortality.
Studies of individuals with HIV have typically treated these social, economic and structural
determinants as separate (or, independent) conditions or indicators when assessing their impacts
on subsequent health outcomes, including substance use. For example, research has explored the
independent impact of food insecurity on heavy alcohol use272 and illicit drug use273,274 as well as
other HIV- and health-related outcomes such as treatment non-adherence,275,276 and
immunological and virologic responses to HIV treatment;277-279 or the independent impact of
HIV-related stigma on substance use,280-282 late linkage to HIV care,283 cART initiation and
treatment uptake, and suboptimal ART adherence,33,158,161,162 mental health conditions, access to
and usage of health and social services;33 or the independent impact of perceived discrimination
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such as unfair treatment on cART adherence;163,284 or the independent impact of social support
on substance use,285 risk behaviours;286 or the independent impact of under-housing or unstable
housing, as a structural determinants of health, on substance use,267 medical care, and health
outcomes;287 or the independent impact of incarceration, as a structural determinants of health,
on substance use,288,289 treatment adherence.290,291
Although assessing the independent impact of these indicators – i.e., using regression
modeling with food insecurity, for example, as separate statistical predictors – may also have
implications for HIV programs and interventions, methodologically, such an approach is not
without limitation.292 Social determinants have the potential to co-occur (i.e., co-present) and
then may follow certain clusters/patterns (i.e., tend to be positively correlated). Therefore, such
analytic approaches assessing the independent impacts may fail to account for the dependency
and overlap of these social determinants.292 While uncovering overlapping patterns of social
determinants has been a challenge, other statistical approaches such as latent class analyses
(LCA) enable researchers to account for the dependency across a set of overlapped
indicators.293,294 In the context of SDoH, this method offers an important methodological step
forward for empirically considering the inter-relationships between social, economic and
structural factors and their joint associations with substance use. We, therefore, used LCA to first
identify the distinct groups of women with similar patterns of social determinants, and then
assessed the impact of the clusters of these determinants on the study outcomes (a brief
description of LCA can be found in Appendix A). This is in line with the available
recommendations with respect to the use of dimensions to characterize SDoH, rather than
separate assessment of such overlapping indicators.
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2.

Chapter 2: Social Determinants of Health and Self-Rated Health Status:
A Comparison between Women with HIV and Women without HIV from
the General Population in Canada1

2.1. Introduction
Research has shown substantial improvements in health outcomes of people living with HIV
(PLWH) since the introduction of combination antiretroviral therapy (cART); for example, life
expectancy for those who receive cART has been approaching that of the general population.1,2
Despite the remarkable successes achieved in HIV outcomes, they are still not ideal, particularly
among women living with HIV. A recent Canadian study demonstrated that reductions in healthadjusted life expectancy among those living with HIV were larger for women than men.2 In
addition, Canadian studies have documented that a higher proportion of women experience
poorer “quality of care” in Canada, indicating the existence of gender inequities in access and
adherence to HIV treatment even in a universal healthcare system.3,4
Although HIV is now widely known as a chronic but manageable illness where appropriate
care and treatment services are accessible,5 multiple interpersonal and structural factors –
situated within social determinants of health (SDoH), continue to limit HIV care and treatment
efforts. The World Health Organization (WHO) defines the SDoH as “the conditions in which
people are born, grow, live, work, and age.”6 Researchers have described the contribution of
these socio-structural disadvantages in shaping the HIV epidemic among PLWH.7-9

1

A version of this chapter has been published: Shokoohi M, Bauer GR, Kaida A, et al. Social Determinants of
Health and Self-Rated Health Status: A Comparison between Women with HIV and Women without HIV from the
General Population in Canada. PLoS One. 2019;14(3):e0213901. doi:10.1371/journal.pone.0213901
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In turn, living with HIV can also cause greater vulnerability to socio-structural
disadvantages; for example, PLWH experience food insecurity even after an HIV diagnosis, and
employment loss, particularly among women.10,11 Despite advances in HIV interventions, PLWH
continue to experience challenges to maintaining their health due to the barriers linked with
SDoH.8,9,12 For example, socioeconomic inequities, housing instability, food insecurity, HIVrelated stigma, and discrimination have been correlated with poorer HIV care, treatment
responses, and clinical outcomes.10,12-17 Women living with HIV are a population that face
relatively lower socioeconomic status, and broader, systemic inequities that impact their health
and wellbeing.3,4
In Canada, women now represent nearly one-quarter of the estimated 75,500 PLWH.18
Women living with HIV in Canada are disproportionately from communities that experience
marginalization. For example, according to 2014 national surveillance data, 35.6% and 30.6% of
new HIV diagnoses in women were identified as Black and Indigenous (Aboriginal),
respectively.18 Canadian women living with HIV were shown having higher vulnerabilities to
substance use, particularly cigarette smoking and illicit drug use, than Canadian women with a
similar age/ethnoracial background.19 Additional experiences of disadvantage, with regard to
social determinants in particular, can result in poorer health outcomes, even in countries where
cART is widely available.9 However, the magnitude of inequalities in underlying socio-structural
barriers among WLWH compared with the broader population have not yet been investigated as
general population studies do not accurately identify HIV status, and HIV cohort studies often do
not include enough women to ensure robust comparison to the broader population to assess
differences. Understanding socio-structural barriers that WLWH face in excess of what would be
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expected is essential to minimize vulnerability to HIV, eliminate inequities in the HIV care
cascade, reduce vulnerabilities to poor outcomes, and improve health and well-being.
Therefore, this study took advantage of comparable measures in two large data sets— the
Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS) for women
living with HIV (WLWH) and the Canadian Community Health Survey (CCHS) for women of
the general population—to investigate socio-structural determinants and self-rated health status
among WLWH, and then compare them with the assumed HIV-negative general population of
women, standardizing for age and ethnoracial variables.
2.2. Methods

2.2.1 Study cohorts
CHIWOS: We used data from the Canadian HIV Women’s Sexual and Reproductive Health
Cohort Study (CHIWOS) of WLWH enrolled at time-point 1 between 2013 and 2015. As a
community-based research study, CHIWOS applied the Greater Involvement of People Living
with HIV/AIDS (GIPA) and Meaningful Involvement of Women Living with HIV/AIDS
(MIWA) principles such that WLWH were integral to all steps of the research process.20,21
CHIWOS enrolled 1,422 WLWH aged ≥ 16, residing in British Columbia (BC), Ontario, and
Quebec. Participants were recruited through peers, HIV clinics, AIDS Service Organizations,
and online networks.20 The survey was completed during an in-person interview at clinic or
community sites or participants’ homes, or via phone/Skype if this was not possible. Information
was collected using structured questionnaires, administered by trained Peer Research Associates
(PRA) in English or French. Participants provided written or oral informed consent at enrolment.
CHIWOS was approved by the Research Ethics Boards of Simon Fraser University, University
of British Columbia/Providence Health, Women’s College Hospital and McGill University
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Health Centre. CHIWOS was approved by the Research Ethics Boards of Simon Fraser
University, University of British Columbia/Providence Health, Women’s College Hospital and
McGill University Health Centre.
CCHS: The Canadian Community Health Survey (CCHS) is a nation-wide populationbased survey administered by Statistics Canada that collects self-reported data on various healthrelated information of approximately 65,000 Canadian residents annually.22 Briefly, the CCHS
uses a multistage, stratified cluster sampling design to target ~98% of Canadians aged ≥12 for
inclusion in all provinces and territories. The CCHS excludes people living on reserves, full-time
members of the Canadian Forces, the institutionalized residents, and residents of some remote
areas. For the purpose of the present research, we used Statistics Canada’s Public Use Microdata
Files to create a combined CCHS dataset within two years of 2013/2014. For consistency with
CHIWOS, we limited the CCHS’s analytic sample to women aged ≥16 years old, residing in the
three provinces (analytic sample = 46,851). To study day-to-day discrimination, we used the
CCHS-Rapid Response on the Everyday Discrimination Scale (EDS) performed separately in
2013 (analytic sample = 6,936). CCHS collects data using both computer-assisted personal and
telephone interviews. Statistics Canada’s Research Data Centre at the University of Western
Ontario provided researchers of the current study with access to the CCHS microdata.

2.2.2 Measures
The most widely used Canadian SDoH framework recognizes that the following socio-structural
determinants can help elucidate existing health differences: Aboriginal status, disability, early
life events, education, employment and working conditions, food insecurity, health services,
gender, housing, income and income distribution, race, social exclusion, social safety net, and
unemployment and job security.23 We chose only those measures whose content and/or wording
76

were similar in the question stems allowing the measures to be comparable between the two
surveys.
The following measures were compared: relationship status (single, living common-law or
married, and separated/widowed/divorced), education level (below high school, completed high
school, above high school to non-university degree, and obtained university degree), yearly
personal income (<$20,000, $20,000 to $39,999, ≥ $40,000, and Not Stated), yearly household
income (<$20,000, $20,000 to $39,999, and ≥ $40,000), and the main source of income
(wages/salaries [paid jobs], employment insurance/compensation/welfare, others [e.g., Dividends
and interest, Benefits from Pension Plan, no income, etc.], and don’t know/not stated).
CHIWOS examined food sufficiency and food security using Statistics Canada’s 4-item
adult measure from the Household Food Security Survey Module.24 The matched items were also
found in CCHS. Food sufficiency was measured with a question about past-year household food
sufficiency, with responses recoded into three categories: always had enough of the kinds of
food they wanted to eat, had enough but not always the kinds of food they wanted to eat, and
sometimes/often did not have enough to eat. Household food security over the last 12 months
was measured by three items, “worried that food would run out,” “The food did not last, and
there was no money to get more,” and “could not afford to eat balanced meals.” Binary response
options for each item were created as 1 for “Sometimes/Often true” and 0 for “Never true.” We
summed these three items to form a four-category ordinal measure: 0: food secure, 1: mildly
food insecure, 2: moderately food insecure, and 3: severely food insecure. CCHS did not
measure food security in BC; for comparability, we provided estimates for only Ontario and
Quebec in CHIWOS.
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Perceived social support was measured using a 4-item abbreviated version of the Medical
Outcome Study Social Support Survey (MOS-SSS),25 measuring four domains of
emotional/informational, tangible, affectionate, and positive social interaction. Possible
responses included strongly disagree (score 0), disagree, agree, and strongly agree (score 3) in
CCHS and a five-point Likert scale, with responses recoded into four categories as none of the
time (score 0), a little of the time, some or most of the time, and all of the time (score 3). Items
were summed (range 0–12 points), with higher scores implying greater perceived social support.
For the purpose of comparison, we created a binary measure with ≤6 indicating poorer social
support. The analysis was limited to data from Quebec as CCHS did not measure social support
in BC and Ontario.
Racial discrimination and gender discrimination measures were quantified using a
modified version of the Everyday Discrimination Scale,26 with 5-item version in CCHS and 6item version in CHIWOS. CCHS respondents were asked to specify how often they had
experienced various forms of day-to-day mistreatments “because of your race” or “because of
your gender.” Items included “You are treated with less courtesy or respect than other people,”
“You receive poorer service than other people at restaurants or stores,” “People act as if they
think you are not smart,” “People act as if they are afraid of you,” and “You are threatened or
harassed.” CHIWOS asked the first question in two separate items, “You are treated with less
courtesy,” and “You are treated with less respect.” The CCHS’s items were on a five-point scale
(at least once a week, a few times a month, a few times a year, less than once a year, never),
while they were on a six-point scale in CHIWOS (never, almost never, not that often, sometimes,
frequently, almost every day). Two three-category measures were created for racial and gender
discrimination, representing: never or almost never experienced any of the mistreatments,
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infrequent experience indicating less than once a year or not that often for any of the
mistreatments, and frequent experience indicating more than once, or sometimes, or more in a
year for any of the mistreatments.
Self-rated health status was measured in both surveys using a single question, “In general,
would you say that your health is…?” We included an ordinal variable with five possible
responses (excellent, very good, good, fair, and poor), and a binary recoded variable (poor/fair
vs. good/very good/excellent).

2.2.3 Statistical analyses
Proportions and associated 95% confidence intervals (CIs) for each measure were first estimated
in CHIWOS (i.e., observed estimates). Then, the proportion of the same measure was estimated
in the CCHS. Survey weights were incorporated into the analyses to account for the survey
complexity and provide population-level estimates. The 95% CIs were constructed through the
bootstrap variance estimation technique using a set of 500 replicates to account for the complex
survey design effects.27 Standardization method was used to account for the differences in
population structure by age and ethnoracial group (S Table 2.1). These two variables are
considered as important confounders representing non-modifiable characteristics that differ
between the study samples but are not a result of HIV status. To do this, we first produced a 16category variable representing CHIWOS’s age and ethnoracial group structure (i.e., age with
four categories: 16-35, 36-45, 46-55, or >55; and ethnoracial statues with four categories: white,
African, Caribbean, Black (ACB), Indigenous, or other/multi-ethnicities. We applied CHIWOS’s
combined age and ethnoracial distribution to the CCHS sample to make the two study
populations of CHIWOS and CCHS identical with regard to the distribution of these two
variables. After controlling the confounding impact of these two variables, we then provided the
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age-/ethnoracial-standardized estimates (i.e., expected estimates) of the SDoH measures and selfrated health. Standardization combines stratum-specific prevalence into a single summary
estimate through taking a weighted average.28
We reported the standardized prevalence differences (SPDs) to quantify the differences
between the two study samples for each SDoH measure as well as self-rated health. The SPDs
were calculated as the proportion of the observed estimates in CHIWOS minus the expected
estimates from the CCHS adjusted for age/ethnoracial group identity; with the SPDs > 0
indicating a greater proportion of the given determinant among WLWH and can be interpreted as
the proportion of WLWH experiencing an excess above what would be expected based on the
general population women. The 95% CIs were calculated using the methods of variance
estimates recovery (MOVER).29 CIs excluding 0 are indicative of statistical significance at
p<0.05. All analyses were performed using Stata version 15.
2.3. Results

2.3.1 Demographics
Women in the general population (CCHS data) were older than those in the CHIWOS sample:
34.4% of the general population women versus only 12.0% of WLWH were >55 years old.
Around three-quarter of general population women were White (75.2%) and the rest were either
Black (3.2%), Indigenous (2.4%) or other/multi ethnicities (19.2%). However, the ethnoracial
identities of CHIWOS sample were White (41.1%), African/Caribbean/Black (29.4%),
Indigenous (22.3%), and other ethnicities (7.2%). The distribution of age and ethnoracial groups
for both CHIWOS and CCHS is presented in (S Table 2.1).
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The mean age of all WLWH at time-point 1 was 42.8 (standard deviation [SD]: 10.6). The
majority identified as cisgender/non-transgender women (sex-labeled-at-birth and gender identity
congruent) (96%) while the rest identified as transgender women. Almost one-quarter (25.1%)
were living with HIV for 5 years or less, 40.2% were living with HIV for 6-14 years, and less
than one-third were living with HIV for more than 14 years. Overall, 61.0% were optimally on
HIV treatment (i.e., treatment adherence ≥ 95%), 22.0% were sub-optimally on HIV treatment
(treatment adherence < 95%), while the rest at time-point 1 of the survey were not engaged in
HIV treatment. Among those who were on treatment (either optimally or sub-optimally), 87.0%
reported an undetectable viral load (i.e., <50 copies/mL). The history of lifetime injection drug
use, sex work involvement, and incarceration was reported by 30.9%, 16.6%, and 36.9% of
WLWH, respectively (S Table 2.2).

2.3.2 Relationship, education, income and source of income
Proportions of indicators of relationship status, education, poverty, and main source of income
differed significantly between WLWH and estimates expected based on the age-/ethnoracialstandardized general population. The proportion who were single was higher among WLWH
compared with the general population (48.7% vs. 26.6%; SPD 22.1% [95% CI: 18.8, 25.4]),
while a lower proportion of WLWH reported being married or in a common-law relationship
status than their general population counterparts (32.1% vs. 55.3%; SPD -23.2% [95% CI: -26.7,
-19.6]). A lower proportion of WLWH had a university education than the general population
(14.1% vs. 27.9%; SDP -13.7% [95% CI: -16.8, -10.6]), whereas a higher proportion had an
education level of less than high school (16.1% vs. 12.3%; SPD 3.8% [95% CI: 1.5, 6.1]). More
than two-thirds (70.3%) of WLWH versus less than one-third (28.1%) of women of the general
population reported a personal income <$20,000 annually, yielding an SPD 42.2% (95% CI:
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39.1, 45.2). A higher proportion of WLWH also reported a household income <$20,000 than the
estimate expected in the general population sample (65.3% vs. 10.9%; SPD 54.4% [51.5, 57.3]).
Finally, 22.1% of WLWH compared with 69.9% of their counterparts in the general population
reported having wages/salaries (i.e., paid jobs) as their main source of income (SPD -47.8% [50.9, -44.6]), while a high proportion of WLWH (62.2%) reported having an employment
insurance/compensation/welfare as their main source of income versus only 9.5% of the general
population women (SPD 52.7% [95% CI: 49.5, 55.8]) (Table 2.1).
Table 2.1: Comparing Sociodemographic Variables of Women Living with HIV
(CHIWOS; 2013-2015) and the General Population of Women in Canada (CCHS; 20132014)
CHIWOS*

(1)

CCHS estimates*
CCHS

£

SPD¥

AER Std.†
(2)

(1) – (2)

Relationship status
Single

Married or common-law

Separated/divorced/widowed

48.7

24.3

26.6

22.1

(46.1, 51.3)‡

(23.7, 24.8)

(24.6, 28.7)

(18.8, 25.4)

32.1

58.0

55.3

-23.2

(29.7, 34.6)

(57.3, 58.7)

(52.7, 57.9)

(-26.7, -19.6)

19.2

17.7

18.1

1.1

(17.2, 21.3)

(17.2, 18.3)

(15.8, 20.4)

(-1.9, 4.2)

16.1

15.4

12.3

3.8

(14.2, 18.1)

(14.9, 16.0)

(11.0, 13.6)

(1.5, 6.1)

37.6

24.7

23.9

13.7

(35.1, 40.2)

(24.0, 25.4)

(21.9, 25.9)

(10.5, 16.9)

32.2

30.6

35.9

-3.7

(29.8, 34.7)

(29.8, 31.3)

(33.4, 38.4)

(-7.1, -0.11)

Education
Less than high school

High school completed

Diploma/trade/college
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University degree

14.1

29.3

27.9

-13.8

(12.4, 16.1)

(28.6, 30.1)

(25.4, 30.4)

(-16.8, -10.6)

70.3

29.1

28.1

42.2

(67.8, 72.6)

(28.4, 29.9)

(26.1, 30.0)

(39.1, 45.2)

17.2

24.8

24.5

-7.3

(15.3, 19.3)

(24.1, 25.5)

(22.4, 26.7)

(-10.1, -4.1)

10.1

30.0

33.1

-23.0

(8.7, 11.8)

(29.2, 30.8)

(30.4, 35.8)

(-26.1, -19.5)

2.4

16.1

14.3

-11.9

(1.7, 3.3)

(15.5, 16.8)

(12.3, 16.3)

(-14.0, -9.7)

65.3

9.3

10.9

54.4

(62.8, 67.8)

(8.9, 9.8)

(9.5, 12.3)

(51.5, 57.3)

20.6

20.4

18.9

1.7

(18.5, 22.8)

(19.7, 21.0)

(16.8, 21.1)

(-1.29, 4.74)

14.1

70.3

70.2

-56.1

(12.3, 16.0)

(69.6, 71.1)

(67.8, 72.6)

(-59.1, -53.0)

22.1

59.2

69.9

-47.8

(20.0, 24.3)

(58.4, 60.1)

(67.6, 72.2)

(-50.9, -44.6)

Employment insurance/

62.2

4.8

9.5

52.7

compensation / welfare

(59.6, 64.7)

(4.40, 5.1)

(7.6, 11.4)

(49.5, 55.8)

15.0

29.4

17.0

-2.0

(13.3, 17.0)

(28.7, 30.0)

(15.7, 18.3)

(-4.1, 0.4)

0.70

6.6

3.6

-2.9

(0.38, 1.30)

(6.2, 7.1)

(2.6, 4.6)

(-3.9, -1.7)

(≥Bachelor’s degree)
Yearly personal income

a

<20,000 CAD b

20,000 to <40,000 CAD
≥ 40,000 CAD

Not stated

Yearly household income
<20,000 CAD

20,000 to <40,000 CAD
≥ 40,000 CAD

Main source of income
Wages/salaries (paid jobs)

Others (ex. dividends and
interest, pension, no income,
etc.))
Don’t know or not stated
*

The Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS; N=1,422) and the
Canadian Community Health Survey (CCHS; analytic N=46,851); ‡ Data are % (95% Confidence Intervals (CIs)); £
Unstandardized weighted estimates are reported from CCHS; † AER Std.: Age- and ethnoracial-standardized
expected estimates from CCHS; ¥ SPD: standardized prevalence difference (% (95% CIs)), with positive (negative)
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values indicating higher (lower) prevalence in WLWH in excess of (less than) what would be expected of Canadian
women of similar ages/ethnoracial backgrounds; a aged > 17 years old; b Canadian dollar (CAD)

2.3.3 Food security
Proportions of food insufficiency and food insecurity were substantially higher in WLWH
compared with expected estimates from the general population women. A higher proportion of
WLWH reported sometimes or often their household did not have enough to eat over the last 12
months (15.7% vs. 2.6%; SPD 13.1% [95% CI: 10.9, 15.7]), and had enough but not always the
kinds of food (53.7% vs. 15.3%; SPD 38.4% [95% CI: 34.4, 42.4]). The analysis of the
individual items of food security scale showed that a higher proportion of WLWH reported their
household sometimes/often “worried that food would run out before you got money to buy
more” (65.7% vs. 17.9%), “the food bought didn’t last and there wasn’t any money to get more”
(62.9% vs. 14.3%), and “couldn’t afford to eat balanced meals” (62.7% vs. 14.0%). Overall, a
higher proportion of WLWH reported experiencing severe (54.1% vs. 10.2%; SPD 43.9% [95%
CI: 40.2, 47.5]), moderate (10.3% vs. 5.3%; SPD 5.0% [95% CI: 2.6, 7.6]), and mild (8.2% vs.
5.2%; SPD 3.0% [95% CI: 1.1, 5.1]) food insecurity than the expected values in the general
population (Table 2.2).
Table 2.2: Comparing Food Sufficiency and Food Security between Women Living with
HIV (CHIWOS; 2013-2015) and the General Population of Women in Canada (CCHS;
2013-14)
CHIWOS*

(1)

CCHS estimates*
CCHS

£

SPD¥

AER Std.†
(2)

(1) – (2)

82.0

-51.5

Food sufficiency
Always had enough of

30.5

89.6

84

(27.8, 33.4)‡

(88.9, 90.2)

(79.2, 84.8)

(-55.4, -47.5)

53.7

9.1

15.3

38.4

always the kinds of food

(50.7, 56.7)

(8.5, 9.7)

(12.7, 18.0)

(34.4, 42.4)

Sometimes or often did

15.7

1.3

2.6

13.1

not have enough to eat

(13.7, 18.1)

(1.1, 1.6)

(1.7, 3.6)

(10.9, 15.7)

34.3

90.8

82.1

-47.8

(31.5, 37.2)

(90.2, 91.4)

(79.5, 84.7)

(-51.5, -43.8)

65.7

9.2

17.9

47.8

(62.7, 68.5)

(8.6, 9.8)

(15.3, 20.5)

(43.8, 51.5)

37.1

93.3

85.7

-48.5

(34.3, 40.1)

(92.7, 93.9)

(83.3, 88.0)

(-52.2, -44.7)

62.9

6.7

14.3

48.5

(59.9, 65.7)

(6.1, 7.2)

(12.0, 16.7)

(44.7, 52.2)

37.3

92.8

86.0

-48.6

(34.4, 40.3)

(92.2, 93.3)

(83.5, 88.4)

(-52.4, -44.8)

62.7

7.2

14.0

48.6

(59.7, 65.5)

(6.6, 7.7)

(11.6, 16.5)

(44.8, 52.4)

27.4

88.6

79.3

-51.9

(24.8, 30.2)

(88.0, 89.3)

(76.7, 82.0)

(-55.6, -48.0)

8.2

4.1

5.2

3.0

(6.7, 10.0)

(3.7, 4.5)

(4.1, 6.4)

(1.1, 5.1)

10.3

2.7

5.3

5.0

(8.6, 12.3)

(2.4, 3.0)

(3.6, 6.9)

(2.6, 7.6)

54.1

4.5

10.2

43.9

the kinds of food
Had enough, but not

Food security items
Item 1) Food run out
Never

Sometimes/often

Item II) Food did not last
Never

Sometimes/often

Item III) Could not afford
for balanced meal
Never

Sometimes/often

Overall Food security

a

Food secure

Mildly food insecure

Moderately food insecure

Severely food insecure
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(51.0, 57.0)

(4.0, 5.0)

(8.1, 12.2)

(40.2, 47.5)

CHIWOS-Ontario/Quebec (N=1,066) and CCHS-Ontario/Quebec (N=33,704); ‡ Data are % (95% Confidence
Intervals (CIs)); £ Unstandardized weighted estimates are reported from the Canadian Community Health Survey
(CCHS); † AER Std.: Age- and ethnoracial-standardized expected estimates from CCHS; ¥ SPD: standardized
prevalence difference (% (95% CIs)), with positive (negative) values indicating higher (lower) prevalence in
WLWH in excess of (less than) what would be expected of Canadian women of similar ages/ethnoracial
backgrounds; a The summation of three binary items (0, indicating Never true and 1, indicating sometimes/often
true) of the scale produced an index ranging from 0 to 3; 0: food secure, 1: mild food insecurity, 2: moderate food
insecurity, and 3: severe food insecurity.
*

2.3.4 Social support and discriminations
Analyzing the overall binary measure of perceived social support showed that a higher
proportion of WLWH reported poorer social support compared with the general population
women adjusted for age and ethnoracial group status (30.3% vs. 2.9%; SPD 27.4% [95% CI:
22.2, 33.0]). WLWH reported experiencing frequent racial discrimination (46.4% vs. 9.6%; SPD
36.8% [95% CI: 31.9, 41.8]) and frequent gender discrimination (54.4% vs. 8.4%; SPD 46.0%
[95% CI: 42.6, 51.6]) than the expected values of the general population women (Table 2.3).
Table 2.3: Comparing Social Support, and Racial and Gender Discrimination between
Women Living with HIV (CHIWOS; 2013-2015) and the General Population of Women in
Canada (CCHS; 2013-2014)
CHIWOS

(1)

CCHS estimates
CCHS

£

SPD¥

AER Std.†
(2)

(1) – (2)

Perceived social support*,a
Poor

Good

30.3

1.9

2.9

27.4

(25.6, 35.5)‡

(1.5, 2.3)

(0.7, 5.1)

(22.2, 33.0)

69.7

98.1

97.1

-27.4

(64.5, 74.4)

(97.7, 98.5)

(94.9, 99.3)

(-33.0, -22.2)

45.6

93.5

87.1

-41.5

Race discrimination**
Never
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Infrequent

Frequent

(43.0, 48.2)

(92.2, 94.8)

(82.2, 92.1)

(-47.1, -36.0)

8.0

1.1

3.3

4.7

(6.7, 9.6)

(0.65, 1.48)

(0.5, 6.1)

(1.7, 7.9)

46.4

5.4

9.6

36.8

(43.8, 49.0)

(4.1, 6.6)

(5.3, 13.8)

(31.9, 41.8)

37.5

89.3

89.4

-51.9

(35.0, 40.0)

(88.2, 90.5)

(87.0, 91.7)

(-55.3, -48.4)

8.2

2.6

2.2

6.0

(6.9, 9.7)

(2.1, 3.1)

(1.2, 3.2)

(4.3, 7.8)

54.4

8.1

8.4

46.0

(51.8, 56.9)

(7.0, 9.0)

(6.2, 10.6)

(42.6, 51.6)

Gender discrimination**
Never

Infrequent

Frequent
*

CHIWOS-Quebec (N=355) and CCHS-Quebec (N=11,780); ** CHIWOS-all N=1,422 and CCHS rapid survey
(N=6,936); ‡ Data are % (95% Confidence Intervals (CIs)); £ Unstandardized weighted estimates are reported from
the Canadian Community Health Survey (CCHS); † AER Std.: Age- and ethnoracial-standardized expected
estimates from CCHS; ¥ SPD: standardized prevalence difference (% (95% CIs)), with positive (negative) values
indicating higher (lower) prevalence in WLWH in excess of (less than) what would be expected of Canadian women
of similar ages/ethnoracial backgrounds; a The summation of four items, each having four options (0 to 3), produced
an index ranging from 0 to 12; with a lower score indicating lower level of social support. A binary measure was
created based on the mid-point threshold score: score mid-point or below (i.e., ≤ 6) indicated poor/low perceived
social support, and scores above mid-point (i.e., > 6) indicated better/good perceived social support.

2.3.5 Overall health status
A higher proportion of WLWH reported poor and fair overall health status than the estimates
expected based on the age-/ethnoracial-standardized assumed HIV-negative women. The
aggregated proportion of these two options (i.e., fair/poor health condition), indicating a lower
level of overall health status, was higher among WLWH than the general population women
(24.8% vs. 12.6%; SPD: 12.2% [95% CI: 9.4, 15.0]) (Table 2.4).
Table 2.4: Comparing Self-rated Overall Health Status between Women Living with HIV
(CHIWOS; 2013-2015) and the General Population of Women in Canada (CCHS; 20132014)
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CHIWOS

Self-rated health

CCHS estimates
CCHS

£

SPD¥

AER Std.†
(2)

(1) – (2)

20.7

21.9

-13.6

(6.9, 9.8)

(20.0, 21.4)

(19.5, 24.2)

(-16.3, -10.8)

26.9

37.5

35.8

-8.9

(24.6, 29.3)

(36.7, 38.3)

(33.6, 37.9)

(-12.0, -5.7)

40.1

30.0

29.7

10.3

(37.5, 42.6)

(29.1, 30.8)

(27.3, 32.1)

(6.8, 13.8)

19.0

8.8

8.9

10.2

(17.1, 21.2)

(8.3, 9.2)

(7.5, 10.2)

(7.8, 12.7)

5.7

3.0

3.7

2.0

(4.6, 7.1)

(2.8, 3.3)

(2.8, 4.7)

(0.51, 3.6)

75.2

88.2

87.4

-12.2

(72.9, 77.4)

(87.6, 88.7)

(85.8, 89.0)

(-15.0, -9.4)

24.8

11.8

12.6

12.2

(22.6, 27.1)

(11.3, 12.3)

(11.0, 14.2)

(9.4, 15.0)

(1)

A five-category measure
Excellent

8.3
‡

Very good
Good
Fair
Poor
A binary measure
Excellent/v. good/good
Fair/poor
*

The Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS; N=1,422) and the
Canadian Community Health Survey (CCHS; analytic N=46,851); ‡ Data are % (95% Confidence Intervals (CIs)); £
Unstandardized weighted estimates are reported from CCHS; † AER Std.: Age- and ethnoracial-standardized
expected estimates from CCHS; ¥ SPD: standardized prevalence difference (% (95% CIs)), with positive (negative)
values indicating higher (lower) prevalence in women living with HIV (WLWH) in excess of (less than) what would
be expected of Canadian women of similar ages/ethnoracial backgrounds.

2.4. Discussion
Drawing on data from the largest cohort study of WLWH in Canada, we found that 42.2% and
43.9% of WLWH respectively reported an annual personal income <$20,000—a low income cutoff indicating poverty—and severe food insecurity, in excess of what would be expected of
Canadian women of similar ages/ethnoracial backgrounds. Additionally, a higher proportion of
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WLWH reported experiencing the proxy indicators for social exclusion including poor perceived
social support, and racial and gender discriminations compared with what would be expected.
The self-rated health, as a proxy but holistic measure of health, was also lower in WLWH. While
previous research highlighted the greater socio-structural disadvantages and economic hardships
among WLWH, we are not aware of previous comparisons between these two populations.
Although this analysis did not permit assessment of whether living with HIV exacerbated
inequities in SDoH or whether such inequities increase risk of acquiring HIV or (likely) a
mixture of both, a large proportion of WLWH in Canada are living with multiple and
overlapping disadvantages with regard to social and economic participation is unjust and of huge
concern. The concentration of financial hardship, food insecurity, and social exclusion – with
having the potential for exposure to increased magnitude of chronic and acute stressors, poses a
wide range of barriers that negate the ability of individuals to consistently engage in the HIV
care/treatment cascade, e.g., retention in care30 and cART initiation and continuation,12 and
further undermine attempts to optimize treatment outcomes. Recent studies have documented the
role of food insecurity, for example, on cART non-adherence and incomplete HIV viral
suppression.10,15 Such level of risk has also been realized for social exclusion determinants14 as
found notably prevalent in WLWH in the present study. These findings highlight the need for
multi-component interventions targeted at SDoH inequity reduction, particularly in those women
with an increased risk for treatment interruptions, discontinuation, and non-adherence due to
limited socio-structural resources.
The substantial differences in the study determinants and self-assessed health identified
between the two samples would provide evidence on the socio-structural determinants of
WLWH to aid with policy development and resource allocation. Given the concern surrounding
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the growing proportion of WLWH in Canada,18 our findings have implications for evoking calls
for gender-specific tailored service, a complex and multidimensional model of care and service
delivery, as the current care approaches appear to be inadequate to address women's
comprehensive needs. The women-centered model of HIV care that has already been envisioned
by target population is recommended to be a useful model of care for guiding policy and practice
to improve care and health outcomes.31 Such models of care require targeting the persistent
health inequalities in women with HIV, relative to either men with HIV3,4 or women of the
general population, through a social-determinants framework, an approach in which a wide range
of disciplines contribute to addressing the underlying barriers and reducing health inequities.32
The socio-structural approach of addressing the fundamental causes of health inequities are
imperative to achieve the UNAIDS “90-90-90 targets”—the universal commitments of HIV
epidemic elimination by 2030.33
This analysis has also significant implications for designing strategies that support WLWH
through social service programs, and reinforcing social support and resilience with the objective
of facilitating women’s access to care, promoting health and wellbeing, health equity, and social
justice. Programs supporting social service delivery have important implications, especially now
that HIV care has shifted toward chronicity. The provision of transportation supports, financially
accessible complementary services, and providing flexible program schedules can facilitate
access to care among women with socio-economical disadvantages.34 The integration of social
programs into health service delivery can help address socio-structural adversities and facilitate
women's participation in HIV care.
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2.4.1 Strengths and Limitations
To our knowledge, this is the first research investigating the inequities with socio-structural
determinants of health and the self-rated health between WLWH and assumed HIV-negative
women of the general population. However, this study is not without limitations. First, we
compared the health determinants among WLWH with the assumed HIV-negative women of the
general population. However, due to small population estimates of WLWH in Canada—97 per
100,000 females18—we believe the inclusion of WLWH in the comparison group would not
substantially impact on our findings. Furthermore, the substantial differences identified between
the two surveys may be partly due to differences in population structure other than
age/ethnoracial group, factors which were not accounted for in standardization. Moreover, selfreport data may be prone to social desirability bias, particularly in CCHS data. CHIWOS
attempted to mitigate the impact of this bias using trained peer research associates (PRAs), who
shared an experience of living with HIV, to administer the surveys. Also, CHIWOS’s nonrandom sampling design may undermine the generalizability of these findings.

2.4.2 Conclusion
These findings provide information on the upstream determinants of health inequalities in
WLWH indicating that a high proportion of WLWH in Canada experienced much worse
economic hardships, food insecurity, social exclusions as well as poor/fair self-reported health,
in excess of what would be expected. These findings support the need for the integration of
socio-structural approaches and health equity into practice to address women’s unique needs.
These findings also advocate for social service delivery and programming as well as further
resource allocation to reduce socially constructed, unjust, and avoidable inequalities in health in
this population. Addressing these needs when providing individual-tailored HIV care and
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treatment services will promote the clinical care of a sizable proportion of women with HIV
living in poverty. Future research needs to focus on targeted exclusion-reduction interventions,
e.g., poverty- and discrimination-reduction strategies, in this population. Future research could
also assess the independent and/or clustered impact of these social determinants of health (e.g.,
race discrimination, gender discrimination) plus other relevant social determinants in the field of
HIV such as HIV-related stigma on health outcomes of WLWH. Applying advanced statistical
techniques such as decomposition analysis35 – a technique to assess health inequalities through
decomposing the overall inequality in the study outcomes into the inequality in each contributing
determinants, and latent class analysis (LCA)36 – a method to identify the latent class/clusters of
individuals who experience the unique adversities with respect to the social determinants, can
help researchers better explore the association of these determinants with HIV outcomes. This
data on SDoH inequalities can help investigators develop interventions to address disparities
experienced by WLWH to improve their health outcomes, and identify mechanisms through
which these determinants may reinforce or directly contribute to inequitable vulnerabilities
among WLWH.
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2.5. Supplementary Tables
S Table 2.1: Age-Ethnoracial Distributions of both the CHIWOS (2013-2015) Cohort of
Women Living with HIV and the CCHS (2013-2014) Data of the Corresponding General
Population Women in Canada.
CHIWOS estimates

CCHS estimates

(N=1,422)

(N=46,851)a

%

Unstandardized

Standardized

%

%

Ethnoracial and age groups
16-35 (years)

10.2b

21.1c

10.2d

36-45

11.4

11.2

11.4

46-55

12.5

13.9

12.5

> 55

7.0

29.0

7.0

16-35

7.5

1.1

7.5

36-45

11.5

0.7

11.5

46-55

7.8

0.8

7.8

> 55

2.6

0.7

2.6

Indigenous 16-35

7.0

1.0

7.0

36-55

8.4

0.4

8.4

36-45

5.2

0.4

5.2

46-55

1.7

0.6

1.7

16-35

1.4

7.9

1.4

36-45

2.4

4.4

2.4

46-55

2.6

3.1

2.6

> 55

0.8

3.7

0.8

White

Black

Others

a

Out of 128,310 respondents, 46,851 (36.5%) were the corresponding general population women for the current
study: women aged 16+ residing in three provinces of BC, ON, QC; b Data are presented as percentages; d Chi
Square test showed a significant difference between the two samples of CHIWOS and unstandardized CCHS (Pvalue < 0.001); c Standardization made the two study populations of CHIWOS and CCHS identical with regard to
the distribution of age and ethnoracial group.
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S Table 2.2: Characteristics of Women Living with HIV (WLWH) – the Baseline Survey of
the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS),
2013-2015
Variables

Age, year (mean [SD])

n (%) or mean [SD]

42.8 [10.6]

Age groups (years) (N = 1,422)
16-35

372 (26.2)

36-45

479 (33.7)

46-55

400 (28.1)

> 55

171 (12.0)

Ethno-racial group (N = 1,422)
White

584 (41.1)

African/Caribbean/Black

418 (29.4)

Indigenous

318 (22.3)

Other

102 (7.2)

Study province (N = 1,422)
Ontario

717 (50.4)

British Columbia

356 (25.0)

Quebec

349 (24.6)

Years living with HIV (N = 1,374)
< 6 years

345 (25.1)

6-14 years

552 (40.2)

> 14 years

477 (34.7)

Taking treatment (N = 1,415)
Yes, optimal (≥ 95%)

863 (61.0)

Yes, suboptimal (< 95%)

312 (22.0)

Not engaged in treatment

240 (17.0)

Undetectable (50 copies/mL) viral load among WLWH on

1018 (87.0)
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treatment (N=1,170)
History of injection drug use (N = 1,421)
History of sex work involvement (N=1,321)
History of incarceration (N=1,420)

439 (30.9%)
219 (16.6)
5246.9)
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3.

Chapter 3: Substance use patterns among women living with HIV
compared with the general female population of Canada1

3.1. Introduction
Substance use is a common health risk behaviour among people living with HIV (PLWH), who
have a demonstrated greater prevalence than their general population counterparts.1-3 Substance
use is considered a major barrier to successful HIV care and treatment4-9 despite the substantial
advances obtained from combination antiretroviral therapy (cART), e.g., improved life
expectancy in PLWH.10 Substance use independently or by interaction with other factors such as
psychiatric disorders and socioeconomic marginalization has the potential to limit the remarkable
benefits of cART and pose additional barriers to HIV prevention efforts and medical care.6-9,11-14
Previous studies have reported the negative impacts of tobacco smoking,12 problematic
alcohol consumption,13 and illicit drug use (e.g., heroin)4,8 on HIV care cascade outcomes. The
optimal levels of these outcomes such as retention in care and adherence to HIV treatment are
critical in promoting the health of PLWH and maintaining treatment as prevention (TasP)
targets.15 Beyond its interruption of care and treatment, substance use can also interfere with
cART metabolism and virological response,16,17 and contribute to excess mortality.12,18 For
example, in a study of 17,995 PLWH on treatment, smoking increased the rate of death by 1.94
times, with 1.84 and 2.41 times in men and women with HIV, respectively.18

1

A version of this chapter has been published: Shokoohi M, Bauer GR, Kaida A, et al. Substance use patterns
among women living with HIV compared with the general female population of Canada. Drug Alcohol Depend.
2018 Oct 1;191:70-77. doi: 10.1016/j.drugalcdep.2018.06.026.
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Substance use vulnerability appears to have greater impacts on HIV and clinical outcomes
among women than men with HIV. For example, women with injection drug use (IDU) history
and Indigenous ancestry had lower optimal adherence to treatment (47.8%) relative to their male
HIV-positive counterparts with (57.7%) and without (83.8%) such vulnerabilities.19 Women with
IDU history were also found to be 18% less likely to achieve HIV RNA viral suppression than
their male counterparts.20 Other than the unique experiences of HIV infection among women
(e.g., pregnancy), drug use along with greater experiences of other psychosocial, economic and
structural challenges may account for gender-related differences in HIV outcomes.20-22
However, substance use prevalence among women living with HIV (WLWH) has not been
well-characterized, particularly in Canada. Population-based research has either overlooked
collecting data on WLWH, or has not had adequate sample size to provide estimates for WLWH
and comparisons to the broader population.23,24 Women now constitute more than half of all
individuals living with HIV worldwide25 and represent nearly one-fourth of the estimated 75,500
PLWH in Canada; almost doubled from the 1990s.26 Understanding the prevalence of substance
use in a geographically diverse sample of WLWH relative to general population women is
important because of the profound implications for HIV management and to assess the need for
harm reduction and socio-structural supports for women who use substances.
Therefore, the objective of this research was to characterize the prevalence of cigarette
smoking, alcohol consumption, non-prescribed cannabis use, and illicit drug use from the
Canadian HIV Women’s Sexual and Reproductive Cohort Study (CHIWOS), a large
community-based study of WLWH in Canada. We estimated the prevalence for substance use in
CHIWOS, and compared them with data from HIV-negative women of the general population,
standardized to the age/ethnoracial distribution of WLWH. Our aim was to document substance
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use disparities among WLWH, to explore differences based on HIV status and to identify needs
with regard to resource allocation, particularly given the implications of substance use in the
context of HIV-related medical care.
3.2. Methods

3.2.1 Participants
CHIWOS sample: We used data from the baseline survey of the Canadian HIV Women’s Sexual
and Reproductive Health Cohort Study (CHIWOS) conducted between 2013 and 2015.
CHIWOS is a large community-based study of WLWH (≥16 years; 3.8% trans women), residing
in British Columbia (BC), Ontario, and Quebec. Study design and sampling procedure were
published elsewhere.27 Briefly, we applied the Meaningful Involvement of Women Living with
HIV/AIDS principle, reflecting the recognition of the rights and responsibilities of individuals
living with HIV as equal partners to actively engage throughout the design and delivery of
HIV/AIDS services to strengthen the responses to HIV/AIDS epidemics.28 A sample of 1,422
WLWH were recruited from HIV clinics, AIDS Service Organizations, peers, and online
networks.24 The survey was administered by Peer Research Associates (PRAs), many of whom
also shared the experience of living with HIV, who were hired and trained in community-based
research conduction.27 The average 120-minute-long surveys were administered either through
in-person interviews at clinic, community sites, or participants’ homes, or via phone/Skype.
CHIWOS was approved by the Research Ethics Boards of Simon Fraser University, University
of British Columbia/Providence Health, Women’s College Hospital and McGill University
Health Center.
CCHS sample: We used data from the 2013-2014 cycle of the Canadian Community
Health Survey (CCHS), a nation-wide cross-sectional survey administered by Statistics Canada.
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Detailed documentation is available elsewhere.29 Briefly, CCHS is designed to provide
nationally representative estimates on health status, health care utilization, and health
determinants of Canadians aged 12 years or older residing in private dwellings of all provinces
and territories (~98% coverage), excluding populations living on reserves/Indigenous
settlements, institutions, Canadian Force Bases, and some remote regions. Data are collected
using computer assisted personal and telephone interview software. Consistent with CHIWOS,
CCHS analyses were restricted to women aged ≥16 years old, residing in the three provinces
(analytic sample = 46,851). Measures of cigarette smoking, alcohol consumption, non-prescribed
cannabis use and illicit drug use with similar content and wording were compared between the
two surveys.

3.2.2 Measures
Although cigarette smoking and alcohol consumption were collected from all CCHS
respondents, measures of drug use were not collected in Ontario and Quebec; for comparability,
we provided estimates of drug use for only BC participants in CHIWOS.
Cigarette smoking: In CHIWOS, cigarette smoking history was measured as, “What is
your cigarette (tobacco) smoking history?” with four response options (regular, occasional,
former, and never). In CCHS, the same question was asked with three response options (daily,
occasionally, not at all). To be consistent with the CCHS definition, we categorized WLWH who
reported at least one cigarette/day (equivalently, at least 30 cigarettes/month) as “daily” smokers
irrespective of how they were self-identified. As such, 67 self-identified occasional smokers
were recoded as daily smokers and two cases who reported cigarette smoking regularly were
recoded as occasional smokers. Two measures were created to compare the two surveys: a)
nonsmokers at the time of interview (i.e., former or none) versus current smokers (i.e., daily or
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occasional), and b) a three-category measure: nonsmokers, occasional smokers, and daily
smokers. We also reported cigarette smoking intensity/quantity among current smokers. A fivecategory measure was created to compare the two surveys: nonsmokers (former or never), <1
cigarette/day or <30 cigarettes/month, 1-10 cigarettes/day, 11-19 cigarettes/day, and ≥20
cigarettes/day.
Alcohol consumption: Last-year alcohol consumption pattern was examined in both
CHIWOS and CCHS. A four-category comparable measure was created in each survey: none
(did not drink in the past 12 months), ≤1 time/week, 2-3 times/week, and ≥4 times/week. CCHS
measured the monthly pattern of binge drinking as, “How often in the past 12 months have you
had 4 or more drinks on one occasion?” with six response categories: never, less than once a
month, once a month, 2 to 3 times a month, once a week, and more than once a week. The same
question but in the last month was measured in CHIWOS, with an open-ended response option
indicating the number of times. Binge drinking was compared between the two surveys under the
assumption that past-year binge drinking patterns were consistent with past month. We created a
measure with similar response categories: no alcohol consumed, alcohol consumed but no binge
drinking, binge drinking less than once a week (i.e., equivalently, less than 3 times a month), and
binge drinking at least once a week (i.e., equivalently, four times or more a month). In CHIWOS,
33 women reported last-month binge drinking without specifying the number of times over the
last month; therefore, instead of treating them as missing values, we categorized them into “less
than once a week.”
Drug use: We compared the use of the following drugs available in the two surveys in BC:
cannabis, cocaine or crack, speed (amphetamine), and heroin. CCHS asked respondents, “Have
you used [any of these drugs] in the past 12 months?”, affirmative responses were further
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followed, “How often [did you use any of these drugs in the past 12 months]?” with the
following response options: less than once/ month, 1 to 3 times/month, once/week, more than
once/week, and every day. CHIWOS measured cannabis use as, “What is your cannabis use
history?” with the following response categories: a) regularly in the last 30 days, b) occasionally
in the last 30 days, c) used in the past year but not in the past 30 days, d) used in the past but not
in the past year, e) never used or only ever used it once or twice. To be consistent with CCHS,
CHIWOS’s response options ‘b’ and ‘c’ were considered as occasional cannabis use. CHIWOS
participants with a positive history of cannabis use were also followed, “Have you used cannabis
mainly for medicinal reasons or recreational reasons, or both?” We recoded medicinal
(prescribed) use of cannabis use as non-recreational use, while any other recreational reasons
(alone or in combination with medicinal use) were considered as non-prescribed cannabis use.
This distinction was made as CCHS aimed to measure the use of illicit drugs, but not
prescription drugs.
CHIWOS assessed the use of crack or cocaine, speed, and heroin over the last 3 months.
Positive responses were additionally followed to measure the frequency of use as, daily, at least
once/week, and less than once/week. The same information was assessed in CCHS, but over the
past year. Crack and cocaine use were measured in one single question in CCHS, while
CHIWOS measured them separately. Therefore, daily use of any of these two drugs was
considered as daily crack or cocaine use.
For the purpose of comparison, we created a three-category measure for cannabis use and
crack or cocaine use as: none (i.e., former or never), occasional (< once/week), and regular use
(≥ once/week). As the absolute “n” for speed (amphetamine) and heroin use did not meet the
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minimum CCHS vetting guideline, we combined regular and occasional use and then created a
binary variable for each of these two drugs: none vs. occasional/regular use.

3.2.3 Data analysis
We reported the prevalence and the 95% confidence intervals (CI) of each substance from the
CHIWOS sample. We then obtained the prevalence of the same substances from the CCHS
sample, using sampling weights that Statistics Canada assigned each respondent to correspond to
the number of Canadian residents they represent. The bootstrap variance estimation technique
using a set of 500 replicates was used to obtain the 95% CI of the CCHS estimates.30 To address
the imbalanced distribution of age and ethnoracial groups, we used a standardization method
which combines stratum-specific prevalences into a single summary estimate through taking a
weighted average.31 Standardization obtains these weights in averaging from a standard
population. In the present study, these weights were obtained from the CHIWOS data set and
applied to CCHS data. To do this, we created a 16-category variable representing CHIWOS’s
age and ethnoracial group distribution (i.e., four age categories: 16-35, 36-45, 46-55, or >55; four
ethnoracial categories: white, African, Caribbean, Black (ACB), Indigenous, or other/multiethnicities). We then applied CHIWOS’s age and ethnoracial group distribution to CCHS to
produce a second set of estimates in which CCHS and CHIWOS samples had a similar
distribution with respect to these two variables.
The standardized prevalence differences (SPD) were reported to quantify the differences
between the two surveys for each substance use. The SPD is a commonly used measure for the
purpose of population health assessment and provides information on the public health impact.
The SPD was computed by subtracting the CCHS expected estimates standardized to age and
ethnoracial groups from the CHIWOS observed estimates; with an SPD greater than zero (i.e.,
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the null) denoting a greater prevalence of the given substance in WLWH. The SPD’s 95% CI
was provided using the methods of variance estimates recovery (MOVER),32 with 95% CI
excluding 0 indicating statistical significance at p<0.05. The analyses were performed using
Stata version 15.
3.3. Results

3.3.1 Demographics
WLWH differed from the unstandardized general population data by age and ethnoracial groups
as well as relationship status, education and yearly personal income levels (Table 3.1). Greater
proportions of women in the unstandardized general population were older and belonged to
white ethnoracial group than WLWH. Other characteristics of these two samples are presented in
Table 3.1, along with the prevalences in the standardized CCHS data. After standardization, the
CCHS estimates had identical age and ethnoracial group structure. All subsequent comparisons
of substance use were conducted using standardized data.
Overall 83% and 87% of WLWH reported taking HIV medication and having a suppressed
viral load (i.e., <50 c/mL), respectively. The median time living with HIV since diagnosis was 11
years (IQR: 7, 17) (data not shown).
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Table 3.1: The Distribution of Age, Ethnoracial Groups, Relationship Status, Education Status, and Yearly Personal Income
in the Cohort of Women with HIV Compared with the Assumed HIV-Negative Women of the General Population in Canada.
CHIWOS estimates

CCHS estimates

(N=1,422)

(N=46,851)*
Unstandardized

Standardized

% (95% CI)

% (95% CI)c

8,749

21.1 (20.6, 21.7)

10.2d

11.4 (9.8, 13.2)

4,582

11.2 (10.6, 11.5)

11.4

178

12.5 (10.9, 14.3)

5,775

13.9 (13.4, 14.5)

12.5

> 55

99

7.0 (5.7, 8.4)

12,020

29.0 (28.5, 29.6)

7.0

16-35

107

7.5 (6.3, 9.0)

457

1.1 (0.9, 1.3)

7.5

36-45

163

11.5 (9.9, 13.2)

280

0.7 (0.5, 0.9)

11.5

46-55

111

7.8 (6.5, 9.3)

333

0.8 (0.6, 1.1)

7.8

> 55

37

2.6 (1.9, 3.6)

268

0.7 (0.5, 0.8)

2.6

Indigenous 16-35

100

7.0 (5.8, 8.5)

424

1.0 (0.9, 1.2)

7.0

36-55

120

8.4 (7.1, 10.0)

161

0.4 (0.3, 0.5)

8.4

36-45

74

5.2 (4.2, 6.5)

176

0.4 (0.3, 0.5)

5.2

46-55

24

1.7 (1.1, 2.5)

255

0.6 (0.5, 0.7)

1.7

16-35

20

1.4 (0.9, 2.2)

3,286

7.9 (7.4, 8.4)

1.4

36-45

34

2.4 (1.7, 3.3)

1,837

4.4 (4.0, 4.9)

2.4

N

% (95% CI)

N

16-35 (years)

145

10.2 (8.7, 11.9)

36-45

162

46-55

Ethnoracial and age groups
White

Black

Others

107

46-55

37

2.6 (1.9, 3.6)

1,271

3.1 (2.7, 3.5)

2.6

> 55

11

0.8 (0.4, 1.4)

1,539

3.7 (3.4, 4.1)

0.8

Single

689

48.7 (46.1, 51.3)

10,438

24.3 (23.7, 24.8)

26.6 (24.6, 28.7)

Married, common-law

545

32.1 (29.7, 34.6)

24,971

58.0 (57.3, 58.7)

55.3 (52.7, 57.9)

Separated/divorced/widowed

271

19.2 (17.2, 21.3)

7,636

17.7 (17.2, 18.3)

18.1 (15.8, 20.4)

Less than high school

227

16.1 (14.2, 18.1)

6,568

15.4 (14.9, 16.0)

12.3 (11.0, 13.6)

High school completed

532

37.6 (35.1, 40.2)

10,514

24.7 (24.0, 25.4)

23.9 (21.9, 25.9)

Diploma/trade/college

456

32.2 (29.8, 34.7)

12,998

30.6 (29.8, 31.3)

35.9 (33.4, 38.4)

200

14.1 (12.4, 16.1)

12,474

29.3 (28.6, 30.1)

27.9 (25.4, 30.4)

<20,000 CADb

997

70.3 (67.8, 72.6)

12,263

29.1 (28.4, 29.9)

28.1 (26.1, 30.0)

20,000 to <40,000 CAD

244

17.2 (15.3, 19.3)

10,425

24.8 (24.1, 25.5)

24.5 (22.4, 26.7)

≥ 40,000 CAD

144

10.1 (8.7, 11.8)

12,620

30.0 (29.2, 30.8)

33.1 (30.4, 35.8)

Not stated

34

2.4 (1.7, 3.3)

6,795

16.1 (15.5, 16.8)

14.3 (12.3, 16.3)

Trans women

54

3.8 (2.9, 4.9)

--- e

---e

--- e

Relationship status

Education status

University degree (≥Bachelor’s
degree)
Yearly personal income a

* Out of 128,310 respondents, 46,851 (36.5%) were eligible for the current study: women aged 16+ residing in three provinces of BC, ON, QC; a aged > 17 years
old; b Canadian dollar (CAD); c 95% CIs were not estimated for standardization variables; d Standardization made the two study populations identical with regard
to age and ethnoracial group structure; e Not available as CCHS does not contain data identifying trans status.
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3.3.2 Cigarette smoking
A higher prevalence of cigarette smoking frequency and intensity was reported among WLWH
compared with estimates expected based on the age-/ethnoracial-standardized women of the
general population. Current cigarette smoking (i.e., daily/occasional) was reported by 43.7% of
WLWH relative to 17.8% of the expected estimates of general population (SPD 25.9%),
indicating that 25.9% (i.e., 259 per 1000) of WLWH reported current cigarette smoking, in
excess of what would be expected of Canadian women of similar ages/ethnoracial backgrounds.
Daily cigarette smoking was reported by 40.7% of WLWH versus 13.9% of expected estimates
from general population women (SPD 26.8%). WLWH tended to smoke cigarette more intensely
than the expected estimates of the general population (Table 3.2).
Table 3.2: Comparison of Cigarette Smoking between Women with HIV (N=1,422) and
Assumed HIV-Negative Women of the General Population (N=46,851).
Cigarette smoking measures

CHIWOS

(1)

CCHS estimates
CCHS

£

SPD¥

AER Std.†
(2)

(1) – (2)

82.2

-25.9

Overall cigarette smoking
Nonsmoker (i.e., former/never)

56.3

84.3

(53.7, 58.9)‡ (83.7, 84.9) (80.8, 83.7)
Current smokers (i.e., daily/occasional)

43.7
(41.1, 46.3)

15.7

17.8

(15.1, 16.3) (16.3, 19.2)

(-28.9, -22.9)
25.9
(22.9, 28.9)

Current cigarette smoking status
Nonsmoker (i.e., former/never)

57.0
(54.4, 59.6)

Occasional smokers a
Daily smokers b

84.3

82.2

(83.7, 84.9) (80.8, 83.7)

-25.2
(-28.2, -22.2)

2.3

3.8

3.9

-1.6

(1.6, 3.2)

(3.5, 4.2)

(3.2, 4.6)

(-2.6, -0.5)

40.7

11.9

13.9

26.8
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(38.1, 43.3)

(11.3, 12.4) (12.5, 15.2)

(23.9, 29.7)

Intensity of cigarette smoking
Nonsmoker (i.e., former/never)c

57.0
(54.4, 59.6)

<1 cig/day or <30 cig/month

1 to 10 cig/day

>10 to <20 cig/day
≥ 20 cig/day

84.4

82.4

(83.8, 85.0) (80.9, 83.9)

-25.4
(-28.4, -22.4)

2.3

2.5

2.5

-0.2

(1.6, 3.2)

(2.3, 2.8)

(2.1, 2.9)

(-1.0, 0.8)

20.4

6.6

7.8

12.6

(18.3, 22.6)

(6.2, 7.0)

(6.7, 9.0)

(10.2, 15.1)

5.4

3.2

4.0

1.4

(4.4, 6.8)

(2.9, 3.4)

(3.2, 4.8)

(0.1, 3.0)

14.9

3.3

3.3

11.6

(13.1, 16.9)

(3.0, 3.6)

(2.8, 3.8)

(9.8, 13.6)

‡

Data are % (95% CI); £ unstandardized weighted estimates are reported and the 95% CI was constructed using
bootstrap method; † Age- and ethnoracial-standardized expected estimates based on women of the general
population from CCHS; ¥ SPD: standardized prevalence difference (% (95% CI)); the 95% CI was constructed using
MOVER algorithm; a Occasional smokers (<1 cigarette/day or <30 cigarettes/month); b Daily smokers (≥1
cigarettes/day or ≥30 cigarettes/month); c Because of missing values in variable intensity of cigarette smoking, the
proportion of the first and second categories if different from the same categories in variable current cigarette
smoking status, while the absolute numbers is the same.

3.3.3 Alcohol consumption
WLWH more frequently reported no alcohol consumption compared with the expected estimates
(40.7% vs. 28.0%). The proportion of alcohol consumption categories among WLWH than
expected estimates from standardized general population data was: 46.8% vs. 52.2% consumed
alcohol ≤1 time/week, 7.0% vs. 12.9% consumed alcohol 2-3 times/week, and 5.5% vs. 6.9%
consumed alcohol 4+ times/week. The monthly pattern of binge drinking in WLWH was: 15.4%
vs. 30.6% for less than once/week (SPD -15.2%), and 4.6% vs. 3.9% for at least once/week (SPD
0.7%). The combination of these two categories showed that 20.0% of WLWH reported binge
drinking at least once/month compared with 34.5% in women of the general population (Table
3.3).
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Table 3.3: Comparison of Alcohol Consumption between Women with HIV (N=1,422) and
Assumed HIV-Negative Women of the General Population (N=46,851)
CHIWOS

(1)

CCHS estimates
CCHS

£

SPD¥

AER Std.†
(2)

(1) - (2)

28.0

12.7

Alcohol consumption frequency
None (Never/none in specified time)

40.7

24.5

(38.2, 43.3)‡ (23.7, 25.4) (25.4, 30.5)
≤1 time a week

46.8
(44.2, 49.4)

2-3 times a week

7.0
(5.7, 8.4)

4+ times a week

51.3

52.2

(50.4, 52.1) (49.6, 54.8)
15.1

12.9

(14.5, 15.7) (11.5, 14.1)

(9.1, 1.4)
-5.4
(-9.1, -1.7)
-5.9
(-7.7, -3.9)

5.5

9.1

6.9

-1.4

(4.4, 6.8)

(8.7, 9.5)

(5.8, 8.1)

(-3.0, 0.4)

41.0

24.6

28.0

13.0

Binge drinking categories a
No alcohol consumed

(38.5, 43.7)
Alcohol consumed, not binge

39.0
(36.4, 41.5)

Binge drinking less than once a week

15.4
(13.6, 17.4)

Binge drinking at least once a week

(23.8, 25.5) (25.4, 30.6)
40.3

37.5

(39.5, 41.1) (34.9, 40.0)
30.9

30.6

(30.1, 31.7) (28.7, 32.4)

(9.4, 16.7)
1.5
(-2.1, 5.1)
-15.2
(-17.8, -12.6)

4.6

4.2

3.9

0.7

(3.6, 5.9)

(3.9, 4.5)

(3.3, 4.4)

(-0.3, 2.1)

‡

Data are % (95% CI); £ unstandardized weighted estimates are reported and the 95% CI was constructed using
bootstrap method; † Age- and ethnoracial-standardized expected estimates based on women od the general
population from CCHS; ¥ SPD: standardized prevalence difference (% (95% CI)), and the 95% CI was constructed
using MOVER algorithm; a CHIWOS measured the last-month pattern of binge drinking, while CCHS measured the
last-year pattern of binge drinking.
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3.3.4 Drug use
Last-month non-prescribed cannabis use in WLWH from BC was almost two times greater than
last-year use of this drug from women of the general population in BC: 14.6% vs. 6.6% reported
regular use (SPD 8.0%), and 18.1% vs. 6.1% reported occasional use (SPD 12.0%). The results
of last 3 months use of illicit drug use compared with last-year use of these drugs showed a
higher proportion of WLWH in BC reported cocaine or crack use: 16.8% vs. 0.1% for regular
use (SPD 16.7%), and 8.2% vs. 1.5% for occasional use (SPD 6.7%), regular/occasional speed
use (2.5% vs. 0.1%; SPD 2.4%), and regular/occasional heroin use (11.3% vs. 0.1%; SPD
11.2%) (Table 3.4).
Table 3.4: Comparing Illicit Drug Use between Women Living with HIV and Assumed
HIV-Negative Women of the General Population*.
CCHS estimates

CHIWOS
Drug use a

CCHS

£

SPD¥

AER Std.†
(2)

(1) – (2)

4.5

6.6

8.0

(3.4, 5.2)

(4.7, 8.6)

(4.1, 8.6)

18.1

7.1

6.1

12.0

(14.4, 22.4)

(6.1, 8.1)

(4.9, 7.2)

(8.1, 16.5)

67.3

88.4

87.3

-20.0

(62.2, 72.1)

(87.2, 89.6)

(83.5, 91.1)

(-26.3, -13.9)

16.8

0.1

0.1

16.7

(13.2, 21.0)

(0.01, 0.2)

(0.00, 0.2)

(13.1, 20.9)

8.2

0.7

1.5

6.7

(1)
Non-prescribed cannabis
use b
Regular use c

14.6
(11.3, 18.7)

Occasional use d
None e

‡

Cocaine or crack use
Regular use f

Occasional use g
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None (never or former)

(5.78, 11.61)

(0.4, 1.0)

(0.2, 2.9)

(3.9, 10.3)

75.0

99.2

98.4

-23.4

(70.2, 79.2)

(98.8, 99.5)

(95.0, 101.7)

(-29.2, -17.9)

2.5

0.1

0.1

2.4

(1.3, 4.8)

(0.01, 0.2)

(0.00, 0.2)

(1.2, 4.7)

99.9

-2.4
(-6.2, 0.9)

Speed (amphetamine) use
Regular/occasional use f,g,h

None (never or former)
97.5

99.9

(96.8,

(95.2, 98.68)

(99.8, 100.0)

100.0)††

11.3

0.1

0.1

11.2

(8.4, 15.1)

(0.02, 0.2)

(0.01, 0.2)

(8.3, 15.0)

99.9

-11.2

Heroin use
Regular/occasional use f,g,h

None (never or former)
88.7

99.9

(84.9, 91.6)
*

‡

(96.8,

(-16.1, -7.0)

††

(99.7, 100.0)

100.0)
£

CHIWOS-BC (N=356) and CCHS-BC (N=7,698); Data are % (95% CI); unstandardized weighted estimates are
reported and the 95% CI was constructed using bootstrap method; † Age- and ethnoracial-standardized expected
estimates based on women of the general population from CCHS; ¥ SPD: standardized prevalence difference (%
(95% CI)), and the 95% CI was constructed using MOVER algorithm; †† the upper limit was 102.96% but we made
is to the maximum proportion 100.0%; a CCHS collected data for the period of last 12 months for all drugs, while
CHIWOS collected data on cannabis use for last month and other drugs in last three months; b Any non-prescribed
use of cannabis (i.e., non-medicinal, non-prescribed, self-medicating, or both medicinal and non-medicinal use
simultaneously); c CCHS: every day or at least once a week, while it was measured as using regularly in CHIWOS; d
CCHS: Occasional use (1-3 times a month or less than once a month), CHIWOS: occasional use (occasionally or
used but not in the past 30 days); e No non-prescribed or medicinal cannabis use; f Regular use: at least once a week;
g
Occasional/episodic: less than once a week; h Regular and occasional use were merged in Amphetamine and
Heroin use as the absolute “n” did not meet the minimum vetting guideline.

3.4. Discussion
We found that a considerable proportion of WLWH reported current cigarette smoking, were
intensive cigarette smokers (i.e., ≥20 cigarettes/day), reported binge drinking, and reported
regular/occasional use of non-prescribed cannabis, and other illicit drugs including crack or
cocaine, speed, and heroin. We also provided evidence for an excess prevalence of cigarette
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smoking and the use of non-prescribed cannabis, and other illicit drugs, but a lower to similar
frequency of alcohol consumption, in WLWH compared to their age- and ethnoracial groupsimilar general population counterparts.
While a considerable difference was found between WLWH and their general population
counterparts with regard to drug use and cigarette smoking, but not alcohol drinking, we
acknowledge that these differences could in part be because of other uncontrolled population
background characteristics. For example, prior studies have highlighted the contribution of
socioeconomic factors (e.g., low income, unemployment) and mental health conditions to
substance use among WLWH.5 Moreover, HIV-specific factors such as HIV-related stigma may
play a role in substance use as a maladaptive or avoidant coping strategy.33 However, control of
these in cross-sectional analysis can be problematic in ignoring potential mediation and creating
artificially similar groups that obscure real differences that can result from age (or life stage) and
from systemic discrimination and differential life options across ethnoracial groups.
Our findings were consistent with findings of the few available studies comparing WLWH
with HIV-negative women. A higher proportion of cigarette smoking was found among WLWH
in a 2015 US study (34.6% vs. 18.0% were current cigarette smokers; with an age-ethnoracialeducation-poverty adjusted prevalence difference of 16.6%)2 and a 2014 French study (32%
regular tobacco smokers, with an age-education adjusted prevalence rate ratio of 1.32).3
Consistent with previous research,1 alcohol consumption was comparatively lower in WLWH
than that in the general population; however, it was still one of the most prevalent substances
reported by WLWH in the current study. The reason for the observed lower frequency of alcohol
consumption among WLWH of the current study is unclear. Further research is needed to
explore whether such lower frequency of alcohol use among WLWH is due to the higher use of
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other drugs such as recreational cannabis use. Given the negative impacts of alcohol
consumption on care and treatment outcomes,34 our findings in line with other studies of women
with HIV35 suggest that there is a need for screening of alcohol drinking and targeted
interventions within HIV care.
The comparison of our findings on illicit drug use with extant literature is difficult because
there are few such comparison analyses specifically for WLWH. However, identifying a higher
prevalence of drug use in individuals with HIV than the general population is relevant to the HIV
setting, and suggests the need to ensure that factors that affect substance use among WLWH are
identified and addressed, and that adequate resources are provided for addressing drug use in the
context of HIV care. Limited descriptive studies have also indicated high prevalences of
substance use in WLWH; for example, current cigarette smoking (56%) and concomitant use of
other drugs in smokers (24.4% vs. 4.0% in nonsmokers)12, past-year heavy/hazardous drinking
over an 11-year follow-up period (ranged from 14% to 24%),5 current marijuana use (from 21%
to 14% over the 16-year follow-up period) and daily marijuana use (from 3.3% to 6.1% in all
studied women).36 Future research could examine which factors may contribute to WLWH using
or avoiding substances, including discrimination, HIV-related stigma, intimate partner violence,
and other factors that can lead to initiation or continuation of substance use. The identified
substance use disparities, particularly smoking and illicit drug use, can help researchers explore
pathways leading to greater vulnerability among WLWH.
Given the contribution of substance use to suboptimal HIV outcomes, considering the
mixed evidence for the role of cannabis,37,38 the high substance use prevalence identified in the
current research has important implications for the clinical management of HIV.12,39 This is
particularly important as substance use oftentimes co-presents with other health-related problems
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such as psychiatric comorbidities and socio-structural barriers, that interactively impact HIV
outcomes in individuals with HIV including WLWH.40-42 These findings highlight the need to
make interventions available to women who use both drugs and antiretroviral therapy,
particularly in cases where the substance use interferes with maintenance of effective HIV
treatment.34,43 Integration of substance use treatment services into HIV primary care settings may
contribute to enhancing the quality of HIV care and care delivery.9,39,44 Our findings also
advocate for tailored, women-centred harm reduction strategies in which women’s unique needs
are effectively recognized,45 and peer-driven interventions through which peers can also
contribute to the care and treatment programs delivery.46 Having access to pharmacologic and
psychotropic substance use and harm reduction services through this model of care is essential to
reduce use and harms of substance use.6,7,9 To improve greater involvement and adherence to
treatment, one recommendation is that such a model of care delivery also provides sustained
follow-up with regular evaluations of HIV therapies to substance-using WLWH.39,43,47
This study had some limitations. CHIWOS recruited WLWH through Peer Research
Associates (PRAs) – a non-random sampling design. Additionally, self-report data on substance
use, a potentially stigmatizing behaviour, is subject to social desirability bias. In particular, this is
of concern for data from the general population. However, this potential bias might have been
mitigated in CHIWOS by using the PRAs, who also shared the experience of living with HIV.
This was an attempt to build trust with WLWH, to allow for them to better contribute to the
research in sharing their sensitive information.24 Moreover, we compared the measure of
substance use in WLWH with the assumed HIV-negative women of the general population.
Because of small population estimates of WLWH in Canada – 97 per 100,000 females,26 the
inclusion of WLWH in the assumed HIV-negative group would not substantially change our
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estimates. Furthermore, while CHIWOS collected data on cisgender (non-trans) women and
trans women with HIV, CCHS does not contain data identifying trans women; therefore, it is
both likely that there are also trans women in CCHS and it is impossible to adjust for gender
identity.
In conclusion, substance use was prevalent among women living with HIV, with
prevalences of cigarette smoking and illicit drug use in excess of what would be expected, but
not of alcohol consumption and binge drinking. Due to their negative impacts on HIV outcomes,
morbidity, and mortality, these results highlight the need for future research and programming to
better understand factors that may contribute to substance use within the group of WLWH, and
to intervene on these factors, or on health risk factors within HIV care settings. Future research
may also be useful in identifying substance users through screening methods, in educating HIV
care providers concerning screening for substance use problems, and in addressing specific
causal pathways for use of substances and their impacts on HIV outcomes.
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4.

Chapter 4: Patterns of social determinants of health associated with drug
use among women living with HIV in Canada: a latent class analysis1

4.1. Introduction
Illicit drug use, particularly opioids and stimulants, is common among people living with HIV
(PLWH). For example, 10%, 24%, and 39% of PLWH in a US study reported heroin,
amphetamines, and cocaine use, respectively, by any administration route.1 Although data on the
prevalence of drug use among women living with HIV (WLWH) is limited, 28.6% of WLWH
reported recent crack cocaine use, with 3.2% as persistent users.2 In Canada, available evidence
showed that 25.0% and 11.3% of WLWH reported recent crack cocaine and heroin use (by any
route), respectively.3
Illicit drug use remains one of the most important factors influencing engagement in the
HIV care cascade among individuals with HIV.1,4-6 Much evidence has documented poorer HIV
treatment outcomes among people who use drugs, particularly among WLWH.5-11 For example,
greater suboptimal combination antiretroviral therapy (cART) adherence was documented
among WLWH who reported a history of drug use than among women who did not, or among
men regardless of drug use.7 Drug use also predicts increased risk of disease progression, HIV
transmission, and mortality,1,2,10 and continues to complicate HIV care and treatment efforts
among PLWH.12,13 Although active drug use has been shown to complicate the clinical
management of individuals with HIV and common comorbidities such as hepatitis C, increasing
evidence documents how marginalization and criminalization of people who use/inject drugs
1
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interferes with access and adherence to HIV medications.14 Particular attention, therefore, needs
to be given to such drug use practice throughout the course of HIV care and treatment among
WLWH.
Although some determinants of illicit drug use are well documented (e.g., demographics,
cognitive, behavioural),15 few studies have explored the role of the social determinants of health
(SDoH). The SDoH are the conditions (e.g., economic and social marginalization, and various
forms of discrimination) in which people are born, work, live, and age, and the wider set of
forces shaping the conditions of daily life that greatly contribute to health inequalities.16 Greater
adversities regarding these living conditions can lead to high levels of physiological and
psychological stresses arising from coping with stressors.16 For PLWH, HIV-related stigma in
intersection with other social determinants (e.g., race and gender discrimination)17 can result in
coping behaviours such as illicit drug use18 to help contend with worries and stresses,19 which
can in turn increase vulnerabilities to HIV-related health outcomes.18,20-22
Notably, multiple dimensions of SDoH tend to co-occur, and may cluster together into
common combinations. Such concomitant determinants have been consistently treated as
independent when studied in association with drug use. For example, previous studies have
assessed the separate association of HIV stigma,23 food insecurity,24 unemployment,25 and low
social support26 with drug use. However, there are limited data examining how clustering of
these determinants is related to drug use. Such evidence is essential for developing HIV care and
treatment programs to address potentially modifiable adversities and reduce their impacts on the
lives of WLWH. Drawing on the Canadian HIV Women’s Sexual and Reproductive Health
Cohort Study (CHIWOS),27 we conducted a latent class analysis (LCA) to uncover underlying
clusters of SDoH. LCA as a data reduction strategy classifies individuals into mutually exclusive
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and exhaustive latent classes using multiple categorical observed variables.28 LCA has been a
useful technique for identifying population subgroups in different disciplines (e.g., substance
using women at risk for HIV.29 We then applied inverse probability weighting to address
confounding and selection bias in examining the association of the clusters of SDoH with drug
use.
4.2. Methods

4.2.1 Study sample
We used data from CHIWOS (www.chiwos.ca), a community-based cohort study. As previously
described,27 CHIWOS is a large cohort of WLWH (≥16 years; trans inclusive) residing in the
Canadian provinces of British Columbia (BC), Ontario, and Quebec. WLWH (n=1,422) were
interviewed during 2013-2015 (time-point 1) and after ~18-months (time-point 2; n=1,252). We
considered 170 participants (11.9%) lacking time-point 2 data as censored (i.e., lost to followup). Participants were recruited through peers, HIV clinics, AIDS service or community-based
organizations, word of mouth, and other methods.30 Trained Peer Research Associates (PRAs)
administered the survey through in-person interviews at clinics, community sites, or participants’
homes, or via phone/Skype. Informed consent was obtained from all participants prior to the
interview, consistent with the ethics protocol approved by Simon Fraser University, University
of British Columbia/Providence Health, Women’s College Hospital, and McGill University
Health Centre.

4.2.2 Drug use
Recent drug use was defined as last three months at the first time-point and last six months at the
second time-point, and included use of opioids (heroin, speedballs, Dilaudid, non-prescribed
methadone, OxyContin/Oxycodone, morphine, Talwin & Ritalin) or stimulants (cocaine, crack,
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crystal methamphetamine, amphetamine, MDA). The regular (daily or at least once/week) or
episodic (less than once/week) use of these drugs was ascertained among those who reported any
use. Due to small proportions in the episodic use category (i.e., ~1%), a binary outcome at timepoint 2 was created: use of any vs. no drugs.

4.2.3 SDoH indicators
A set of potentially modifiable SDoH that have the potential to co-occur among WLWH were
examined at time-point 1, including: racial discrimination, gender discrimination, enacted HIV
stigma, perceived social support, barriers to access to care, food security, housing status, income
level, employment status, education, recent sex work involvement, and recent incarceration.
Included SDoH indicators: a) were measured at the first survey time-point, b) are potentially
modifiable, c) were currently or recently experienced, and; d) align with the Canadian list of
SDoH19 (HIV-related stigma being an exception specific to PLWH). Selection of SDoH was
limited to current or recent conditions to avoid the potential for collider stratification bias31 that
could be introduced in a selected (HIV-positive) sample by studying earlier social determinants
that may have affected HIV status.
Racial discrimination was measured with the 8-item Everyday Discrimination Scale
(current study α=0.96)32. In line with operationalization used in the prior research,33 WLWH who
reported discriminatory experiences due to their race (e.g., treated with less courtesy, respect)
sometimes, frequently, or almost every day were considered as having experienced racial
discrimination. The same scale (with the same definition) focusing on discriminatory
mistreatments due to gender was used to measure gender discrimination (α=0.94). Enacted HIV
stigma was measured using three items of Wright's abridged 10-item version of Berger's HIV
Stigma Scale (α=0.85), measuring the extent to which WLWH experienced enacted/personalized
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stigma toward PLWH.34 Experience of HIV-related stigma was defined if WLWH reported any
HIV-related discriminatory events with strongly agree/agree response options (i.e., been hurt by
people’s reaction, stopped socializing, or lost friends). Social support was examined by the 4item Medical Outcome Study: Social Support Survey, measuring emotional-informational,
tangible, affectionate, and positive social interaction supports (α=0.85). The overall mean score
ranged from 1 to 5, with > 2 indicating poor social support availability.35 Difficulties in access to
care was assessed using the 12-item Barriers to Access to Care Scale, measuring barriers
experienced due to geography/distance, medical and psychological service, community stigma,
and personal resource (α=0.93). The overall mean severity scores ranged from 1 to 4, with ≥ 2
signifying severe/significant barriers.21 Past-year experiences of food security were examined by
three items: fears of running out of food; experiences of running out of food; and unaffordability
of balanced meals, yielding an overall score ranging 1-6, with > 1 indicating food insecurity.36
Income level was defined as low if participants reported having a yearly household income level
< $20,000. Current employment status was categorized as unemployed (no income or income
only from non-employment sources such as unemployment/welfare, dividends and interest, or
pension) vs. employed (any paid job). Current education level was dichotomized as below high
school vs. completed high school or more. Current housing status was also measured.
Participants who reported residing in places such as a self-contained room, transition house,
halfway house, safe house, or outdoors were considered as unstable housing. Past six months sex
work involvement was also included, and defined as having been provided with money, drug,
shelter, food, etc. in exchange for sex. Finally, any past year experience of incarceration was
included as a structural-level determinant indicating social exclusion.
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4.2.4 Covariates
The following covariates were hypothesized to be associated with either both SDoH clusters and
drug use or only drug use: age (continuous); ethnoracial groups (white/Caucasian,
African/Caribbean/Black, Indigenous, others); province (BC, Ontario, Quebec); city size (large,
others); sexual orientation (heterosexual, LGBQ); relationship status (married/commonlaw/relationship, others); years living with HIV (<6 years, 6-14 years, > 14 years); cART status
(optimal [≥ 95% adherence], suboptimal [< 95% adherence], not engaged in HIV treatment);
ever diagnosed with a mental health condition; resilience (10-item Resilience Scale) ; any history
of childhood sexual/physical violence; any experience of adulthood
sexual/physical/verbal/action-limited violence; having been under the care of Child Protection
Services or in foster care; and alcohol use (abstainers/low, moderate [1-7 drinks/week], heavy [>
7 drinks/week]). Drug use history before or at time-point 1 was also included to account for
confounding by outcome history.37 Missing values of covariates under the assumption of missing
at random were singly imputed to reduce the loss of statistical power when computing inverse
probability weights (IPW).38

4.2.5 Latent class analysis (LCA)
We used LCA to identify clusters of SDoH indicators. Under the assumption that all observed
indicators are independent conditional on the latent variable, LCA aims to identify distinct
groups of individuals with similar patterns within an unobserved categorical variable.28 LCA was
started with a two-class model and systematically increased to more classes (S Table 4.1). LCA
provides both class membership probabilities and item-response probabilities condition on class
membership to help interpret the final identified class (Table 4.1). The expectation–
maximization (EM) algorithm with 5,000 iterations was employed to identify the best model
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fit.39 The selection of the best LCA model was informed by using goodness-of-fit indices,
supporting statistics, and interpretability of class memberships. The following fit statistics were
reported: log-likelihood, Akaike’s information criterion (AIC), Bayesian information criterion
(BIC), and sample-size-adjusted BIC (aBIC), and consistent AIC (CAIC).40-42 Lower values of
these criteria indicate better fit and parsimony. Two supporting statistics were also reported:
Entropy as a measure of classification accuracy, with values approaching to 1 indicating better
class separation,43 and the percentage of seeds associated with the fitting models, with values
close to 100% indicating they were unlikely to have hit the local maxima. For each model, the
log-likelihood was replicated with 1,000 random starting values to avoid local maxima. Under
the assumption of missing at random, LCA accounted for missing values of the SDoH indicators
using the full information maximum likelihood estimation. LCA was conducted using SAS
PROC LCA procedure.44

4.2.6 Models and estimations
We used inverse probability weights (IPW)45,46 to account for confounding due to the presence of
potentially imbalanced covariates across the SDoH clusters, and inverse probability censoring
weights (IPCW) to account for prospective selection bias due to potentially non-random loss to
follow-up/censoring (S Table 4.2). The product of these two weights yielded the final stabilized
weights (S Table 4.3), producing a pseudo-population in which the independent variable and
covariates are unassociated (S Table 4.4). In fitting models through IPW, we assumed correct
specification of IPW models, conditional exchangeability, and positivity.47

4.2.7 Control of confounding using IPW
SDoH clusters were modeled using a multinomial logistic regression to estimate stabilized
weights: the numerator was computed as the marginal probability of the SDoH clusters divided
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by the denominator, which was computed as the probability that a participant was assigned to an
SDoH cluster given the covariates and opioid/stimulant use history. These models were all
performed among participants without censored information in time-point 2.

4.2.8 Control of selection bias using IPCW
Additionally, to account for any potential selection bias due to differential loss-to-follow-up at
time-point 2, we estimated IPCW using logistic regression models: numerator was defined as the
probability of not being censored given SDoH, and denominator was computed as the probability
of not being censored given SDoH, covariates and opioid/stimulant use history.

4.2.9 Association of SDoH clusters with drug use
The association between SDoH clusters and any opioid/stimulant use was examined using
generalized linear models with log link and Poisson distribution; crude and weighted risk ratios
(RRs) and 95% confidence intervals (CIs) were reported. Further adjustment was made for
imbalanced covariates after applying the IPW. These analyses were conducted using Stata 15.

4.2.10 Sensitivity analysis
We reported E-value to evaluate the extent to which residual (unmeasured) confounding might
explain away the observed associations, and computed as: E = RR* + sqrt{RR* × RR* – 1},
where RR* = 1/RR for RR < 1.48 E-value is a representation of the minimum strength of
association that an unmeasured confounder would need to have with SDoH clusters and drug use
to nullify the observed associations.
4.3. Results

4.3.1 SDoH classes
Prevalences for individual social determinants ranged from 6.3% (N = 82/1307) and 6.5% (N =
92/1419) for recent sex work involvement and incarceration to 71.8% (N = 1004/1398) and
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77.8% (N = 1098/1412) for enacted HIV stigma and unemployment, respectively (Table 4.1).
After considering LCA fit statistics and model interpretability, the four-class model was
determined as the optimal number of classes (S Table 4.1). These four classes included WLWH
with either none/least SDoH adversities (class 1 labeled as no/least SDoH adversities: N = 94
[6.6%]); WLWH who predominantly reported experiencing race and gender discrimination along
with HIV-related stigma and barriers in access to care, but without economic hardship indicators
(class 2 labelled as discrimination/stigma: N = 256 [18.0%]); WLWH who mainly reported food
insecurity, low household income, and unemployment, accompanied with HIV-related stigma
(class 3 labeled as economic hardship: N = 430 [30.2%]); and WLWH who experienced gender
and race discrimination, HIV-related stigma, low social support, access to care difficulties, food
insecurity, low income, and unemployment (class 4 labeled as most SDoH adversities: N = 642
[45.2%]).
Table 4.1: Class Membership Probabilities and Item-Response Probabilities of Social
Determinants of Health (SDoH) from Latent Class Analysis among Women Living with
HIV – CHIWOS (N=1,422).
None/least Discrimination

Economic

Most SDoH

SDoH

and Stigma

hardship

adversities

(N = 94;

(N = 256;

(N = 430;

(N = 642;

6.6%)b

18.0%)

30.2%)

45.2%)

No

0.00

0.40c

0.91

0.18

Yes

0.00

0.60

0.09

0.82

Noned

1.00

0.00

0.00

0.00

Gender discrimination

No

0.00

0.33

0.91

0.04

(818/1415; 57.1%)

Yes

0.00

0.67

0.09

0.96

None

1.00

0.00

0.00

0.00

No

0.00

0.22

0.40

0.17

SDoH measures

Race discrimination
a

(708/1408; 50.3%)

Enacted HIV stigma

131

(1004/1398; 71.8%)

a

Yes

0.00

0.78

0.60

0.83

None

1.00

0.00

0.00

0.00

Low social support

No

0.00

0.51

0.51

0.37

(722/1367; 52.8%)

Yes

0.00

0.49

0.49

0.63

None

1.00

0.00

0.00

0.00

High barriers to access to No

0.00

0.43

0.55

0.36

care

Yes

0.00

0.57

0.45

0.64

(725/1371; 52.8%)

None

1.00

0.00

0.00

0.00

Food insecurity

No

0.00

0.63

0.31

0.18

(907/1416; 64.1%)

Yes

0.00

0.37

0.69

0.82

None

1.00

0.00

0.00

0.00

Low income

No

0.00

0.90

0.21

0.11

(901/1379; 65.3%)

Yes

0.00

0.10

0.79

0.89

None

1.00

0.00

0.00

0.00

Unemployment

No

0.00

0.67

0.09

0.02

(1098/1412; 77.8%)

Yes

0.00

0.33

0.91

0.98

None

1.00

0.00

0.00

0.00

Low education

No

0.00

1.00

0.83

0.75

(227/1415; 16.0%)

Yes

0.00

0.00

0.17

0.25

None

1.00

0.00

0.00

0.00

Unstably housed

No

0.00

0.99

0.90

0.83

(152/1422; 10.7%)

Yes

0.00

0.01

0.10

0.17

None

1.00

0.00

0.00

0.00

Recent sex work practice No

0.00

0.99

0.95

0.90

(82/1307; 6.3%)

Yes

0.00

0.01

0.05

0.10

None

1.00

0.00

0.00

0.00

Recent incarceration

No

0.00

1.00

0.96

0.88

(92/1419; 6.5%)

Yes

0.00

0.00

0.04

0.12

None

1.00

0.00

0.00

0.00

b

(n/N; %) indicating the prevalence of the SDoH indicators under the study; Class membership probabilities; c
Item-response probabilities, indicating the probability of experiencing a SDoH indicator for each identified latent
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class; d We categorized each SDoH measure into three categories: No: indicating either did not have/experience this
determinant, Yes: indicating either living/experiencing this determinant, None: indicating either did not experience
any of these 12 determinants or experienced only one (i.e., least). Item response probabilities of “Yes” category ≥
0.50 are bolded, and item response probabilities of “None” category with 100% are underlined. The “None”
category was added to produce a distinct class named “None/least SDoH adversities” to ease interpretation of the
latent classes and reduce LCA model complexity.

4.3.2 Participants’ characteristics
WLWH were an average of 42.8 [SD 10.6] years of age, with 584 (41.1%) members of the white
ethnoracial group, 1237 (87.3%) heterosexual, 689 (48.5%) single, 552 (40.2%) living with HIV
for 6-14 years, 863 (70.0%) self-reporting optimal cART adherence; 819 (62.7%) and 1057
(80.4%) reported exposure to violence as children and adults, respectively, 573 (40.7%) reported
a mental health diagnosis, and 140 (10.1%) were heavy alcohol users. The distributions of these
covariates across the SDoH clusters are presented in Table 4.2.
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Table 4.2: Characteristics of Women Living with HIV (WLWH) across the Social Determinants of Health (SDoH) Classes –
CHIWOS Time-point 1, 2013-2015 (N = 1,422).
Overall
Variables
Age, yrd (mean [SD])

42.8 [10.6]

SDoH classes
None/least

Discrimination/

Economic

Most

adversities

stigma

hardship

adversities

39.2 [10.3]

43.5 [10.6]

42.9 [11.5]

43.1 [10.0]

P-valueb

0.007
<0.001

Ethno-racial group
White/Caucasian

584 (41.1)a

58 (61.7)

97 (37.9)

219 (50.9)

210 (32.7)

African/Caribbean/Black

418 (29.4)

23 (24.5)

109 (42.6)

123 (28.6)

163 (25.4)

Indigenous

318 (22.3)

7 (7.4)

29 (11.3)

60 (14.0)

222 (34.6)

Other

102 (7.2)

6 (6.4)

21 (8.2)

28 (6.5)

47 (7.3)
<0.001

Province
Ontario

717 (50.4)

50 (53.2)

131 (51.2)

235 (54.6)

301 (46.9)

British Columbia

356 (25.0)

13 (13.8)

49 (19.1)

65 (15.1)

229 (35.7)

Quebec

349 (24.6)

31 (33.0)

76 (29.7)

130 (30.2)

112 (17.5)

Living in large cities

1169 (82.2)

83 (88.3)

203 (79.3)

345 (80.2)

538 (83.8)

0.106

Bing heterosexual

1237 (87.3)

85 (90.4)

237 (93.3)

395 (91.9)

520 (81.4)

<0.001
<0.001

Relationship status
Single (non-married)

689 (48.5)

40 (42.6)

100 (39.1)

201 (46.7)

348 (54.4)

Married/common-law

454 (32.0)

44 (46.8)

103 (40.2)

134 (31.1)

173 (27.0)

Others

277 (19.5)

10 (10.6)

53 (20.7)

95 (22.1)

119 (18.6)

Years living with HIV

0.001
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< 6 years

345 (25.1)

23 (25.0)

40 (15.7)

128 (31.4)

154 (24.8)

6-14 years

552 (40.2)

35 (38.0)

118 (46.7)

140 (34.3)

259 (41.8)

> 14 years

477 (34.7)

34 (37.0)

96 (37.8)

140 (34.3)

207 (33.4)
0.001

Taking HIV treatment
Yes, optimal (≥ 95%)

863 (70.0)

65 (69.9)

163 (64.7)

279 (65.0)

356 (55.5)

Yes, suboptimal (< 95%)

312 (22.0)

12 (12.9)

52 (21.4)

74 (17.2)

172 (26.8)

Not engaged in treatment

240 (17.0)

16 (17.2)

35 (13.9)

76 (17.7)

113 (17.6)

Mental health diagnosis

573 (40.7)

26 (28.0)

93 (36.6)

134 (31.6)

320 (50.3)

<0.001

Resiliency (below median)c

662 (47.1)

22 (23.66)

104 (40.9)

172 (40.6)

364 (57.4)

<0.001

Childhood violence

819 (62.7)

34 (38.6)

138 (56.8)

211 (53.8)

436 (74.7)

<0.001

Adulthood violence

1057 (80.4)

52 (59.1)

189 (77.5)

284 (71.9)

532 (90.5)

<0.001

Child development events

326 (23.0)

10 (10.6)

33 (13.0)

74 (17.3)

209 (32.7)

<0.001
0.132

Heavy alcohol use
Abstainers/low (< 1 drink/week)

956 (69.1)

64 (68.8)

174 (68.5)

302 (71.1)

419 (68.1)

Moderate (1-7 drinks/week)

288 (20.8)

22 (23.7)

60 (23.6)

88 (20.7)

118 (19.2)

Heavy (> 7 drinks/week)

140 (10.1)

7 (7.5)

20 (7.9)

35 (8.2)

78 (12.7)

Before study entry

234 (16.8)

3 (3.2)

10 (3.9)

48 (11.24)

173 (27.5)

<0.001

At entry (time-point 1)

244 (17.5)

2 (2.2)

11 (4.3)

50 (11.9)

181 (28.8)

<0.001

Drug use historyd

a

Data are presented as N(%) unless specified; b P-values are for the chi-square test for categorical covariates and one-way ANOVA for continuous covariates; c
Scores ranged 10-70, with higher scores indicating increased resilience (median=64); d Opioid/stimulant use histories before and at time-point 1.
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4.3.3 SDoH clusters and drug use
Overall, opioid/ stimulant use at time-points 1 and 2 were respectively reported by 244 (17.5%)
and 212 (17.2%.). Drug use at time-point 2 was reported by 143 (26.4%) among WLWH with
most SDoH adversities, with 53 (14.1%), 13 (5.6%) and 3 (3.5%) for economic hardship,
discrimination/stigma, and no/least SDoH classes, respectively (Figure 4.1). The crude
regression analysis demonstrated that WLWH in the no/least SDoH adversities,
discrimination/stigma, and economic hardship classes had significantly lower likelihood of
opioid/stimulant use than WLWH in the most SDoH adversities class. Compared with the most
SDoH adversities class, weighted analysis showed that WLWH in no/least SDoH class were at
87% decreased risk of drug use (RR 0.13, 95% CI: 0.03, 0.58), while an association was not
observed for other classes. Additionally, WLWH in the no/least SDoH class were at decreased
risk of drug use compared to WLWH in the economic hardship class (RR 0.13, 95% CI: 0.03,
0.63) and discrimination/stigma class (RR 0.15; 95% CI: 0.03, 0.78) (Table 4.3).
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Figure 4.1: Prevalence of Drug Use According to the Social Determinants of Health (SDoH)
Classes Obtained from Latent Class Analysis (LCA) – CHIWOS.

Illicit drugs included a) Stimulants: cocaine, crack (crack cocaine), crystal, speed (amphetamine) and MDA; and b)
Opioids: heroin, speedballs (heroin+ cocaine), Dilaudid (hydromorphone), non-prescription use of methadone,
OxyContin/Oxycodone, morphine, Talwins & Ritalin. These drugs were measured at baseline (time-point 1, 201315) and in ~18 month follow up (time-point 2; 2015-17). Analytic sample size for these prevalences was 1,395 at
time-point1 and 1,236 at time-point 2.
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Table 4.3: Inverse Probability Weighted Estimates of the Association of the Social Determinants of Health (SDoH) Classes
with Drug Use among Women Living with HIV (WLWH) – CHIWOSa
Observed estimates

E-value for the observed
estimates c

Crude RRb
c

(95% CI)

Economic hardship class vs.

0.53

SDoH classes

Most SDoH adversities
Discrimination/stigma class vs.

0.21
(0.12, 0.37)

None/least adversities class vs.

0.13 (0.04,

Most SDoH adversities

0.40)

Discrimination/stigma class vs.

0.40

None/least adversities class vs.
Economic hardship
None/least adversities class vs.
Discrimination/stigma

<0.001

<0.001

(0.18, 2.1)

0.95

0.760

0.82

0.539

(0.44, 1.52)
<0.001

0.13

0.008

(0.03, 0.58)
0.002

0.87

0.678

(0.44, 1.68)
0.015

(0.07, 0.76)
0.61

P-value

(0.67, 1.34)

(0.22, 0.71)
0.24

Weighted RR

Weighted RR

Upper CI

---

---

---

---

14.86

2.84

---

---

14.86

2.55

11.81

1.88

(95% CI)

(0.40, 0.71)

Most SDoH adversities

Economic hardship

P-value

0.13

0.011

(0.03, 0.63)
0.440

0.15
(0.03, 0.78)

0.024

a

N = 1,236 in crude analysis and N= 1,225 in weighted analysis; b RR: risk ratio (95% confidence intervals: CI); c This is a sensitivity analysis evaluating the
extant to which an unmeasured confounder would explain away the exposure-outcome estimates observed for the association between the SDoH classes and drug
use. E-value was check for the observed point estimate and the upper 95% CI that is close to the null RR = 1.
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The sensitivity analysis suggested that these associations were relatively robust to potential
unmeasured confounding. For instance, for the observed RR: 0.13 for drug use among those with
no/least SDoH adversities versus those with most adversities, an unmeasured confounder
correlated with both exposure and outcome by RRs of ~14.86-fold each, above and beyond the
measured confounders, would explain away the observed association, but weaker confounding
would not. Such an E-value for the upper 95% limit of the same association was 2.84-fold
(Table 4.3).
4.4. Discussion
In our study of data from a large prospective cohort of WLWH in Canada, we observed that most
WLWH reported experiencing multiple forms of a set of mutually reinforcing SDoH. We
identified two partially overlapped SDoH clusters of discrimination/stigma and economic
hardship as well as one cluster containing most of the SDoH adversities. Most notably, we found
that the prevalence of self-reported opioid/stimulant use was approximately seven times higher in
WLWH who experienced the most SDoH adversities than those experiencing no/least adversity
(26.4% vs. 3.5%). WLWH with no/least adversity were substantially less likely to report drug
use at ~18 months follow up compared with WLWH experiencing an accumulation of social
disadvantages.
Overall, the high prevalence of socio-structural adversities among WLWH is consistent
with existing knowledge that women experience substantial SDoH vulnerabilities and multiple
forms of these adversities.49,50 The majority of the SDoH indicators were well-distinguished
across the SDoH classes using LCA analysis, except for low education, unstable housing, sex
work involvement, and incarceration. That these four determinants were less distinctive may be
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due to their relatively low proportions, likely resulted in a low overall impact on drug use in the
current sample of WLWH.
We documented that the clustered classes of multiple SDoH adversities were associated
with drug use. Notably, no difference was observed in the risk of drug use for the two classes of
discriminations/stigma and economic hardship compared with the class with most SDoH
adversities and also the same risk of drug use was estimated when WLWH in the no/least class
were compared with WLWH in these two classes. Such findings may help shed light on the
processes that generate and reinforce well-documented syndemics of HIV and substance use, by
showing the role that each specific cluster of SDoH may play in initiation/continuation of drug
use. Our results suggest that improving modifiable social determinants may be crucial to
addressing this syndemic.51 Harm reduction and treatment interventions need to seriously
consider the important role of multiple SDoH – regardless of their types. Drug treatment
programs that mainly focus on behaviour change interventions may result in limited impact if no
additional efforts are made to change the social environments of drug users.52
Our findings may also have implications for HIV care and treatment programs by
illuminating the association of current social determinants with illicit drug use, which has been
shown to create challenges within the HIV care cascade. Prior evidence has demonstrated how
income level,53 HIV stigma,22 and food insecurity increase vulnerabilities to suboptimal cART
adherence by limiting access to HIV care and treatment services, and affecting individuals’
health seeking behaviours. Illicit drug use, e.g., crack cocaine, also impacts HIV clinical care
through the same mechanism of HIV treatment interruptions.2,10,11,54 Individually or combined,
these factors can threaten the benefits accompanied with early HIV treatment initiation and the
commitments toward eliminating the HIV pandemic. Paying particular attention to these
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interlinked social and drug use determinants should be a key priority in efforts to improve HIV
medical care for WLWH, and merits continued and thorough investigation. Given the impacts of
these SDoH adversities and risk practices on HIV care and treatment outcomes, these findings
indicate a need for regular assessment of these factors and targeted support for women with
greater needs within routine HIV care,55 which if addressed holistically, may reduce the
likelihood of suboptimal HIV clinical outcomes.
While this study took advantage of CHIWOS as the largest community-based research
cohort of WLWH in Canada, it had some limitations. First, non-random sampling of the
participants may limit the generalizability and interpretation of our findings. Second, we relied
on self-reported drug use, which may be subject to social desirability bias; however, participants
were interviewed by PRAs who also experienced living with HIV (and in some cases, using
drugs), and this may have limited such bias. Third, although unmeasured confounding is a source
of bias in observational research, our sensitivity analysis showed that relatively strong
unmeasured confounding would be required to nullify the observed associations.
The current research has several strengths despite these limitations: First, we used data
from a nationwide large sample of WLWH. Second, our research extends the relatively limited
extant knowledge on drug use among women with HIV. Third, our research contributes to
theoretical development through examining the inclusion of detailed individual-level data of
current and modifiable social determinants as leading stressors in the target population’s daily
life. Fourth, we demonstrated how these determinants cluster together using LCA, a probabilitybased technique that provides a better insight into the underlying clusters of the individual SDoH
indicators given the concurrent occurrence of these determinants. Fifth, IPW was used to account
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for both confounding and selection bias. Finally, the survey had a high retention rate (88%) after
18 months of follow-up.
Despite a growing body of evidence on the independent associations between social
determinants and drug use, less focus has been put on ways these determinants overlap, or on
their clustering impacts on drug use. The complex relationships between the SDoH indicators,
the documented (individual) associations with barriers to care, and stigma that surrounds both
drug use and many aspects of social adversity suggest that HIV care programs will need to make
intentional efforts to ensure that patients have full access to optimal care across the HIV care
cascade. Our findings support the targeted assessment of multiple social determinant and drug
use vulnerabilities; HIV-specific and women-centered care models have good potential to create
the kind of low-stigma environment that would allow for these issues to be both assessed and
addressed.56 Developing evidence-based treatment for drug dependence, including harm
reduction strategies, requires a recognition of the role of social determinants of health.
Individuals with these socio-structural adversities in intersection with drug use may continue to
experience greater challenges with regard to HIV treatment adherence and HIV outcomes;
therefore, the continued support for individuals with greater vulnerabilities is required.
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4.5. Supplementary Tables
S Table 4.1: Comparison of Goodness-of-fit Measures for Different Class Models (N=1,422)

a

Model

LLa

AICb

BICc

CAICd

Entropy

% seedse

1-class

-12363.0

10080.9

10207.2

10231.2

1.000

100%

2-class

-8582.2

2569.1

2826.9

2875.9

1.000

100%

3-class

-8271.3

1997.4

2386.7

2460.7

0.843

98.4%

4-classf

-8030.0

1564.9

2085.6

2184.6

0.831

93.5%

5-class

-7966.5

1487.8

2140.0

2264.0

0.819

35.0%

6-class

-7922.1

1449.0

2232.7

2381.7

0.814

15.0%

7-class

-7889.8

1434.5

2349.7

2523.7

0.745

32.4%

b

c

Log-Likelihood (LL); Akaike information criterion (AIC); Bayesian information criterion (BIC); d Consistent
AIC (CAIC), e Percentage of seeds associated with best fitted model (% seeds); f 4-class model had the lowest BIC
and CAIC. Moving forward to model with more classes, entropy suggested lower classification accuracy (e.g.,
~10% reduction from 4-class to 7-class). In addition, the 4-class model had a higher percentage of seeds associated
with best fitted model (i.e., increased confidence that the best solution was achieved even though it is not a fit
criterion). Fit indices/statistics align with model interpretability suggested the 4-class model provided a better fit
with plausible distribution of the sample within each class.
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S Table 4.2: Characteristics of Women Living with HIV (WLWH) who were Lost to
Follow-up (i.e., Censored), CHIWOS, 2013-2017

Variables

Not Lost to follow up

Lost to follow up

(N = 1252)

(N = 170)
0.057

SDoH classes
Class 1: No/least SDoH adversities

88 (7.03)

6 (3.53)

Class 2: Discrimination/Stigma

232 (18.53)

24 (14.12)

Class 3: Economic adversities

381 (30.43)

49 (28.82)

Class 4: Most SDoH adversities

551 (44.01)

91 (53.53)

Age, yrd (mean [SD])

42.9 [10.61]

42.2 [10.34]

0.430
0.062

Ethno-racial group
White/Caucasian

515 (41.13)

69 (40.59)

African/Caribbean/Black

380 (30.35)

38 (22.35)

Indigenous

272 (21.73)

46 (27.06)

85 (6.79)

17 (10.00)

Other

P-value

0.018

Province
Ontario

637 (50.88)

80 (47.06)

British Columbia

299 (23.88)

57 (33.53)

Quebec

316 (25.24)

33 (19.41)

Living in large cities

1029 (82.19)

140 (82.35)

0.958

heterosexual

1095 (87.81)

142 (83.53)

0.116
0.596

Relationship status
Single (non-married)

612 (48.92)

77 (45.56)

Married/common-law

394 (31.49)

60 (35.50)

Others

245 (19.58)

32 (18.93)
0.648

Years living with HIV
< 6 years

310 (25.49)

35 (22.15)

6-14 years

487 (40.05)

65 (41.14)
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> 14 years

419 (34.46)

58 (36.71)
0.012

Taking HIV treatment
Yes, optimal (≥ 95%)

759 (60.91)

104 (61.54)

Yes, suboptimal (< 95%)

264 (21.19)

48 (28.40)

Not engaged in treatment

223 (17.90)

17 (10.06)

Mental health diagnosis

499 (40.21)

74 (44.58)

0.282

Resiliency (below median)

568 (45.81)

94 (56.97)

0.007

Childhood violence

708 (61.51)

111 (71.15)

0.019

Adulthood violence

918 (79.07)

139 (90.26)

0.001

Child development events

269 (21.55)

57 (33.73)

<0.001
0.011

Heavy alcohol use
Abstainers/low (< 1 drink/week)

865 (70.44)

94 (59.12)

Moderate (1-7 drinks/week)

242 (19.71)

46 (28.93)

Heavy (> 7 drinks/week)

121 (9.85)

19 (11.95)

Before study entry

187 (15.19)

47 (28.31)

<0.001

At entry (time-point 1)

193 (15.70)

51 (30.72)

<0.001

Stimulant/opioid use
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S Table 4.3: Distributions of the Estimated Weights for the Classes of the Social
Determinants of Health (SDoH), Censoring, and both, CHIWOS, Time-point 1, 2013-2015
Mean (SD)

Percentiles
5th

25th

50th

75th

95th

Stabilized weights for
SDoH weights
Class 1

0.90 (1.30)

0.16

0.26

0.46

0.95

3.21

Class 2

0.96 (0.82)

0.39

0.54

0.74

1.04

2.20

Class 3

1.00 (0.67)

0.50

0.63

0.80

1.12

2.26

Class 4

0.99 (0.60)

0.48

0.60

0.81

1.18

2.01

Overall

0.98 (0.73)

0.43

0.58

0.78

1.13

2.18

0.99 (0.08)

0.91

0.94

0.98

1.02

1.14

Class 1

0.89 (1.38)

0.15

0.26

0.45

0.93

3.18

Class 2

0.97 (0.86)

0.39

0.53

0.73

1.02

2.30

Class 3

1.02 (0.75)

0.47

0.62

0.78

1.13

2.35

Class 4

0.97 (0.55)

0.50

0.62

0.81

1.15

1.89

Overall

0.98 (0.76)

0.43

0.58

0.77

1.12

2.12

Stabilized weights for
censoring weights
Overall
Stabilized weights for
final weights
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S Table 4.4: Inverse-Probability Weighted Estimates of the Parameters of a Marginal
Structural Model for the Association of the Classes of the Social Determinants of Health
(SDoH) on Drug Use among Women Living with HIV (WLWH), CHIWOS, Canada, 20132017
SDoH classesa
Variables

No/least SDoH

Discrimination/

Economic

adversities

stigma

adversities

0.99 (0.95, 1.02)

0.99 (0.97, 1.01)

1.00 (0.98, 1.01)

1

1

1

Indigenous

1.01 (0.29, 3.46)

0.91 (0.5, 1.66)

0.88 (0.56, 1.38)

African/Caribbean/Black

0.75 (0.36, 1.56)

0.87 (0.57, 1.32)

0.96 (0.67, 1.38)

Other

0.58 (0.18, 1.85)

0.98 (0.48, 1.99)

0.99 (0.53, 1.86)

1

1

1

British Columbia

0.61 (0.21, 1.78)

0.63 (0.39, 1.02)

1.05 (0.69, 1.59)

Quebec

0.77 (0.35, 1.67)

0.90 (0.56, 1.45)

1.00 (0.69, 1.43)

Living large size cities

1.08 (0.42, 2.74)

1.11 (0.70, 1.76)

0.96 (0.63, 1.48)

Heterosexual

0.60 (0.14, 2.56)

1.65 (0.86, 3.14)

1.22 (0.76, 1.95)

1

1

1

Married

0.84 (0.38, 1.85)

0.81 (0.53, 1.25)

1.07 (0.74, 1.56)

Others

0.89 (0.31, 2.55)

0.78 (0.49, 1.26)

1.02 (0.68, 1.53)

< 6 years

1

1

1

6-14 years

1.22 (0.49, 3.05)

0.88 (0.52, 1.49)

0.91 (0.62, 1.34)

> 14 years

1.53 (0.68, 3.48)

0.89 (0.52, 1.52)

0.95 (0.63, 1.41)

Age, yr (mean)
Ethno-racial groups
White/Caucasian

Study province
Ontario

Relationship status
Single (non-married)

Years living with HIV

Taking HIV treatment
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Yes, optimal

1

1

1

Yes, suboptimal

0.57 (0.23, 1.42)

1.11 (0.66, 1.87)

1.02 (0.67, 1.55)

Not in treatment

0.75 (0.32, 1.78)

0.97 (0.55, 1.70)

0.89 (0.59, 1.36)

Mental health diagnosis

1.44 (0.66, 3.18)

0.82 (0.55, 1.23)

0.94 (0.68, 1.31)

Resiliency (below median)

0.48 (0.22, 1.03)

0.90 (0.6, 1.34)

0.97 (0.71, 1.34)

Childhood violence

1.02 (0.51, 2.03)

0.89 (0.59, 1.34)

0.95 (0.69, 1.32)

Adulthood violence

0.71 (0.33, 1.53)

0.90 (0.55, 1.45)

0.92 (0.62, 1.37)

Childhood development events

0.67 (0.22, 2.02)

0.98 (0.56, 1.70)

0.96 (0.63, 1.45)

1

1

1

Moderate (1-7 drinks/week)

1.55 (0.55, 4.34)

0.98 (0.62, 1.57)

0.87 (0.58, 1.30)

Heavy (> 7 drinks/week)

0.30 (0.12, 0.79)b

1.68 (0.79, 3.55)

0.97 (0.57, 1.67)

Before study entry

0.95 (0.17, 5.38)

0.84 (0.37, 1.90)

0.88 (0.55, 1.41)

At entry (time-point 1)

0.89 (0.16, 5.06)

0.72 (0.32, 1.58)

0.95 (0.61, 1.50)

Heavy alcohol use
Abstainers/low (< 1 drink/week)

Stimulant/opioid use

a

b

Base class in multinomial logistic regression was most SDoH adversities; Further adjustment for this imbalanced
covariate resulted in no changes in the regression estimates presented in Table 3.
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5.

Chapter 5: A Latent Class Analysis of the Social Determinants of Health
Impacting Heavy Alcohol Consumption among Women Living with HIV
in Canada: The Canadian HIV Women’s Sexual and Reproductive
Health Cohort Study1

5.1. Introduction
Heavy alcohol consumption is prevalent among individuals living with HIV, including women.13

For example, a study conducted in the United States (US) over an 11-year follow-up period

found that almost half of women living with HIV (WLWH) reported any past-year alcohol
consumption, with 14% to 24% reporting heavy/hazardous drinking,1 defined as ≥ 4 drinks per
occasion or > 7 drinks/week.4 Research in Canada has documented that 20% (i.e., 15.4% less
than once a week and 4.6% weekly) of WLWH reported any past-month binge drinking, defined
as ≥ 4 drinks per occasion,5 compared to 34.5% (i.e., 30.6% less once a week and 3.9% weekly)
from general population women of similar ages/ethnoracial backgrounds.3
While less frequent in WLWH than the general population,3 heavy alcohol use has been
shown to be negatively associated with outcomes along the HIV treatment cascade. For example,
Monroe et al. in a US longitudinal study found that heavy drinkers and frequent binge drinkers
were respectively associated with inferior retention in HIV care and lower visit adherence.6
Research on WLWH has also documented the impact of heavy drinking and poor HIV outcomes;
for example, Barai et al. in a secondary analysis of data collected in a US randomized control
1

A version of this chapter has been published: Shokoohi M, Bauer GR, Kaida A, et al. A Latent Class Analysis of
the Social Determinants of Health Impacting Heavy Alcohol Consumption among Women Living with HIV in
Canada: The Canadian HIV Women’s Sexual and Reproductive Health Cohort Study. AIDS and Behavior. 2019;
doi: 10.1007/s10461-019-02454-3.
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trial found heavy drinking as a barrier to achieving viral suppression,7 appearing through
alteration of virus infectivity, immune response, tissue injury and inflammatory markers.8-10 In
addition, heavy drinking accounts for considerable mortality among WLWH; e.g., Neblett et al.
in a US longitudinal cohort of WLWH found that heavy drinking independently increased the
risk of earlier death by 40% (aHR = 1.40).11 Indeed, a better recognition of heavy drinking has
implications for HIV care and treatment. Further, the identification of such prevalent but
modifiable risk-taking practices is essential to improve the health and wellbeing of WLWH, who
now represent almost one-quarter of all new HIV diagnoses in Canada.12
While extant research has shown the association of increased heavy drinking with
sociodemographic factors (e.g., age and race/ethnicity) as well as psychological, and treatment or
clinical factors (e.g., viral load and CD4 indictors),1,11,13-16 less has been explored through a
social determinants of health (SDoH) framework. SDoH are living conditions in which people
are born, live, work, and age,17 and represent structural causes of health problems.17,18 SDoH are
particularly important among WLWH as an array of socio-structural adversities such as low
income, food insecurity, low social support, stigma and discrimination have been reported.19,20
Approaches informed by an SDoH framework may examine such daily living stressors that
contribute to WLWH’s likelihood of initiating or continuing heavy/hazardous drinking as a
coping behaviour. This framework underscores the complex dynamic of social, economic and
structural factors that have the potential to cluster together; a key feature of these determinants
that has been methodologically less taken into account.
In the present study, we explored the association between SDoH and heavy alcohol use
among WLWH in Canada. As SDoH tend to co-occur in particular combinations,20 we examined
the concomitant patterns of these determinants using latent class analysis (LCA). We then
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explored the association of the clustered SDoH with heavy drinking. This research is informed
by an SDoH framework contending that upstream socio-structural determinants share or
influence individuals’ health,17 as well as a syndemics framework referring to disease-social
condition interactions that synergistically influence the health of a population within the context
of persistent social inequalities.21 Understanding the unique (distinct) clusters of social
determinants through which heavy drinking may be impacted and/or intervened on can help
address alcohol use among WLWH.
5.2. Methods

5.2.1 Study sample
We used data from the community-based Canadian HIV Women’s Sexual and Reproductive
Health Cohort Study (CHIWOS). As previously described,22,23 CHIWOS enrolled WLWH aged
≥16 years, including transgender women, residing in the provinces of British Columbia (BC),
Ontario, or Quebec. A total sample of 1,422 were interviewed during 2013-2015 (time-point 1),
and 1,252 after ~18-months (2016-17, time-point 2). Participants who had died or did not
participate in time-point 2 were considered as censored (i.e., lost to follow-up; N = 170; 11.9%).
Participants were recruited from HIV clinics, community-based organizations, peers, and online
networks. The survey was administered via trained peer research associates (PRAs) through
face-to-face interviews at clinics, community sites, participants’ homes, or via phone/Skype.23
CHIWOS was approved by the Research Ethics Boards of Simon Fraser University, University
of British Columbia/Providence Health, Women’s College Hospital and McGill University
Health Centre.
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5.2.2 Alcohol use measures
Alcohol use measures at time-point 2 were considered as the study outcomes when investigating
its association with SDoH measured at time-point 1. A standard drink was defined as having a
341 ml (12 oz.) bottle of 5% alcohol beer, cider or cooler, or a 142 ml (5 oz.) glass of 12%
alcohol wine, or a 43 ml (1.5 oz.) (single shot) serving of liquor or spirits. Two measures of
alcohol consumption were defined according to the definitions from the available
recommendation:4,5
Weekly alcohol use: The average quantity of drinks per week was computed by multiplying
last-year frequency of alcohol use (with five response options: never, monthly or less, 2-4 times
a month, 2-3 times a week, 4 or more times a week) by quantity of alcohol consumed on a
typical drinking day (with five response categories: 1-2, 3-4, 5-6, 7-9, 10 or more). We used the
midpoint for response options. We then created a three-category measure: nondrinking or low
drinking (< 1 drink/week), moderate drinking (1-7 drinks/week), and heavy drinking (> 7
drinks/week).
Binge drinking: Past-month heavy binge drinking (i.e., ≥ 6 drinks on one single occasion)
at least once/month was measured and categorized into three categories: non-drinking or nonbinge drinking, infrequent binge drinking (< 1/month), or frequent binge drinking (≥ 1/month).
The typical threshold for binge drinking among women is 4 or more drinks;5 however, having a
more conservative measure of two more drinks over the typical binge drinking threshold has
been found to be of value in capturing adequately the nature of problem drinking practice in
other studies.24
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5.2.3 SDoH indicators
The following 12 potentially modifiable current or recent SDoH indicators measured at timepoint 1 were examined: race discrimination, gender discrimination, enacted HIV stigma, social
support, barriers to access to care, food security, housing status, employment status, education,
income level, recent sex work involvement, and recent incarceration. In this study, we only
included the current/recent SDoH indicators to avoid the potential for spurious correlation and
biased estimation known as collider stratification bias.25 Such bias can be introduced in studies
of selected populations (here, WLWH) if they investigate earlier exposures (here earlier social
determinants such as childhood events) that may have affected study inclusion/exclusion criteria
(here HIV status).
We separately measured racial discrimination and gender discrimination, defined as any
discriminatory mistreatments due to race and gender, using the 8-item Everyday Discrimination
Scale.26 Consistent with its operationalized definition,27 WLWH who reported (sometimes,
frequently, or almost everyday) having discriminatory experiences due to their race and gender
were considered as having experienced race discrimination and gender discrimination,
respectively. Three items of Wright's shortened version of Berger's HIV Stigma Scale were used
to measure enacted HIV stigma (i.e., been hurt by people’s reaction, stopped socializing, or lost
friends), indicating the extent to which participants faced mistreatment due to their HIV status.28
Participants who reported any HIV-related discriminatory events with strongly agree/agree
response options were considered as having experienced HIV-related stigma. A 4-item Medical
Outcome Study: Social Support Survey29 was used to gauge perceived social support, measuring
emotional-informational, tangible, affectionate, and positive social interaction supports. The
overall possible mean score ranged from 1-5, with scores > 2 indicating poor social support
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availability.30 Barriers to Access to Care was measured using a 12-item scale.31 Overall possible
mean severity scores ranged from 1-4, with scores ≥ 2 indicating severe/significant barriers.32
Food insecurity over the past 12 months was assessed using three items: fears of running out of
food; experiences of running out of food; and unaffordability of balanced meals. The sum of
these items yielded an overall score ranged 1-6, with scores > 1 indicating food insecure.33 Other
SDoH indicators included yearly household income level (less than $20,000 vs. $20,000 or
more), current employment status (unemployed [e.g., no income or income from nonemployment sources such as employment insurance/compensation/welfare, dividends and
interest, or pension plan] vs. employed [i.e., having any paid jobs]), current education level
(below high school vs. completed high school), current housing status (unstable [e.g., residing in
a self-contained room, transition house, halfway house, safe house, or outdoors] vs. stable
housing), any sex work involvement in the last six months (Yes, No), and any history of
incarceration in the last year (Yes, No).

5.2.4 Covariates
Covariates with potential association with either both SDoH classes and alcohol consumption
measures or only alcohol consumption measures were considered, including: age (continuous;
with its linear and quadratic forms in the model); ethnoracial groups (white,
African/Caribbean/Black, Indigenous, other); city size (large, others); study province (Ontario,
BC, Quebec); sexual orientation (heterosexual, LGBQ); relationship status (single (non-married),
married/common-law, others); years living with HIV (<6 years, 6-14 years, > 14 years);
antiretroviral therapy status (optimal [≥ 95% treatment adherence], suboptimal [< 95% treatment
adherence], not engaged in treatment); ever being diagnosed with a mental health condition by a
care provider (Yes, No); resilience measured using the 10-item version of the Resilience Scale,34

159

ranging 10-70, with higher scores implying increased resilience, dichotomized at its median; any
history of childhood sexual/physical violence (Yes, No); any experience of adulthood
sexual/physical/verbal/action-limited violence (Yes, No); having been under the care of Child
Protection Services or in foster care (Yes, No); last-year cigarette smoking history (never/former,
occasional/regular); last-month non-prescribed cannabis use (never/former, occasional/regular),
last three months any non-prescribed/illicit opioid and/or stimulant use (Yes, No), ever used
alcohol counseling services (Yes, No).

5.2.5 Latent class analysis (LCA)
We conducted LCA to identify the clusters of SDoH assessed at time-point 1. LCA as a data
reduction strategy is a probabilistic model-based clustering technique to detect unobserved but
homogenous patterns of the observed indicators within an unobserved categorical measure. LCA
identifies such latent variable under the assumption that all observed indicators are independent
given the latent variable (i.e., the latent variable is the reason that observed indicators are
correlated).35 The expectation–maximization (EM) algorithm with 5,000 iterations was used to
find the best model fit.36 We started LCA with a 2-class model and progressively increased (S
Table 5.1), for each the log-likelihood was replicated with 1,000 random starting values to
increase the confidence that the best identified model solution is the true maximum likelihood
solution. Therefore, we reported the percentage of seeds associated with best fitting model, with
higher values indicating being unlikely to hit the local maxima. While we predominantly relied
on the interpretability of class memberships, the following fit statistics were also reported to help
obtain the best model: log-likelihood, Akaike’s information criteria (AIC), Bayesian information
criteria (BIC), and sample-size-adjusted BIC (aBIC), and consistent AIC (CAIC),37-39 with their
lower values implying better goodness-of-fit and parsimony. Entropy as a measure of
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classification accuracy was also reported (varied from 0 to 1), with higher values suggesting
clearer separation/distinction among the latent classes.35
As shown in (S Table 5.1), we proposed the 4-class model as the best fitting model of the
SDoH classes among WLWH. The observed prevalence of each item as well as item-response
probabilities (Yes category only) condition on class membership of the 4-class model are
illustrated in Supplementary Figure 1. These four classes included: WLWH who experienced
none or only one SDoH adversity (class 1, labeled as none/least SDoH adversities; 6.6%);
WLWH who predominantly reported experiencing racial discrimination, gender discrimination
and HIV-related stigma, accompanied by experiencing barriers in access to care without
economic hardship experiences (class 2, labeled as discrimination/stigma group; 17.9%);
WLWH who mainly reported food insecurity, low household income, and unemployment
without stigma/discrimination (class 3, labeled as economic hardship group; 31.6%); and
WLWH who experienced gender and racial discrimination, HIV-related stigma, low social
support, greater difficulties access to care, food insecurity, low income, and unemployment
(class 4, labeled as most SDoH adversities; 43.9%). After identification of the fitting model, each
participant was assigned to the SDoH latent classes in which they had the greater posterior
probability. LCA accounted for missing values using the full information maximum likelihood
estimation under the assumption of missing at random. We conduced LCA using the SAS PROC
LCA procedure.35

5.2.6 Models and estimations
Inverse probability weights (IPW) was used to account for confounding bias due to the
potentially imbalanced covariates across the SDoH classes. We also used inverse probability
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censoring weights (IPCW) to account for prospective selection bias due to potentially nonrandom loss to follow-up (S Table 5.2).
Covariate selection: Consistent with recommendations,40 measured covariates that were
potentially associated with the study outcomes were considered. To account for confounding by
outcome history, we also included alcohol use measures at time-point 1.41 Missing values of
covariates considered for generating the weights were singly imputed under the assumption of
missing at random to reduce the loss of statistical power.42
Control of confounding using IPW: We generated stabilized weights using multinomial
logistic regression models: the numerator was computed as the marginal probability of the SDoH
classes (accounting for imbalanced proportions of the SDoH classes) divided by the denominator
which was computed as the probability that a participant assigned to a SDoH class conditioning
on the measured covariates. These models were performed among WLWH without censored
information in time-point 2.
Control of selection bias using IPCW: We first created a binary measure indicating
censored individuals at time-point 2. Then, IPCW using binary logistic regression model was
obtained: the numerator was defined as the probability of not being censored given SDoH
classes, and the denominator was calculated as the probability of not being censored given SDoH
and the study covariates.43
Final stabilized weight: We created the final stabilized weight using the product of IPW
and IPCW. The distribution of the weights across the SDoH classes is presented in (S Table 5.3).
Under the following assumptions: correct specification of IPW models, conditional
exchangeability, and positivity,44 the final weight removes the association between SDoH
classes, as the main independent variable, and the study covariates43 (S Table 5.4).
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Association of SDoH classes with alcohol use measures: The association between SDoH
classes and alcohol use measures was examined using multinomial logistic regression models as
the alcohol use outcomes had more than two categories. We then estimated crude and weighted
relative-risk ratios (RRR) and 95% confidence intervals (CI). Further adjustment was made for
history of the study outcomes. Additionally, a sensitivity analysis was conducted to evaluate the
extent to which unmeasured confounding would explain away the observed associations. To do
this, we computed the E-values as: E = RRR + sqrt{RRR × RRR – 1}, where RRR referred to the
significant observed estimates. We replaced RRR with RRR* = 1/RRR for those estimates less
than the null (RRR = 1).45 E-value for RRR provides values below, equal to or above the null,
representing the minimum strength of the association between unmeasured confounders with
SDoH clusters and/or alcohol use to nullify the observed associations. These analyses were done
using Stata 15.
5.3. Results

5.3.1 Participants’ characteristics
Characteristics of study participants enrolled in time-point 1 can be seen in Table 5.1. The mean
age was 42.8 [SD 10.6] years old. The largest category identified as white (41.1%), while 29.4%
identified as African/Caribbean/Black, 22.3% as Indigenous, and 7.2% as other. The majority
reported their sexual orientation as heterosexual (87.3%). About one-third (32%) reported being
in a relationship, married, or common-law; 40.2% reported living with HIV for 6-14 years; and
70.0% reported optimal HIV treatment adherence. Childhood and adulthood violence were
reported by 62.7% and 80.4%, respectively. Ever having a mental health diagnosis was reported
by 40.7%. The distribution of these covariates across the SDoH classes is also presented in
Table 5.1.
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Table 5.1: Characteristics of Women Living with HIV Overall and Stratified by Social Determinants of Health (SDoH)
Classes, CHIWOS Survey – Time-point 1
Overall

Variables at time-point 1

SDoH classes at time-point 1
None/least

Discrimination/

Economic

Most

adversities

stigma

hardship

adversities

P-valueb

N

1,422 (100)

94 (6.6)

256 (18.0)

430 (30.2)

642 (45.2)

---

Age, yr (mean [SD])

42.8 [10.6]

39.2 [10.3]

43.5 [10.6]

42.9 [11.5]

43.1 [10.0]

0.007
<0.001

Ethno-racial identity
White

584 (41.1)a

58 (61.7)

97 (37.9)

219 (50.9)

210 (32.7)

African/Caribbean/Black

418 (29.4)

23 (24.5)

109 (42.6)

123 (28.6)

163 (25.4)

Indigenous

318 (22.3)

7 (7.4)

29 (11.3)

60 (14.0)

222 (34.6)

Other

102 (7.2)

6 (6.4)

21 (8.2)

28 (6.5)

47 (7.3)
<0.001

Province
Ontario

717 (50.4)

50 (53.2)

131 (51.2)

235 (54.6)

301 (46.9)

British Columbia

356 (25.0)

13 (13.8)

49 (19.1)

65 (15.1)

229 (35.7)

Quebec

349 (24.6)

31 (33.0)

76 (29.7)

130 (30.2)

112 (17.5)

Living in large cities

1169 (82.2)

83 (88.3)

203 (79.3)

345 (80.2)

538 (83.8)

0.106

Being heterosexual

1237 (87.3)

85 (90.4)

237 (93.3)

395 (91.9)

520 (81.4)

<0.001
<0.001

Relationship status
Single (non-married)

689 (48.5)

40 (42.6)

100 (39.1)

201 (46.7)

348 (54.4)

Married/common-law

454 (32.0)

44 (46.8)

103 (40.2)

134 (31.1)

173 (27.0)
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Others

277 (19.5)

10 (10.6)

53 (20.7)

95 (22.1)

119 (18.6)
0.001

Years living with HIV
< 6 years

345 (25.1)

23 (25.0)

40 (15.7)

128 (31.4)

154 (24.8)

6-14 years

552 (40.2)

35 (38.0)

118 (46.7)

140 (34.3)

259 (41.8)

> 14 years

477 (34.7)

34 (37.0)

96 (37.8)

140 (34.3)

207 (33.4)
0.001

Taking treatment
Yes, optimal adherence (≥ 95%)

863 (70.0)

65 (69.9)

163 (64.7)

279 (65.0)

356 (55.5)

Yes, suboptimal adherence (< 95%)

312 (22.0)

12 (12.9)

52 (21.4)

74 (17.2)

172 (26.8)

Not engaged in treatment

240 (17.0)

16 (17.2)

35 (13.9)

76 (17.7)

113 (17.6)

Mental health diagnosis

573 (40.7)

26 (28.0)

93 (36.6)

134 (31.6)

320 (50.3)

<0.001

Low resiliency (below median)c

662 (47.1)

22 (23.66)

104 (40.9)

172 (40.6)

364 (57.4)

<0.001

Childhood violence

819 (62.7)

34 (38.6)

138 (56.8)

211 (53.8)

436 (74.7)

<0.001

Adulthood violence

1057 (80.4)

52 (59.1)

189 (77.5)

284 (71.9)

532 (90.5)

<0.001

Child development events

326 (23.0)

10 (10.6)

33 (13.0)

74 (17.3)

209 (32.7)

<0.001

Cigarette smoking

616 (43.7)

15 (16.1)

65 (25.5)

176 (41.1)

360 (56.7)

<0.001

264 (18.9)

7 (7.7)

34 (13.4)

75 (17.7)

148 (23.6)

<0.001

244 (17.5)

2 (2.2)

11 (4.3)

50 (11.9)

181 (28.8)

<0.001

3 (3.2)

24 (9.4)

60 (14)

201 (31.3)

3 (3.2)

<0.001

(regular/occasional)
Non-prescribed cannabis use
(regular/occasional)
Drug used
Received alcohol counseling
Weekly alcohol use

0.132
165

Abstainers to low (<1 drink)

956 (69.1)

64 (68.8)

174 (68.5)

302 (71.1)

419 (68.1)

Moderate (1 to 7 drinks)

288 (20.8)

22 (23.7)

60 (23.6)

88 (20.7)

118 (19.2)

Heavy (>7 drinks)

140 (10.1)

7 (7.5)

20 (7.9)

35 (8.2)

78 (12.7)
0.037

Binge drinking
Non-drinkers/no binge drinking

1107 (81.9)

73 (79.4)

214 (85.3)

348 (85.5)

472 (78.5)

14 (1.0)

1 (1.1)

4 (1.6)

1 (0.3)

8 (1.3)

230 (17.0)

18 (19.6)

33 (13.2)

58 (14.3)

121 (20.1)

Infrequent (< 1 per month)
Frequent (≥ 1 per month)
a

b

Data are presented as N (%) unless specified; P-values are for the chi-square test for categorical covariates and one-way ANOVA for continuous covariates; c

Scores ranged 10-70, with higher scores indicating increased resilience (median = 64); d Last three months any non-prescribed/illicit opioid and/or stimulant use
measured.
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5.3.2 Weekly alcohol use
Overall, moderate (1-7 drinks/week) and heavy (>7 drinks/week) alcohol use at time-point 2
were reported by 20.1% and 10.5%, respectively. Heavy alcohol use at time-point 2 was reported
by 6.8% among WLWH in no/least SDoH adversities, 10.2% among WLWH in
discrimination/stigma class, 8.8% among economic hardship class, and 12.6% among WLWH in
the most SDoH adversities class (Table 5.2).
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Table 5.2: Alcohol Consumption Measures (Study Outcomes) Overall and Across the Social Determinants of Health (SDoH)
Classes among Women Living with HIV, CHIWOS Survey
Overall

Alcohol use measures at time-

SDoH classes at time point 1
None/least

Discrimination/

Economic

Most

adversities

stigma

hardship

adversities

88

231

378

540

P-value

point 2
N

1237

Weekly alcohol use*

--0.006

Abstainers to low (<1 drink)

858 (69.4)

55 (62.5)

156 (67.5)

282 (74.6)

365 (67.6)

Moderate (1 to 7 drinks)

249 (20.1)

27 (30.7)

54 (23.4)

65 (17.2)

103 (19.1)

Heavy (>7 drinks)

130 (10.5)

6 (6.8)

21 (9.1)

31 (8.2)

72 (13.3)

Binge drinkingb,*

0.001

Non-drinkers/no binge drinking

952 (77.5)

70 (79.6)

183 (79.2)

309 (82.4)

390 (72.9)

Infrequent (< 1 per month)

155 (12.6)

15 (17.1)

33 (14.3)

32 (8.5)

75 (14)

Frequent (≥ 1 per month)

122 (9.9)

3 (3.4)

15 (6.5)

34 (9.1)

70 (13.1)

a

Data are presented as N (%); b Heavy binge drinking at time-point 2 was defined as having 6 or more drinks in one single occasion; * P-value < 0.05, indicating
that the distribution of both alcohol consumption measures is significantly different across the SDoH classes.
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Our results showed no crude associations between SDoH classes and heavy weekly alcohol
consumption. However, the weighted regression analysis demonstrated that WLWH in no/least
SDoH adversities had lower likelihood of weekly heavy alcohol use than WLWH in
discrimination/stigma class (RRR = 0.10; 95% CI: 0.02, 0.68), economic hardship class (RRR =
0.18; 95% CI: 0.03, 1.04; not significant), and most SDoH adversities class (RRR = 0.11; 0.02,
0.62). While crude associations showed an increased likelihood of moderate weekly alcohol
consumption among WLWH in the no/least SDoH adversity in comparison with other three
classes, no significant association was observed in the weighted analyses (Table 5.3).
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Table 5.3: The Association of Social Determinants of Health (SDoH) Classes on Weekly Alcohol Use using Inverse-Probability
Weighting Analysis among Women Living with HIV in Canada, CHIWOS Survey
Moderate use (1-7 drinks per week)a

Heavy use (> 7 drinks per week)a

Crude estimates

IPW estimates

Crude estimates

IPW estimates

b

RRR (95% CI)

RRR (95% CI)

RRR (95% CI)

SDoH classes at time-point 1

RRR (95% CI)

Economic hardship vs. most adversities

0.82 (0.58 ,1.16)

0.66 (0.43, 1.01)

0.56 (0.36 ,0.87)

0.61 (0.32, 1.13)

0.253

0.060

0.011

0.120

1.23 (0.84 ,1.79)

1.04 (0.59, 1.84)

0.68 (0.41 ,1.15)

1.09 (0.39. 3.03)

0.291

0.866

0.151

0.863

1.74 (1.04 ,2.9)

0.39 (0.09, 1.62)

0.55 (0.23 ,1.33)

0.11 (0.02, 0.62)

0.033

0.200

0.187

0.013

1.50 (1.00 ,2.26)

1.56 (0.87, 2.83)

1.22 (0.68 ,2.20)

1.79 (0.64, 4.95)

0.052

0.135

0.499

0.262

2.13 (1.25 ,3.63)

0.59 (0.14, 2.45)

0.99 (0.40 ,2.49)

0.18 (0.03, 1.04)

0.005

0.473

0.987

0.056

1.42 (0.81 ,2.47)

0.38 (0.08, 1.64)

0.81 (0.31 ,2.11)

0.10 (0.02, 0.68)

0.217

0.196

0.667

0.019

P-value
Discrimination/stigma vs. most adversities
P-value
No/least adversities vs. most adversities
P-value
Discrimination/stigma vs. economic hardship
P-value
No/least adversities vs. economic hardship
P-value
No/least adversities vs. discrimination/stigma
P-value
a

Base Group in Multinomial Logistic Regression: Abstainers to Low [<1 drink/week]); b RRR: relative-risk ratio (95% confidence intervals: CI); c Italicized
estimates indicate having a p-value less than 0.10; d Bold estimates indicate having a p-value less than 0.05.
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5.3.3 Binge drinking
Overall, infrequent (<1/month) and frequent (≥1/month) binge drinking at time-point 2 were
reported by 12.6% and 9.9%, respectively. Frequent binge drinking was reported by 3.4% among
WLWH in no/least SDoH adversities, 7.2% among WLWH in discrimination/stigma class, 9.6%
among economic hardship class, and 12.3% among WLWH in the most SDoH adversities class
(Table 5.2). WLWH in no/least SDoH adversities class were shown to have a lower likelihood
of frequent binge drinking than WLWH in discrimination/stigma class (RRR 0.02; 95% CI:
0.002, 0.21), economic hardship class (RRR = 0.03; 95% CI: 0.01, 0.24), and most SDoH
adversities class (RRR = 0.02; 95% CI: 0.002, 0.13). Furthermore, the likelihood of infrequent
binge drinking was lower among WLWH in no/least SDoH adversities class than those in
discrimination/stigma and the most SDoH adversities classes (Table 5.4).
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Table 5.4: The Association of the Classes of Social Determinants of Health (SDoH) on Binge Drinking using InverseProbability Weighting Analysis among Women Living with HIV in Canada, CHIWOS Survey
Binge drinking < 1 per montha

Binge drinking ≥ 1 per montha

Crude estimates

IPW estimates

Crude estimates

IPW estimates

b

RRR (95% CI)

RRR (95% CI)

RRR (95% CI)

SDoH classes at time-point 1

RRR (95% CI)

Economic hardship vs. most adversities

0.53 (0.34, 0.83)

0.75 (0.35, 1.59)

0.61 (0.39, 0.94)

0.56 (0.29, 1.10)

0.006

0.456

0.028

0.097

0.93 (0.60, 1.46)

1.57 (0.76, 3.22)

0.45 (0.25, 0.82)

0.70 (0.28, 1.70)

0.777

0.217

0.009

0.432

1.11 (0.60, 2.05)

0.20 (0.04, 0.99)

0.23 (0.07, 0.77)

0.02 (0.002, 0.13)

0.728

0.050

0.018

< 0.001

1.74 (1.03, 2.92)

2.09 (0.81, 5.39)

0.74 (0.39, 1.40)

1.23 (0.46, 3.26)

0.036

0.126

0.363

0.671

2.06 (1.06, 4.02)

0.26 (0.04, 1.44)

0.38 (0.11, 1.30)

0.03 (0.01, 0.24)

0.032

0.127

0.126

0.001

1.18 (0.60, 2.32)

0.12 (0.02, 0.69)

0.52 (0.14, 1.86)

0.02 (0.002, 0.21)

0.614

0.017

0.317

0.001

P-value
Discrimination/stigma vs. most adversities
P-value
No/least adversities vs. most adversities
P-value
Discrimination/stigma vs. economic hardship
P-value
No/least adversities vs. economic hardship
P-value
No/least adversities vs. discrimination/stigma
P-value
a

Base Group in Multinomial Logistic Regression: Non-Drinkers/No Binge Drinking; b RRR: relative-risk ratio (95% confidence intervals: CI); c Italicized
estimates indicate having a p-value less than 0.10; d Bold estimates indicate having a p-value less than <0.05.
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5.3.4 Sensitivity analysis
The sensitivity analysis reflected that our observed associations were relatively robust to
potential unmeasured confounding. For example, for the observed RRR: 0.11 for heavy weekly
alcohol consumption among WLWH in the no/least SDoH adversities class versus the most
SDoH adversities class, an unmeasured confounder correlated with both exposure and outcome
by RRRs of ~17.6-fold each, above and beyond the measured confounders, would explain away
the observed association, but weaker confounding would not. Such an E-value for the upper 95%
limit of the same comparison (Upper CI = 0.62) was 2.6-fold. The E-values for the significant
observed associations were reported in (S Table 5.5).
5.4. Discussion
We explored the pattern of alcohol consumption measures and their association with four SDoH
classes in a diverse cohort of WLWH in Canada. We found that 10.5% of WLWH reported
heavy weekly alcohol use at enrollment and 9.9% reported frequent binge drinking at ~18
months follow up, with greater proportion among WLWH who experienced multiple forms of
SDoH adversities than those with no/least SDoH adversity. We also documented that WLWH
with no/least SDoH adversity were less likely to report heavy alcohol consumption relative to
WLWH experiencing either discrimination/stigma or economic hardship or suffering from the
most SDoH adversities. These findings can inform intervention strategies to advance health
among WLWH.
Our research contributes to the literature in several ways. Firstly, we found that a large
proportion of WLWH reported experiencing specific forms of socio-structural adversities
including economic hardship and stigma/discrimination, or multiple types of disadvantages.
Secondly, this study adds to the current understanding of how social determinants clustered
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together and such clustering increased the likelihood of heavy drinking among WLWH. Thirdly,
we documented that the risk of alcohol use did not change much (vs. no/least SDoH class)
whether a women reported experiencing primarily stigma/discrimination, primarily economic
hardship, or the most SDoH adversities. These findings may indicate that in addressing heavy
drinking, it is important to consider the role that any form of SDoH inequities play in shaping
such risk-taking practice. This is particularly important as heavy drinking has been shown to be a
significant predictor of mortality among WLWH of the same cohort in Canada.22 Overall, our
findings suggest that WLWH continue to experience a high level of stress as a result of social
and structural inequalities, contributing to elevated risk of alcohol consumption.46,47
While it is difficult for us to compare our findings directly with prior research, these
findings are in line with the extant literature, implying that a greater level of social adversity is
associated with increased likelihood of heavy drinking among WLWH.1,13,14 Previous studies
have mostly reported the independent impact of individual social factors (either modifiable or
non-modifiable ones) on alcohol use. For example, Cook et al. in a longitudinal study identified
unemployment and low education as the independent predictors of heavy alcohol consumption
among WLWH.1 They also found the independent effect of low education (but not employment
or race/ethnicity) on higher odds of heavy drinking in a trajectory analysis.13 In 2018, KelsoChichetto et al. found an association between alcohol consumption trajectories and
race/ethnicity, but not with annual income levels among WLWH.14 Concentrating on modifiable
social factors, we found a significant association of the clustered SDoH on heavy drinking
among WLWH. While our estimates relied on a set of SDoH indicators gathered on only one
time-period, future research could conduct a trajectory analysis to assess the stability of these
social determinants over time in association with behavioural and HIV treatment outcomes.
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Our study had some limitations. First, CHIWOS used a purposive, nonrandom sampling
approach that may have oversampled WLWH receiving care, who may have different
characteristics such as sociodemographic or socio-structural vulnerabilities than other WLWH.
In turn, CHIWOS also oversampled WLWH experiencing intersecting forms of marginalization
such as sex work and substance use to mitigate sampling bias.22 Second, data on both alcohol use
and social determinants were gathered via self-report, and are subject to social desirability and
recall biases (particularly the past-year frequency and quantity of alcohol use). However, the
survey was administered by PRAs who are also WLWH,22 to build trust with participants in
sharing their information.23
Despite these limitations, this study has several notable strengths. We included a large
sample of WLWH with diverse ethno-racial identities and social-economic experiences, which
may provide a better picture of the target population beyond only those in clinical settings.
Second, this research enhances understanding of the clustered SDoH and their association with
heavy alcohol use. Third, a large proportion of the study sample remained in the follow-up
survey, allowing for assessment of study outcomes which makes temporality between SDoH
classes and alcohol use measures clear. Fourth, use of LCA including 12 SDoH indicators
allowed for data reduction and a clearer presentation of the impact of the clustered SDoH on the
study outcomes. This underscores the interdependent nature of the SDoH beyond their
independent impacts.

5.4.1 Conclusion
Approximately one out of ten WLWH from the CHIWOS cohort met criteria for heavy drinking
and frequent binge drinking, with higher likelihood among those experiencing overlapping forms
of SDoH adversities. Our findings suggest that multiple forms of SDoH adversities – regardless
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of their types – can substantially impact the initiation/continuation of heavy drinking. In the
current era where viral suppression is achieved and an improved survival is expected among
individuals who have access to HIV medications and are on treatment and in care,48,49 adversities
regarding socioeconomic and structural determinants as well as behavioural factors (heavy
drinking) may undermine the efforts of the management of HIV. Effective interventions aiming
to target WLWH who drink at heavy levels should also consider the substantial contribution of
socio-structural barriers that WLWH inequitably experience in their daily life. While integration
of harm reduction approach into HIV care through the women-centered care model may be
considered as an approach in addressing heavy drinking and social barriers,50 more evidencebased research is needed to determine the effectiveness of such interventions. Our findings
highlight the urgency to address SDoH for interventions to be fully beneficial for WLWH who
involve in heavy drinking.
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5.5. Supplementary Tables and Figures
S Table 5.1: Comparison of Goodness-of-fit Measures for Different Class Models (N=1,422)

a

Model

LLa

AICb

BICc

CAICd

Entropy

% seedse

1-class

-12363.0

10080.9

10207.2

10231.2

1.000

100%

2-class

-8582.2

2569.1

2826.9

2875.9

1.000

100%

3-class

-8271.3

1997.4

2386.7

2460.7

0.843

98.4%

4-classf

-8030.0

1564.9

2085.6

2184.6

0.831

93.5%

5-class

-7966.5

1487.8

2140.0

2264.0

0.819

35.0%

6-class

-7922.1

1449.0

2232.7

2381.7

0.814

15.0%

7-class

-7889.8

1434.5

2349.7

2523.7

0.745

32.4%

b

c

Log-Likelihood (LL); Akaike information criterion (AIC); Bayesian information criterion (BIC); d Consistent
AIC (CAIC), e Percentage of seeds associated with best fitted model (% seeds); f 4-class model had the lowest BIC
and CAIC. Moving forward to model with more classes, entropy suggested lower classification accuracy (e.g.,
~10% reduction from 4-class to 7-class). In addition, the 4-class model had a higher percentage of seeds associated
with best fitted model (i.e., increased confidence that the best solution was achieved even though it is not a fit
criterion). Fit indices/statistics align with model interpretability suggested the 4-class model provided a better fit
with plausible distribution of the sample within each class.
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S Table 5.2: Characteristics of Women Living with HIV who were Lost to Follow-up (i.e.,
Censored), CHIWOS, 2013-2017

Variables at time-point 1

Not Lost to follow up

Lost to follow up

(N = 1252)

(N = 170)
0.057

SDoH classes
88 (7.03)a

6 (3.53)

Class 2: Discrimination/Stigma

232 (18.53)

24 (14.12)

Class 3: Economic adversities

381 (30.43)

49 (28.82)

Class 4: Most SDoH adversities

551 (44.01)

91 (53.53)

Age, yr (mean [SD])

42.9 [10.61]

42.2 [10.34]

Class 1: No/least SDoH adversities

0.430
0.062

Ethno-racial group
White

515 (41.13)

69 (40.59)

African/Caribbean/Black

380 (30.35)

38 (22.35)

Indigenous

272 (21.73)

46 (27.06)

85 (6.79)

17 (10.00)

Other

P-valueb

0.018

Province
Ontario

637 (50.88)

80 (47.06)

British Columbia

299 (23.88)

57 (33.53)

Quebec

316 (25.24)

33 (19.41)

Living in large cities

1029 (82.19)

140 (82.35)

0.958

Heterosexual

1095 (87.81)

142 (83.53)

0.116
0.596

Relationship status
Single (non-married)

612 (48.92)

77 (45.56)

Married/common-law

394 (31.49)

60 (35.50)

Others

245 (19.58)

32 (18.93)
0.648

Years living with HIV
< 6 years

310 (25.49)

35 (22.15)

6-14 years

487 (40.05)

65 (41.14)
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> 14 years

419 (34.46)

58 (36.71)
0.012

Taking treatment
Yes, optimal adherence (≥ 95%)

759 (60.91)

104 (61.54)

Yes, suboptimal adherence (< 95%)

264 (21.19)

48 (28.40)

Not engaged in treatment

223 (17.90)

17 (10.06)

Mental health diagnosis

499 (40.21)

74 (44.58)

0.282

Low resiliencyc (below median)

568 (45.81)

94 (56.97)

0.007

Childhood violence

708 (61.51)

111 (71.15)

0.019

Adulthood violence

918 (79.07)

139 (90.26)

0.001

Child development events

269 (21.55)

57 (33.73)

<0.001

516 (41.4)

100 (60.2)

<0.001

226 (18.4)

38 (23.0)

0.150

Drug used

193 (15.7)

51 (30.7)

<0.001

Received alcohol counseling

234 (18.7)

54 (31.8)

<0.001

Cigarette smoking
(regular/occasional)
Non-prescribed cannabis use
(regular/occasional)

0.011

Weekly alcohol use
Abstainers to low (<1 drink)

865 (70.4)

94 (59.1)

Moderate (1 to 7 drinks)

242 (19.7)

46 (28.9)

Heavy (>7 drinks)

121 (9.8)

19 (11.9)
<0.001

Binge drinking
Non-drinkers/no binge drinking
Infrequent (< 1 per month)
Frequent (≥ 1 per month)
a

997 (83.6)

110 (69.2)

12 (1.0)

2 (1.3)

183 (15.3)

47 (29.6)

b

Data are presented as N (%) unless specified; P-values are for the chi-square test for categorical covariates and
one-way ANOVA for continuous covariates; c Scores ranged 10-70, with higher scores indicating increased
resilience (median = 64); d Last three months any non-prescribed/illicit opioid and/or stimulant use measured.
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S Table 5.3: Distributions of the Estimated Weights for the Classes of the Social
Determinants of Health (SDoH), Censoring, and both, CHIWOS, Time-point 1, 2013-2015
Mean (SD)

Percentiles
5th

25th

50th

75th

95th

Stabilized weights for
SDoH weights
Class 1a

0.97 (2.50)

0.12

0.20

0.43

1.00

2.26

Class 2

1.01 (1.04)

0.39

0.51

0.72

0.98

3.19

Class 3

0.99 (0.67)

0.48

0.61

0.79

1.11

2.16

Class 4

0.99 (0.61)

0.48

0.58

0.80

1.16

2.19

Overall

0.99 (0.97)

0.41

0.57

0.78

1.12

2.25

1.00 (0.08)

0.91

0.94

0.98

1.02

1.15

Class 1

1.01 (2.90)

0.12

0.21

0.43

0.99

2.17

Class 2

1.04 (1.16)

0.38

0.51

0.71

1.03

3.3

Class 3

1.00 (0.75)

0.45

0.62

0.78

1.13

2.24

Class 4

0.97 (0.55)

0.51

0.61

0.78

1.12

2.01

Overall

0.99 (1.06)

0.40

0.58

0.76

1.09

2.17

Stabilized weights for
censoring weights
Overall
Stabilized weights for
final weights

a

Class 1: No/least SDoH adversities; Class 2: Discrimination/Stigma; Class 3: Economic adversities; Class 4: Most
SDoH adversities
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S Table 5.4: Inverse-Probability Weighted Estimates of the Parameters of a Marginal
Structural Model for the Association of the Social Determinants of Health (SDoH) Classes
on Alcohol Use Measures among Women Living with HIV, CHIWOS, Canada, 2013-2017
SDoH classesa
Variables

No/least SDoH

Discrimination/

Most SDoH

adversities

stigma

adversities

0.97 (0.93, 1.01)b

0.99 (0.97, 1.01)

1 (0.99, 1.02)

Indigenous

2.07 (0.45, 9.6)

1.08 (0.58, 2.03)

0.88 (0.56, 1.39)

African/Caribbean/Black

0.94 (0.43, 2.03)

0.86 (0.56, 1.32)

0.95 (0.66, 1.37)

Other

0.63 (0.18, 2.21)

1.04 (0.43, 2.53)

0.96 (0.52, 1.78)

British Columbia

0.35 (0.1, 1.23)

0.62 (0.36, 1.07)

0.99 (0.65, 1.52)

Quebec

0.53 (0.19, 1.47)

0.91 (0.54, 1.52)

0.99 (0.69, 1.42)

Living large size cities

1.79 (0.62, 5.14)

1.18 (0.73, 1.92)

0.97 (0.63, 1.47)

Heterosexual

0.27 (0.05, 1.55)

1.37 (0.62, 3.02)

1.19 (0.74, 1.89)

Married

0.74 (0.23, 2.37)

0.76 (0.48, 1.2)

1.03 (0.71, 1.49)

Others

0.67 (0.17, 2.62)

0.64 (0.39, 1.04)

1.05 (0.71, 1.58)

6-14 years

2.23 (0.64, 7.72)

0.85 (0.48, 1.51)

0.9 (0.62, 1.32)

> 14 years

1.76 (0.78, 3.97)

0.81 (0.46, 1.44)

1.01 (0.68, 1.52)

0.45 (0.12, 1.64)

1.28 (0.74, 2.21)

1.05 (0.68, 1.6)

Age, yr (mean)
Ethno-racial groups
(Ref: White)

Study province
(Ref: Ontario)

Relationship status
(Ref: Single)

Years living with HIV
(Ref: < 6 yrs)

Taking treatment
(Ref: Yes, optimal)
Yes, suboptimal
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Not in treatment

0.6 (0.2, 1.77)

1 (0.53, 1.89)

0.87 (0.57, 1.31)

Mental health diagnosis

1.62 (0.49, 5.4)

0.82 (0.53, 1.28)

0.96 (0.69, 1.33)

Low resiliencyc (below median)

0.32 (0.11, 0.91)

1.01 (0.66, 1.55)

0.96 (0.7, 1.32)

Childhood violence

1.15 (0.42, 3.14)

1.08 (0.71, 1.63)

0.97 (0.7, 1.33)

Adulthood violence

0.73 (0.26, 2.06)

0.99 (0.6, 1.62)

0.91 (0.61, 1.36)

Childhood development events

0.42 (0.11, 1.57)

1.22 (0.68, 2.17)

0.96 (0.64, 1.45)

1.11 (0.29, 4.22)

1.2 (0.77, 1.84)

0.97 (0.71, 1.34)

(regular/occasional)

0.44 (0.12, 1.63)

1.19 (0.66, 2.14)

0.8 (0.54, 1.18)

Drug used

2.12 (0.32, 13.91)

0.77 (0.34, 1.73)

0.9 (0.57, 1.4)

Received alcohol counseling

2.16 (0.39, 11.9)

1.53 (0.84, 2.78)

0.79 (0.5, 1.25)

2.39 (0.53, 10.74)

1.23 (0.71, 2.11)

0.84 (0.56, 1.27)

0.3 (0.09, 0.93)

1.66 (0.76, 3.67)

1.09 (0.63, 1.89)

Less than once per month

9.36 (1.18, 74.31)

0.46 (0.17, 1.22)

0.54 (0.23, 1.26)

At least once per month

0.59 (0.26, 1.34)

1.41 (0.76, 2.63)

0.93 (0.59, 1.46)

Cigarette smoking
(regular/occasional)
Non-prescribed cannabis use

Heavy alcohol use
(Ref: Abstainers/low)
Moderate (1-7 drinks/week)
Heavy (> 7 drinks/week)
Binge drinking (Ref: Nondrinkers/no binge drinking)

a

b

Base group in multinomial logistic regression was “the most SDoH adversities”; Data are presented as relative-risk ratio

(RRR) and 95% confidence intervals (CI); c Scores ranged 10-70, with higher scores indicating increased resilience (median =
64); d Last three months any non-prescribed/illicit opioid and/or stimulant use measured.
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S Table 5.5: Sensitivity Analysis of the Magnitude of Potential Unmeasured Confounding
that Would Totally Explain Away the Observed [Significant] Association from the Inverse
Probability Weighting Analysis between the Classes of the Social Determinants of Health
(SDoH) and Alcohol Use Measures

SDoH Clusters

No/least adversities vs. most

E-value

E-value for

E-value

E-value for

for point

CI close to

for point

CI close to

estimate

the null

estimate

the null

Moderate weekly alcohol

Heavy weekly alcohol

usea

usea

---c

---

17.6

2.6

---

---

19.5

2.3

adversities
No/least adversities vs.
discrimination/stigma
Infrequent binging
b

(< 1/month)
No/least adversities vs. most

Frequent binging
(≥ 1/month)b

9.5

1.1

99.5

14.9

---

---

66.1

7.8

16.1

2.3

99.5

9.0

adversities
No/least adversities vs. economic
hardship
No/least adversities vs.
discrimination/stigma
a

Base group: nondrinking or low (< 1 drink per week); b Base group: Non-drinkers/no binge drinking; c
The sensitivity analysis was not done for these estimates as the 95% CIs of their observed point estimate
crossed the null RRR = 1.
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S Figure 5.1: Prevalence and Item-Response Probabilities (= Yes) for each Social Determinant of Health (SDoH) Obtained
from Latent Class Analysis with four Classes among Women Living with HIV– CHIWOS (n=1,422)

RD: Racial Discrimination, GD: Gender Discrimination, ST: HIV-related Stigma, SS: Perceived Social Support, BR: Barriers to Access to Care, FI: Food
Insecurity, LI: Low Household Income, UE: Unemployment, ED: Low Education, HS: Unstable Housing; SW: Recent Sex Work Involvement, IN: Recent
Incarceration;
Class 1 (6.6%): none/least SDoH adversities (the assigned probability for this class was 0), Class 2 (17.9%): a group who mainly experienced
discrimination/stigma, Class 3 (31.6%): a group who mainly experienced economic hardship, Class 4 (43.9%): a group of WLWH who experienced most SDoH
adversities.
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6.

Chapter 6: Integrated Discussion

This last chapter reviews key findings of this research derived from the four peer-reviewed
published papers (Chapters 2-5), the implications of these findings for the HIV care and
treatment and health outcomes of women living with HIV, and highlight future research.
6.1. Summary of key findings
Drawing on the cross-sectional data from the largest cohort study of women with HIV in Canada
(CHIWOS, time-point 1, 2013-2015), we found that a high proportion of women with HIV
reported experiencing social and structural adversities and low quality of life (Chapter 2) as well
as substance use (Chapter 3). In comparison with Canadian women of similar ages/ethnoracial
backgrounds (CCHS, 2013-14), a higher proportion of women with HIV reported living with
poverty (measured by annual personal income) and food insecurity, experienced social exclusion
(measured by poor perceived social support, and racial and gender discriminations), recorded
lower quality of life (measured using a single-item self-assessment of overall health status) (all in
Chapter 2), as well as reported substance use including intensive cigarette smoking, nonprescribed cannabis use, crack-cocaine, speed ,and heroin use (but not alcohol use) (Chapter 3).
Analysis of the longitudinal data of women with HIV (CHIWOS, time-point 1 and 2, 201317) also showed that a substantial proportion of women with HIV reported experiencing multiple
forms of a set of potentially modifiable social determinants of health (SDoH). Latent class
analysis (LCA) identified four distinct SDoH subgroups, consisting of one small cluster of
women with HIV who reported no or least SDoH adversities, two unique clusters including
discrimination/stigma and economic hardship, and one single cluster containing multiple forms
of social adversities (Chapters 4 and 5). Additional analyses also showed that self-reported
opioid/stimulant use (Chapter 4) and heavy alcohol drinking (Chapter 5) were significantly less
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likely to be reported among women living with HIV who reported none/least SDoH than among
women in other three SDoH clusters, regardless of the type of SDoH adversities. These findings
suggested the substantial contribution of the clusters of SDoH adversities to illicit drug use and
heavy drinking among women with HIV.
6.2. Socio-structural adversities
As described, women with HIV were found to experience a high prevalence of individual SDoH
adversities (Chapter 2). They also reported experiencing these adversities in excess of what
would be expected from the assumed HIV-negative general population of women. While direct
comparison of these determinants between individuals with HIV, including women, and the
general population is challenging due to limited comparability of population-based data on the
indicators of SDoH owing to differences in equity measurements as well as general data quality
and availability,1 the current research documented that women with HIV inequitably experienced
greater barriers or difficulties in their daily life in excess of what would be expected. These
findings underscore the importance of the recognition of the social, economic and structural
barriers accounting for health inequities among women, which not only exacerbate the
vulnerability of them to an elevated risk of HIV infection,2 but also, in turn, among women who
are living with HIV, have the potential to negatively impact their ability to optimally navigate the
HIV care and treatment programs.
These findings suggest that to improve the health and well-being of women with HIV,
programs should focus on interventions addressing inequalities that women frequently face. To
do this, the ongoing collection and quality measurement of SDoH indicators across either
surveillance systems or care and treatment programs is necessary.1 Having more comprehensive
data on all aspects of health indicators, with the addition of SDoH measures, would enable health
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care providers to identify the burden of SDoH adversities, gain a broader and more complete
picture of HIV epidemiology, and then address (i.e., through developing structural interventions)
these underlying causes of HIV and health conditions. The CDC emphasizes that without the
collection of all relevant SDoH indicators, a large proportion of HIV data is incomplete in the
context of broader population health, and adds that the increased understanding of SDoH data
“may lend more credibility to the science of SDH, and prevention efforts will be able to use and
execute more contextually appropriate initiatives to reduce health disparities and promote health
equity.”1 Furthermore, identifying such underlying causes is required to be also considered as
one of the main priorities of the extant HIV programs. In this regard, future research should pay
additional attention to how such underlying determinants can be better integrated into the current
priorities of HIV programs.3 In addition to the current focus on the provision of better HIV care
and treatment services, practitioners and public health experts should also strive to ameliorate the
socio-structural adversities that individually (e.g., stigma alone) or in combination (e.g., stigma
and discrimination) continue to result in poor health outcomes among affected people. Improved
data collection on the SDoH indicators may help healthcare providers recognize the leading role
of these barriers and reduce some of these adversities, such as stigma,1,4-6 that these individuals
may frequently encounter in their life.
Addressing SDoH inequalities among women is particularly important as women face
greater vulnerability to discriminatory social, economic, and political processes,7-9 resulting in
greater health inequalities.1 Our findings in support of the current evidence suggest that
experiencing a high degree of SDoH adversities may explain the potential pathways by which
women with HIV experience inequalities in their health outcomes, and support possible
interventions to address the gaps in such health inequalities.10 In addition to their elevated
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vulnerability to HIV infection, women experience socioeconomic inequalities that pose
additional challenges to their HIV care and treatment programs.11 It is believed that a better
understanding of these adversities, for example, stigma, is of paramount public health
importance and the foundation for the development of programs in addressing these adversities
and their resultant health inequalities.11 Consistent with extant evidence, our findings support
structural interventions, referring to public health interventions that improve health through
changing the structural factors – which are aspects of the social, economic, and physical
environment – within which health or health outcomes are produced and reproduced.12 Frieden
believes that interventions focusing on socio-structural levels (e.g., socioeconomic factors) tend
to be more effective as these interventions cover a broader portion of society and require less
individual effort, and can help obtain optimal public health benefits.13
The SDoH adversities are largely the result of the unjust distribution of power and
resources, indicating the important role of policy in addressing these adversities.5,14,15 Therefore,
understanding these leading adversities (i.e., barriers) can help inform healthcare providers
where women interrupt their HIV care along the cascade.16 Our findings also suggest that, in
addition to approaches to prevent, control and manage HIV on the individual (e.g., behavioural)
level factors, it is important to seek strategies to address the underlying social and structural
contributors of health inequalities, such as food insecurity, lack of or low education, HIV stigma,
and discrimination, which have negative impacts on HIV outcomes.4
A growing body of evidence has shown that the SDoH adversities (e.g., food insecurity,17
under-housing,18 gender-related factors,19 and stigma20,21) have been substantially associated
with poor HIV outcomes (e.g., low treatment adherence). This may indicate that the SDoH that
are sensitive indicators of women’s capacity have the potential to impede them prioritizing their
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health care needs over such survival needs. Therefore, if the goal in the current era of effective
HIV treatment is to help individuals with HIV achieve optimum cART outcomes,10,22,23
addressing these key social and structural barriers should be considered as one of the main
priorities of HIV programs. Evidence has supported that reducing the burden of these daily life
challenges or hardships can also help improve HIV outcomes. For example, Martinez et al. in a
12-month prospective clinical trial showed that household food assistance and nutrition
education programs positively improved HIV treatment adherence (defined as on-time
prescription refills).24 With regard to HIV stigma and discrimination, additional research is
required to better understand other pathways through which these barriers can influence
subsequent behaviours, health and well-being. Evidence suggests that interventions such as skill
building through peer coaching, education programs to provide a better understanding of the
diseases/infection, and connecting them with community resources and peers, may help affected
individuals overcome stigma and discrimination and improve their engagement in healthcare
process.25-28 Economic hardship, particularly low annual personal and household income and
food insecurity, were significantly higher among women with HIV versus HIV-free women of
the general population, indicating the need for economic strengthening for women with HIV to
promote utilization of HIV care services.
6.3. Clustered social determinants
A key feature of the social determinants is that they tend to co-occur.29 Therefore, studying
social determinants individually may miss the co-occurring patterns of these determinants. For
example, those living with income insecurity are more likely to be exposed to food insecurity, or
those experiencing racial discrimination and/or HIV-related stigma might be at a higher
likelihood of having lower social support. There has been a growing interest in this phenomenon
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to identify opportunities for impactful strategies dealing with health-related behaviours.ex.30,31
Some studies have analyzed the co-occurrence of these determinants through the count of the
total number or types of social determinants.32 While such additive methods can help provide
information on the burden of the social determinants, they strongly rely on the assumption of
homogeneity in the co-presence of these determinants in a population.30 However, the use of
model-based complex analytical approaches, such as latent class analysis (LCA), can help
provide valuable insights into the complexity of these determinants. In addition, such approaches
can help researchers determine individual indicators of these determinants within the identified
clusters. Further, instead of analyzing these determinants separately in association with a health
outcome, LCA helps explore the impact of clustering of these determinants.
In the current study, our analyses and findings showed that women reported experiencing
complex adversities characterized by social, economic, and structural determinants of health.
LCA analyses demonstrated that social determinants are clustered together and create unique
classes/groups of adversities. Of the four identified SDoH classes, three classes exhibited a
combination of two or more SDoH adversities. While the majority of the study sample reported
experiencing multiple forms of adversities (i.e., class 4), we were able to identify two more
clear/distinct classes of SDoH adversities including stigma/discrimination and economic
hardship that have been the key barriers to prevention as well as care and treatment of HIV
infection from the beginning of its epidemic. In particular, our findings indicated that multiple
forms of discriminatory behaviours had the potential to cluster together (i.e., racial
discrimination, gender discrimination, and HIV-related stigma). Findings also showed that
multiple indicators of economic difficulties were clustered in one unique group. Further, these
two unique classes together tended to cluster and created a more complex class of SDoH (i.e.,
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class 4), which might indicate that the unique clusters of stigma/discrimination and economic
hardship can both independently in their unique clusters and jointly together account for the
majority of health inequalities. These findings also suggest the need to consider multiple social,
economic and structural adversities when analyzing and reporting the severity (e.g., prevalence)
of these determinants and recognizing their detrimental impacts on health outcomes. Examining
one single indicator may not properly characterize the daily living experiences of underserved
individuals such as women with HIV, who typically report experiencing multiple adversities. ex.33
Identifying the patterns of these determinants and examining their grouped/clustered
impact not in separation but in combination has implications for health inequalities reduction and
health promotion programs. The use of such analytic approaches aiming at the identification of
the latent patterns of social determinants can help in the contextualization of the clustered
determinants, as their co-occurrence as well as synergistic impacts may contribute to more
intense adverse health outcomes than if they were experienced (or treated in the analysis) alone.
Moreover, programs targeting multiple determinants (i.e., addressing multiple social, economic,
and structural adversities) would have the potential for a greater impact on public health relative
to the strategies that only address one single adversity. For example, in addressing housing
instability among vulnerable populations, considering other vulnerabilities such as food
insecurity and/or economic pressure is critical. Assessing the pattern of these determinants can
also help prioritize most vulnerable individuals for better support.
6.4. Substance use among women with HIV
Significant efforts have been made over time to reduce adverse clinical and health outcomes
among individuals with HIV in Canada.34 Evidence has suggested that people with HIV,
particularly those in resource-rich nations such as Canada,35-37 have or are approaching a normal
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life expectancy (i.e., that is almost equivalent to that of HIV-uninfected individuals) if they
receive appropriate cART treatment.34,37-41 Such considerable change in the profile of HIV may
give rise to the greater experience of chronic health conditions among these individuals.42
Evidence has also supported such elevated burden of chronic conditions among people receiving
HIV treatment versus their HIV-free counterparts.35,43,44 Aside from the intersection of aging and
HIV infection itself that negatively impact the overall health of these individuals, identifying and
addressing other potential challenges that these individuals continue to experience in gaining a
healthy state remains essential.35 Substance use is one such potential barrier contributing to a
lower survival or quality of life of individuals with HIV compared with individuals without HIV
and it needs to be carefully studied and addressed among these individuals,37,45 particularly
among women, a population with limited resources available on their social and behavioural
factors.46
As described in the Introduction Chapter, the detrimental contribution of substance use to
the elevated poor HIV treatment outcomes and mortality among individuals with HIV has been
well documented.34,42,46-64 Prior research documented that individuals who were involved in
substance use were at elevated risk for suboptimal linkage to and retention in HIV care, HIV
treatment adherence, AIDS-related illness and mortality.42,46,63-66 Substance use is of paramount
importance in ongoing concentration for the management of HIV infection. Literature suggests
that a considerable proportion of non-AIDS-related causes are now the prevailing cause of
mortality among these individuals, yet many of these causes have a strong link with substance
use.42
Our findings suggesting a high prevalence of substance use in the study population have
implications for HIV care and treatment programs in the current era of Treatment as Prevention
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(TasP). These findings may indicate that behavioural barriers yet remain as one of the main
challenges in the management of HIV among women with HIV. These risk-taking practices may
also explain the variations/gaps in the elevated non-AIDS comorbidities and mortality of
individuals with HIV, women in particular, over their counterparts in the general population. As
substance use has the potential to interrupt every step along the cascade, our findings emphasize
that the effectiveness of HIV care and treatment services may rely on how these risk-taking
barriers are effectively addressed.
Evidence has extensively highlighted the need for developing care models where, in
addition to addressing HIV-related care and treatment, substance use is routinely assessed.
Raposeiras-Roubín et al. (2017) believe that the awareness within the health system with respect
to the elevated risks posed by substance use on causes of mortality among individuals with HIV
is suboptimal.67 Dawson-Rose et al. (2017) noted that while primary care clinics are the best
setting to offer screening and interventions for substance use, few HIV clinics routinely assess
substance use. These authors added that implementation of standard practice for screening
substance use in HIV primary care clinics is necessary.68 Nijhawan et al. (2008) believe that
substance use should be discussed without alienating substance users in the context of a trusting
provider-patient relationship.69 It has been emphasized that healthcare providers should ensure
that the overarching goal of substance use interventions is to maintain individuals in HIV
care,69,70 and better manage the HIV/AIDS complications.42 Interventions, either behavioural
(e.g., counselling for tobacco use cessation,71 or a case management intervention model for
alcohol and illicit drug use72), pharmacological (e.g., nicotine patches71 and Vaporised nicotine
products73 for cigarette smoking cessation, lamotrigine for crack cocaine users,74 buprenorphine
and methadone maintenance therapy for illicit drug users75-77), or psychosocial (e.g., contingency
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management treatment for opioids and cocaine78) interventions/supports for individuals with
HIV involving in substance use should become a priority in routine HIV care services. The
integration of these interventions warrants further investigation for the management of the use of
various substances.
Existing research proposed multiple models for integration of HIV care and substance use
interventions, such as69,77 i) a primary care model, through which the HIV treatment provider
prescribes the substitution therapy; ii) an on-site specialist model, through which a substance use
specialist prescribes the substance use interventions; iii) a hybrid model, through which an onsite specialist prescribes the initial induction therapy of the substance use intervention and the
HIV care provider prescribes its maintenance phase; iv) a drug treatment model, through which
both HIV care and substance use services are provided in a substance use clinic setting, v)
directly administered antiretroviral therapy (DAART), is another integrated care that through
which substance using individuals with HIV receive supervised doses of HIV treatment in a
substance use clinic setting,69,79-81 and vi) patient-centered model of care, in which individuals
with HIV receive diverse health-related services, including harm reduction programs, in a
friendly environment setting28,42,67 are offered for maintaining individuals with HIV optimally
engaged in care, and for meeting national and global goals of HIV treatment.82 Similar to the
latter form of model of HIV care, gender-matched-centered model of care has also been
proposed. For example, a women-centered model of HIV care83,84 and a women-centered harm
reduction approach85,86 have been identified as promising models for addressing women’s
comprehensive care needs.84,87-90 Consistent with extant research,28,42,67,84 our findings advocate
for developing women-centered models of care where, in addition to providing multiple
healthcare services, women with HIV can also have access to harm reduction and substance use
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intervention programs. In the Canadian context, O'Brien et al. (2017) underlined that a womencentered approach to HIV care is essential for guiding policy and practice to promote the health
and clinical outcomes for women with HIV.84 These researchers additionally pointed out that
given gaps in care and inequalities in health, models/approaches that address the care priorities
of women living with HIV “must be incorporated into care delivery to ensure that women's
comprehensive care needs are met and to enable diverse populations to benefit equally from
health care advances.”
6.5. Social determinates give rise to elevated risk of substance use
Our research added to the literature demonstrating high prevalences of substance use among
women with HIV. While the prevalences of all studied substances were high, the prevalence of
illicit drug use and cigarette smoking, in particular, were in excess of what would be expected
from the background HIV-negative women (Chapter 2). Our additional analyses using latent
class analysis (LCA) identified distinct subgroups (clusters) of women with HIV characterized
by a set of potentially modifiable social and structural determinants. These analyses showed that
a substantial proportion (93.4%) of study participants reported experiencing two or more types of
SDoH adversities (classes 2-4). Furthermore, our findings demonstrated that illicit drug use and
drinking patterns among women with HIV were socio-structurally distributed, such that women
who experienced less social adversities were less likely to report using these substances than
those in other three classes who experienced distinct levels of SDoH adversities. Future research
should identify and explore interventions addressing social determinants among women with
HIV.
Several theoretical frameworks can help guide our understanding of potential pathways
through which the SDoH clusters increase the risk of substance use. Our research is also
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centrally informed by a social determinants of health (SDoH) framework, highlighting that
political, economic and cultural drivers impact socioeconomic status/position, which in turn
shapes SDoH impacting health and well-being,4,5,91 and influencing health inequities. This
framework mostly focuses on the upstream determinants of health such as education, occupation,
income, housing status, social support, stigma and discrimination. In the context of HIV and
substance use, this framework has been used to emphasize that socio-structural determinants play
a pivotal role in risk-taking behaviours2,92,93 and poor HIV outcomes,94-96 resulting in health
inequalities. Informed by these theoretical frameworks, our findings imply that the
overlapping/clustering social determinants have the potential to severely constrain the ability of
women with HIV to effectively respond to behaviour change strategies. A syndemics theory can
also support these findings. This model links multiple social and structural adversities to cooccurring and synergistic health epidemics that disproportionately affect vulnerable populations,
and magnify the negative impact of disease interaction.97-99 This model highlights the
contribution of the excess burden of “entwined and mutually enhancing health problems” to the
health inequalities,97 fueled by social, economic and structural inequities.98,99 Applications of this
theory to HIV studies have mostly concentrated on factors that synergistically contribute to HIV
risk among vulnerable populations.100,101 A special form of this theory is known as the SAVA
syndemic, referring to the clustering of substance use, violence and HIV/AIDS among
marginalized populations such as women of color living with HIV.102 This model explicitly
advocates for socio-structural interventions that more effectively address the intersecting issues
of substance use, structural adversities such as violence, and poor outcomes which necessitate
systemic work to target the underlying conditions perpetuating health inequities among
marginalized populations.101,102 In accordance with a self-medication model,103 our findings may
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also indicate that women with HIV initiate or continue substance use (e.g., alcohol use) as a
coping strategy to alleviate their daily stressors. This model underscores behavioural coping as a
potentially relevant mediator for the association between multiple social adversities and
substance use.63,104 Consistent with this model, Wardell et al. (2018) in a longitudinal analysis in
Canada showed that greater HIV-related stigma, as a key and relevant SDoH in the context of
HIV, predicted increased maladaptive strategies for coping (e.g., self-blame, denial), and that
maladaptive coping mediated the prospective associations between HIV-related stigma and
alcohol use severity.92
HIV research has extensively accentuated the contribution of social determinants to both
the distribution of HIV infection (i.e., as the drivers of HIV infection) and poor HIV outcomes
(i.e., among those who are living with HIV). Research has also highlighted interventions
addressing social determinants of HIV infection and substance use among affected individuals as
the most effective interventions in addressing poor outcomes and then reducing health
inequalities.69,105-107 For example, Wolitski et al. (2010) in a randomized controlled trial assessed
the longitudinal effects of a structural intervention (i.e., rental assistance on the housing status)
on the health and risk behaviours of homeless and unstably housed people with HIV, and showed
that the receipt of stable housing significantly reduced risk-taking behaviours, improved access
to care, increased adherence to treatment, and improved self-reported physical and mental health
(e.g., depression and perceived stress).108 These studies indicate that if HIV care programs
viewed the patients as a whole, including their social determinants,109 improved outcomes would
be achieved.84 This is particularly of the essence among women with HIV who are unjustly
occupied in the socioeconomically disadvantaged position.84,110-112 Research in Canada, in line
with international research, has noted that these leading determinants, even though essential to
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addressing barriers of HIV care, are challenging to properly address in health care settings since
many of these determinants (e.g., housing, poverty) lie beyond the purview of the health care
system.84,113,114 O'Brien et al. (2017), however, believe that strategies such as interdisciplinary
teams and revised prescription financing policies that address socioeconomic hardship may help
bring greater attention to socio-structural barriers that have negative impacts on women’s careseeking behaviours, HIV outcomes, and overall health.84 In this regard, it is imperative to
continue to educate and advocate for all healthcare professionals to acknowledge socio-structural
factors giving rise to poor health.84,113,115
Our findings indicate that, in addition to the efforts in increasing the number of individuals
receiving cART treatment, the successful management of HIV requires making greater efforts in
addressing the social barriers as well as substance use through the integration of health care
services. Undoubtedly, substantial advances have been achieved in HIV care and treatment
programs, and subsequently substantial reductions have been made in HIV morbidity and
mortality; however, treatment alone does not appear to help end the HIV epidemic. Such
prevalent clustering co-occurring conditions and/or adversities pose a “complex problem” for
patients as well as healthcare providers and health systems that seek to provide coordinated care
to them.116,117 The complexity in care has been referred to individuals with multiple co-morbid
medical and behavioural health conditions whose care is complicated by social factors (e.g.,
poverty) and health system factors (e.g., segregated medical and behavioural healthcare
programs).116 Grembowski et al. (2014) developed a conceptual model and defined complexity
in care as the misalignment between patient needs and the services available for them (i.e., needservice gap), highlighting the need for care systems to address dynamic or complex conditions
and incorporating social, economic, and physical conditions as contextual factors that influence
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patient needs and services delivery.117 In the face of such multiple co-occurring health,
behavioural, and socio-structural adversities that have also been identified in the present study
among women with HIV, research supports that the integration of services that address multiple
services such as substance use treatment, psychosocial support, counselling, and HIV care might
bring about improved health outcomes.69,118 While addressing each service can help improve
care when applied individually, a multidisciplinary strategy such as a gender-focused HIV care
strategy, where various health care needs are considered may better address the comprehensive
needs of women with HIV.69,84,119,120 Women-centred interventions have become an emerging
model for the provision of the comprehensive health care needs of women.83-85,88,118 For
example, Carter et al. (2013) in a comprehensive review explored the concept of women-specific
HIV/AIDS services, as a complex and multidimensional model, and identified the key
dimensions of such model. According to this review, this approach to care is conceptualized to,
for example, create an atmosphere of safety, respect and acceptance; facilitate interaction among
peers; facilitate meaningful access to care through the provision of social and supportive
services; provide gender-, culture- and HIV-sensitive training to health and social care providers;
provide women's social economic needs/supports such as transportation assistance, and food;
conduct gendered HIV/AIDS research.83 Ellsberg et al. (2015) in a review study recommended
women-centered programs as one key intervention to reduce women’s risk of further
victimization and promote their health and wellbeing through providing a combination of
strategies such as psychosocial support, advocacy and counselling, and home visitation.118 These
interventions are closely consistent with the principle of the Greater Involvement of People
Living with HIV/AIDS (GIPA), a critical principle to halting and reversing the HIV epidemic,
which has been formalized to support a greater involvement of individuals with HIV at all levels
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(e.g., policy, programming, care, research) and advocate for their rights.121 Due to the particular
social environment where women with HIV face these adversities (i.e., gendered nature of these
adversities), our findings advocate for further research to identify more culturally tolerated,
women-focused interventions and assess their effectiveness if the care programs are to better
address health inequalities among women, particularly women in greater needs such as substance
users.83,119,120,122
This part of our analysis and findings also adds to the body of evidence supporting that
social determinants are highly inter-correlated,29 a key feature of these determinants that has not
been well taken into account in the analyses of the social determinants with health outcomes.
Extant research has commonly treated these determinants as independent factors in the
assessment of their impacts on the subsequent health outcomes. While this approach has
implications for HIV care and treatment strategies on how to overcome the adversities with each
determinant, future research should take the co-occurrence nature of these determinants into
account. Such analysis has implications for HIV care in a way that any care models should
address multiple adversities of women with HIV.
6.6. Future research and directions
Further research should 1) focus on the reproducibility of the identified latent classes in
populations with different sociodemographic backgrounds and HIV-related clinical
characteristics to see whether similar classes are found and how they contribute to substance use
as well as other health outcomes, 2) identify the predictors of the SDoH latent classes, 3) explore
the SDoH latent classes over time using other mixture models such as latent transition analysis
(LTA),123 4) longitudinally investigate the association of the SDoH latent classes with health
outcomes (e.g., substance use, HIV outcomes) among women with HIV, and 5) develop
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conceptual and analytic strategies to explore how modifiable and non-modifiable SDoH can be
modelled together to capture a detailed picture of the indicators of SDoH among individuals with
HIV. In such models, it is important to assess how non-modifiable SDoH (such as gender,
ethnoracial status) can modify the impact of modifiable SDoH on health outcomes, or how these
modifiable factors may explain (i.e., transmit the impact) the relationship between nonmodifiable SDoH and health outcomes; 6) seek and identify culturally tailored, women-specific
interventions in addressing multiple forms of women’s needs, particularly social adversities and
substance use; and 7) promote linkages between substance use treatment programs and HIV care,
that can be evaluated in the women-centered model of care.
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7.

Appendices

Appendix A: A brief description of latent class analysis and procedures
We used latent class analysis (LCA) to determine latent classes/subgroups of women with HIV
with distinct profiles with regard to the social determinants of health (SDoH) based on 12
observed categorical indicators including racial discrimination, gender discrimination, enacted
HIV stigma, perceived social support, barriers to access to care, food security, housing status,
income level, employment status, education, recent sex work involvement, and recent
incarceration. LCA is a data-driven probabilistic model commonly used to identify the levels of
the categorical latent variables representing classes (groups) with similar profiles based upon
conditional probabilities. LCA uses the expectation-maximization (EM) algorithm1 – an iterative,
maximum-likelihood estimation approach, to estimate the unknown parameters.2 The maximum
number of iterations was set to 5000 (the default number in SAS LCA procedure) in the EM
estimation procedure for the replication of the log-likelihood value to ensure that a best-fit
solution is obtained. As an iterative approach, EM algorithm begins with a set of starting values
and proceeds with a series of steps of parameter estimation and re-estimation iterations until
[some] designated criterion is reached. As an attempt to avoid suboptimal estimates produced by
local maxima of the likelihood function, multiple random sets of starting values (i.e., in the
present study, 1000 random starting values) was used.
We started LCA with a 2-class model and systematically increased to an 8-LCA model to
examine the LCA solutions. Model interpretability along with the following goodness-of-fit
indices or/and information criteria were considered to choose the best number of latent classes:
Log-Likelihood, Akaike information criterion (AIC), Schwarz Bayesian information criterion
(BIC), Consistent AIC (CAIC), and [relative] Entropy. Lower values for the AIC, BIC and CAIC
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imply better model fit, while higher entropy reflects better classification or class distinction, with
approaching 100% indicating clear delineation or better separation of latent classes (varied
between 0 to 1).3,4 In addition, we reported the percentage of seeds associated with best fitting
model as a diagnostic information on the random starting value process; higher percentages
indicate that the model appears to be well-identified (i.e., highly unlikely to have hit local
maxima).
Missing data
In LCA, where the latent class membership is always missing, manifest indicators used to
estimate the latent classes may also come with missing values. Under the assumption of missing
at random (MAR) – even though this assumption is sometimes ignored,5 LCA computes LCA
parameters accounting for missing values of observed indicators (here, SDoH indicators)
typically by maximum-likelihood estimation using the EM algorithm so that all available
information are used to estimate the best model,2 except for those participants with full missing
data for all observed indicators (Note: participants with missing values for the study outcomes in
Chapter 4 and 5 were excluded from the associational analyses between clustering SDoH and
substance use.
EM algorithm
As explained above, LCA estimates unknown parameters using the expectation-maximization
(EM) algorithm1 which is maximum-likelihood estimation approach with iteration when some
parts of the data is missing; e.g., the hidden classes,2 in each iteration two steps of the E-step and
M-step is followed. The iterative process between the E-step and M-step aims to generate a
sequence of parameter estimates that converges reliably to a local or global maximum of the
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likelihood function.5 The first step is computed using the expected value of the log of the
likelihood function, given the observed data and the initial parameter estimates (i.e., sometimes
called starting values)6 which can be specified either by the researchers (if there is enough
evidence knowing the distribution of these parameters – called user-specified starting values)7 or
randomly. In the current research, random starting values (referring to any positive integer value)
were specified. SAS program starts with the default starting value of 1/NCLASS for Gamma [γ]
parameters, where NCLASS refers to the number of classes specified to estimate the class
membership probabilities – unknown or hidden classes. One issue with the specification of the
random starting values is that some starting values may bring about local solutions that are not
reflecting the global maximum of the likelihood. In such case and to avoid this happen, multiple
sets of starting values were specified and the solution with the best likelihood was chosen.7 The
second step, the M-step, the algorithm maximizes the function to give new values of the
parameter estimates, replaces the initial estimates of the starting values by the updated/new
estimates of the parameters, and then returns to the first step (E step). This process (algorithm)
iteratively continues until changes in either the parameter estimates or log-likelihood function
reach some predefined level of precision (convergence criterion default set to 0.000001) in which
the iteration halts.
Parameters
LCA estimates two sets of parameters:7 1) class membership probabilities (i.e., called as Gamma
[γ] parameters), representing the probabilities that each participant falls into each class. For each
participant, the sum of these probabilities across estimated classes equals one (i.e., 100%); and 2)
class-specific item-response probabilities (i.e., called as Rho [𝜌]), representing the probabilities
of each indicator predicting the class memberships. The Rho (𝜌) parameters express the
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correspondence between the observed items and the latent classes. We did not include covariates
predicting class membership probabilities into the model. Instead, we adjusted for covariates in a
separate regression model after identifying the best fitting model in this step. This is called a
three-step approach through which investigators examine the association between the best-fitted
latent categorical variable and a distal outcome variable after class membership has already been
determined.8,9 In comparison with the approach in which LCA process and regression models are
combined in a joint model, the multi-step approach (i.e., conducing LCA and regression analyses
separately) may attenuate associations; however, the multi-step approach allows the researchers
to run multivariable regression analysis adjusted for a large set of covariates. In the presence of
having numerous covariates required to be adjusted for the association of the latent classes and
the distal outcomes, adjustment process may affect the CLA structure in the one-step approach,
while it is unlikely to occur in the multi-step approach.9,10
LCA models use distributional assumptions to estimate classes, by which the measure of
distance in LCA is provided. For example, with binary items – which will be treated as outcomes
in the process of LCA, such distributional assumptions must follow a binary-outcome
distribution: a) items are assumed to be independent within each class, b) items are assumed to
be distributed marginally as Bernoulli. This distribution has two possible outcomes: a) Y=1
("success") occurs with probability 𝜌 and Y=0 ("failure") occurs with probability 1 minus 𝜌,
where 0 < 𝜌 <1. In the present study, success meant experiencing an SDoH adversity and failure
meant not experiencing that SDoH adversity. We also added another category to the SDoH
indicators indicting that individuals either experienced none of the 12 SDoH indicators or only
one of these indicators. This additional step helped create a better reference group representing
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those who wither experienced none of the 12 SDoH adversities or only one of them, labeled as
those who none/least SDoH adversity. Each indicator has a probability function as follows:

𝑓(𝑦) = {

1−𝜌
𝜌

𝑓𝑜𝑟 𝑦 = 0
}
𝑓𝑜𝑟 𝑦 = 1,

alternatively as,
𝑓(𝑦) = (𝜌𝑖 )𝑦 (1 − 𝜌𝑖 )(1−𝑦𝑖 )
For example, if we assume that Y = 1 representing that a women experienced food insecurity,
and Y = 0 indicating no experience of food insecurity. Our sample tells us that the probability of
women with HIV with food insecurity is approximately 64%. So, 𝜌 is 64%; therefore, P (Y=1) =
0.64 and P(Y=0) = 0.36. The same likelihood function will be obtained as follow:
If Y=1, the likelihood is: 𝑝(𝑦𝑖 = 1) = (0.64)1 (1 − 0.64)(1−1) = 0.64, 𝑜𝑟 64%
and, if Y=0, the likelihood is: 𝑝(𝑦𝑖 = 0) = (0.64)0 (1 − 0.64)(1−0) = 0.36, 𝑜𝑟 36%
These illustrations show that the likelihood function of the statistical distribution provided the
likelihood of an event occurring (i.e., SDoH indicator as an outcome variable). Put differently, in
the case of discrete-outcome variables, the likelihood of an event is the same as the probability of
the event occurring.
As mentioned above, one of the assumptions is independence between items/outcomes
within each class. To make this simple, let’s think about another item, experiencing enacted
HIV-related stigma. If we take a sample, the probability of having experienced stigma is
approximately 72% (𝜌2=72%). Under assumption of independence of these two items
(outcomes), the probability of occurring both food insecurity and experiencing HIV stigma is the
product of the probability of the occurrence of each adversity separately:
𝑃(𝑌1 = 1, 𝑌2 = 1) = (𝜌1 × 𝜌2 ) = 0.64 × 0.72 = 0.46
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Generally, the likelihood of any set of outcomes when no predictors included can be expressed
as:
𝐽
𝑦

𝑃(𝑌𝐽 = 𝑦𝐽 ) = ∏ 𝜌𝑗 𝑗 (1 − 𝜌𝑗 )(1−𝑦𝑗)
𝑗=1

LCA models are special cases of more general models called Finite Mixture Models.11,12 A finite
mixture model expresses the distribution of a set of outcome variables, Y, as a function of the
sum of weighted distribution likelihoods. More generally, a finite mixture model can be
expressed as:
𝐶

𝑓(𝑌) = ∑ 𝛾𝑐 𝑓(𝑌|𝑐)
𝑐=1

This is the conditional distribution of Y given c which is a sequence of independent Bernoulli
variables. For example, for two observed indicators (Y1 and Y2), we can express the LCA model
as:
𝐶

𝑓(𝑌) = ∑ 𝛾𝑐 𝑓(𝑌1 |𝑐)𝑓(𝑌2 |𝑐)
𝑐=1

where, 𝛾𝑐 is the probability of class c, (𝑌1|𝑐)is the probability of occurring Y1 in class c (which is
a conditional probability), and (𝑌2 |𝑐) is the probability of occurring Y2 in class c (a conditional
probability). More generally, an LCA for the response vector of J variables (j = 1, . . . , J) with C
classes (c = 1, . . . ,C) when no predictors of class membership included can be expressed as:
𝐶

𝐽
𝑦𝑖𝑗

𝑓(𝑦𝑖 ) = ∑ 𝛾𝑐 ∏ 𝜌𝑗𝑐 (1 − 𝜌𝑗𝑐 )1−𝑦𝑖𝑗
𝑐=1

𝑗=1

where, i refers to observations, 𝛾𝑐 (Gamma) is the probability that an individual is a member of
SDoH class/group c, 𝑦𝑖𝑗 is the observed response of individual i to the item j, 𝜌𝑗𝑐 is the
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probability of a positive response to item j (i.e., experiencing an SDoH indicator) from an
individual from class c.
LCA assumes that all observed indicators are independent given a class, called as local
independence. By this, any association between observed variables/items is accounted for only
by the presence of the latent class. Put differently, the latent class is the reason that variables are
correlated; this is why indicators within classes are assumed to be independent (local
independence). SAS tests this assumption using a chi-square test when the indicators as included
in the models as binary; however, in the present study, we used three-category SDoH measures
and then skipped this test and assumed that the estimated latent classes were locally independent.
Software
We used PROC LCA (https://methodology.psu.edu),13 a SAS procedure for latent class analysis,
using using % macro alc. We also used a user-defined macro code named %macro it to produce
the summary statistics of all requested models. In addition, %itemresponseplot and
%identificationplot macros were used to produce plots assisting in the evaluation of models.
Details of these macros are described by Berglund.14 Parameters were estimated by maximum
likelihood using the expectation maximization (EM) algorithm. LCA used a baseline-category
multinomial logistic regression (as we included three-category SDoH indicators) to predict latent
class membership.
Model evaluation
To select the best fitting model, in addition to the interpretability of the classes, we relied on
information criteria obtained from parsimony indices: 1) log-likelihood = -2ln(L), where ln(L) is
the log-likelihood of the model; 2) Akaike information criterion (AIC) = -2ln(L) + 2p, where p is

225

the number of estimated model parameters; 3) Schwarz Bayesian information criterion (BIC) = 2ln(L) + p*ln(N), where N is the total number of observations; 4) consistent AIC (CAIC) with
CAIC = -2ln(L) + p * (1 + ln(N)). The convergence method was set to the maximum absolute
deviation (convergence criterion default set to 0.000001).

SAS procedure for LCA analysis
/* Import csv into SAS */
libname sdh "F:\Statistical analysis - Objective 2\Wave 2 and 1 - Merged SDH analysis\SAS\LCA 12";
proc import out=sdh.SdhfromCSV12
datafile = "F:\Statistical analysis - Objective 2\Wave 2 and 1 - Merged
- SDH analysis\SDH variables12.csv" dbms=csv replace; getnames=yes;
dataraw=2;
run;
/* Creating three-category indicators from the binary SDoH indicators */
data Sdh.LCAanalysis12;
set Sdh.SdhfromCSV12;
array zzz stigma bacs edu food house income racism sexism socsup
unemploy sexwork prison;
do over zzz;
zzz = zzz +1;
end;
run;

/* Contents and frequencies */
proc contents;
run;
proc freq data = Sdh.LCAanalysis12;
tables stigma bacs edu food house income racism sexism socsup unemploy
sexwork prison;
run;

/* LCA analysis from starting with one LCA-model, increased to eight */
/*Step A: Use %macro alc to run several LCA models (i.e., 1 to 8)*/
%macro alc (nc);
proc lca data=Sdh.LCAanalysis12 outest=Sdh.outests1&nc
outpost=Sdh.outposts1&nc;
id part_id;
title2 "LCA analysis with 12 SDH indicators";
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nstarts 1000;
nclass &nc;
items stigma bacs edu food house income racism sexism socsup unemploy
sexwork prison;
categories 3 3 3 3 3 3 3 3 3 3 3 3;
seed 100000000;
rho prior=1;
cores 1;
run;
%mend alc;
%alc(1); %alc(2); %alc(3); %alc(4); %alc(5); %alc(6); %alc(7); %alc(8);

/* Step 2: Use %macro it to summarize Model Fit Comparisons of 8 models */
%macro it (nc);
data Sdh.outests1&nc;
set Sdh.outests1&nc;
nclass=&nc;
run;
%mend;
%it(1); %it(2); %it(3); %it(4); %it(5); %it(6); %it(7); %it(8);
/*Then concatenating the output datasets of 8 models to produce a summary
data set called allfit_alc using PROC PRINT */
data Sdh.allfit_alc;
set Sdh.outests11 - Sdh.outests18;
run;
proc print;
run;
proc print data=Sdh.allfit_alc noobs label;
title "Model fits for variables";
label nclass="# classes" log_likelihood="LL" degrees_of_freedom="DF";
var nclass LOG_LIKELIHOOD DEGREES_OF_FREEDOM G_SQUARED AIC BIC CAIC
ABIC ENTROPY;
run;
/* The above code creates a table with all model fit statistics of the 8 LCA
models.*/
/* The best (optimal) LCA fitted model was obtained in this step. */

/* Model with 4 classes was chosen as the best LCA model */
/* Two evaluation tools are used to assist in model selection*/
/* The “item response” and “model identification” plots are produced using
the %itemresponseplot and %identificationplot macros */
%INCLUDE "C:\Users\Mostafa\Desktop\Proc LCA\SAS Graphics
Macros\LcaGraphicsV2\LcaGraphicsV2 (1).sas";
proc lca data=Sdh.LCAanalysis12
outpost=Sdh.posts1_4c_alc
outseeds=Sdh.outseeds_4c_alc
outparam=Sdh.outparm_4c_alc
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outstderr=Sdh.outstderr_4c_alc;
id part_id;
title2 "LCA analysis test data with 4 classes";
nclass 4;
nstarts 1000;
items stigma bacs edu food house income racism sexism socsup
unemploy sexwork prison;
categories 3 3 3 3 3 3 3 3 3 3 3 3;
seed 262169154;
rho prior=1;
cores 1;
run;
%itemresponsePlot(ParamDataset=Sdh.outparm_4c_alc);
%IdentificationPlot(SeedsDataset=Sdh.outseeds_4c_alc);
proc freq data=Sdh.outposts14;
tables best / plots=freqplot(type=barchart scale=percent);
run;
proc format;
value bestf 1='Most SDH adversities' 2='none/least SDH' 3='Economic hardship'
4='Stigma/discrimination' ;
run;
/* This order was changed in the process of analysis with */
proc freq data=Sdh.outposts14;
tables best / plots=freqplot(type=barchart scale=percent);
format best bestf.;
run;
* Export into Stata;
proc export data=Sdh.outposts14 outfile= "F:\Statistical analysis - Objective
2\Wave 2 and 1 - Merged - SDH analysis\SAS\LCA 12\SAStoSTATA12.dta";
run;

SAS Output for a 4-LCA model
The SAS System

12:53 Tuesday, August 7, 2018
LCA analysis SDH data

10

Data Summary, Model Information, and Fit Statistics (EM Algorithm)

Number of subjects in dataset:
Number of subjects in analysis:
Number of measurement items:
Response categories per item:
Number of groups in the data:
Number of latent classes:

1422
1422
12
3 3 3 3 3 3 3 3 3 3 3 3
1
4

NOTE: A data-derived prior was applied to the rho parameters to help
avoid parameter estimates on boundary values of zero and one.
Rho starting values were randomly generated (seed = 100000000).
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No parameter restrictions were specified (freely estimated).
Seed selected for best fitted model:
1165345913
Percentage of seeds associated with best fitted model:

93.70%

The model converged in 78 iterations.
Maximum number of iterations: 5000
Convergence method: maximum absolute deviation (MAD)
Convergence criterion: 0.000001000
=============================================
Fit statistics:
=============================================
Log-likelihood:
-8030.01
G-squared:
1366.87
AIC:
1564.87
BIC:
2085.59
CAIC:
2184.59
Adjusted BIC:
1771.10
Entropy:
0.83
Degrees of freedom:
531341
Test for MCAR
Log-likelihood:
-7346.58
G-squared:
1283.90
Degrees of freedom: 2921792
Class membership probabilities: Gamma estimates (standard errors)
Class:
1
2
3
4
0.4345
0.0661
0.3083
0.1911
(0.0214)
(0.0066)
(0.0225)
(0.0170)
Item response probabilities: Rho estimates (standard errors)
Response category 1: (this section was omitted by the authors)
.
.
Response category 2
Class:
1
2
3
4
stigma
:
0.8317
0.0018
0.6048
0.7800
(0.0170)
(0.0044)
(0.0263)
(0.0293)
bacs
:
0.6384
0.0014
0.4509
0.5696
(0.0219)
(0.0038)
(0.0268)
(0.0346)
edu
:
0.2477
0.0004
0.1683
0.0059
(0.0187)
(0.0021)
(0.0199)
(0.0099)
food
:
0.8185
0.0017
0.6880
0.3707
(0.0184)
(0.0042)
(0.0259)
(0.0365)
house
:
0.1701
0.0003
0.0980
0.0146
(0.0160)
(0.0017)
(0.0154)
(0.0085)
income
:
0.8893
0.0017
0.7943
0.1004
(0.0178)
(0.0043)
(0.0254)
(0.0370)
racism
:
0.8234
0.0013
0.0948
0.5967
(0.0248)
(0.0038)
(0.0278)
(0.0375)
sexism
:
0.9604
0.0015
0.0864
0.6734
(0.0198)
(0.0040)
(0.0393)
(0.0366)
socsup
:
0.6265
0.0014
0.4909
0.4996
(0.0217)
(0.0038)
(0.0268)
(0.0354)
unemploy
:
0.9814
0.0020
0.9132
0.3264
(0.0101)
(0.0047)
(0.0170)
(0.0441)
sexwork
:
0.1068
0.0002
0.0464
0.0091
(0.0137)
(0.0013)
(0.0119)
(0.0078)
prison
:
0.1204
0.0002
0.0398
0.0013
(0.0138)
(0.0014)
(0.0106)
(0.0070)
Response category

3 (this section was omitted by the authors)

.
.
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Appendix E: CHIWOS and CCHS surveys
A. CHIWOS
A1) Detailed CHIWOS Wave 1 Survey, English format, can be found here:
http://www.chiwos.ca/wp-content/uploads/2014/08/CHIWOS-May-13-2014-En.pdf
A2) Detailed CHIWOS Wave 2 Survey, English format, can be found here:
http://www.chiwos.ca/wp-content/uploads/2012/04/CHIWOS-Wave-2-Survey2016.02.12-EN_clean.pdf
B. CCHS
Detailed Canadian Community Health Survey (CCHS; 2013) is accessible here:
http://www23.statcan.gc.ca/imdb/p3Instr.pl?Function=getInstrumentList&Item_Id=1525
67&UL=1V&

Selected list of variables in both CHIWOS and CCHS used in objectives 1a and 1b

Demographic
variables
Sex (SEX)

Age

CCHS 2013-2014

CHIWOS study, 2013-2015

Comparisons/categories

SEX_Q01, DHH_SEX
If necessary, ask: (Is
[respondent name] male
or female?)
1 Male [will be excluded]
2 Female
(DK, RF are not allowed)

S1-Q2b. What gender do
you currently live as in your
day-to-day life?
Select one.
Man [if only selection, end
interview]
Woman
Sometimes man, sometimes
woman
Third gender, or something
other than male or female
Don't know
Prefer not to answer
ANC_Q03 , ANC_03
What is
^SPECRESPNAME’s age?
|_|_|_| Age in years

This will be used for
limiting the study on
only females/women
including trans women.
We exclude the estimates
for men in the CCHS
data.

ANC_Q03
What is ^YOUR1 age?
|_|_|_| Age in years

Age will be a categorical
variable and will be used for
the adjustments

This will be used to
standardize the
prevalences
Limit the study to only
those people aged ≥16.
Age categories:
16-25
26-35
36-45
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CCHS 2013-2014

Ethnic – race

SDC_Q4A
To which ethnic or cultural
groups did ^YOUR2
ancestors belong? (For
example: French, Scottish,
Chinese, East Indian)
SDC_4B
01 Canadian
SDC_4B
02 French
SDC_4C
03 English
SDC_4D
04 German
SDC_4E
05 Scottish
SDC_4F
06 Irish
SDC_4G
07 Italian
SDC_4H
08 Ukrainian
SDC_4I
09 Dutch
(Netherlands)
SDC_4J
10 Chinese
SDC_4K
11 Jewish
SDC_4L
12 Polish
SDC_4M
13 Portuguese
SDC_4N
14 South Asian
(e.g. East Indian, Pakistani,
Sri Lankan)
SDC_4T
15 Norwegian
SDC_4U
16 Welsh
SDC_4V
17 Swedish
SDC_4P
18 First Nations
(North American Indian)
SDC_4Q
19 Métis
SDC_4R
20 Inuit
SDC_4S
21 Other - Specify

CHIWOS study, 2013-2015

S1-Q7. What do you consider
to be your racial and/or ethnic
background?
Select all that apply.
Aboriginal person living in
Canada (e.g., First Nations,
Métis, and Inuit)
Indigenous Person from a
country outside of Canada
Black African (e.g., Nigerian,
Somali)
Black Caribbean (e.g.,
Haitian)
Black Other (e.g., Black
Canadian)
Caucasian/White
Chinese or Taiwanese
Filipino
Japanese
Korean
Latin American (e.g., Chilean,
Costa Rican, Mexican)
South Asian (e.g., Indian,
Bangladeshi, Pakistani,
Punjabi, and Sri Lankan)
Southeast Asian
(e.g.,Cambodian, Laotian,
Malaysian, Vietnamese)
Arab (e.g., Egyptian, Kuwaiti,
and Libyan)
West Asian (e.g. Iraqi, Isreali,
Lebanese, Afghani, Iranian)
Central Asian (e.g.,
Kazakhstan, Kyrgyzstan,
Tajikistan, Turkmenistan)
Multiple races / Multiracial /
“Mixed”
Other, please specify:
_________________
Don’t know
Prefer not to answer

Comparisons/categories
46-55
56+
This will be used to
standardize the
prevalences

Ethnoracial groups:
Indigenous
White
African, Caribbean,
Black (ACB),
Other ethnicities
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CHIWOS study, 2013-2015

Comparisons/categories

DK, RF
Go to SDC_C04B
And

SDC_Q4B_1, SDC_41
^ARE_C ^YOU1 an
Aboriginal person, that is,
First nations, Métis or Inuk
(Inuit)? First Nations
includes Status and NonStatus Indians.
1 Yes
2 No
DK, RF
SDC_N4B_2
(^ARE_C ^YOU1 First
Nations, Métis or Inuk
(Inuit)?)
SDC_42A
1 First
Nations (North American
Indian)
SDC_42B
2 Métis
SDC_42C
3 Inuk
(Inuit)
DK, RF

SDC_Q4C
you may belong to one or
more racial or cultural
groups on the following
list. Are you?
SDC_43A
01 White
SDC_43C
02 South
Asian (e.g., East Indian,
Pakistani, Sri Lankan, etc.)
SDC_43B
03
Chinese
SDC_43D
04 Black
SDC_43E
05
Filipino
SDC_43F
06 Latin
American
SDC_43H
07 Arab
SDC_43G
08
Southeast Asian (e.g.,
Vietnamese, Cambodian,
Malaysian, Laotian, etc.)
SDC_43I
09 West
Asian (e.g., Iranian,
Afghan, etc.)
SDC_43K
10
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Province

Korean
SDC_43J
11
Japanese
SDC_43M
12 Other
- Specify
DK, RF
ADM_D3A
Ontario
British Columbia
Québec

CHIWOS study, 2013-2015

Provinces:
Ontario
British Columbia
Québec

Comparisons/categories

This will be used to limit
the study to only the
people of these three
provinces
Ontario
British Columbia
Québec
Participants with onreserve status will be
excluded from the
analytic sample.

Behavioural
variables
Alcohol use (ALC)
Definition of a
standard drink

Now, some questions about
^YOUR2 alcohol
consumption.
When we use the word
‘drink’ it means:
- one bottle or can of beer
or a glass of draft
- one glass of wine or a
wine cooler
- one drink or cocktail with
one and a half ounces of
liquor.

A standard drink was
considered to be contained
13.45 grams of pure alcohol or
the equivalent of 0.6 ounces
(oz) of 100% alcohol and was
defined as: 341 ml (12-oz)
bottle of 5% alcohol "beer,
cider or cooler", 142 ml (5-oz)
glass of 12% alcohol "wine",
and 43 ml (1.5-oz) serving of
"liquor or spirits".
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Alcohol frequency

Question identifier:
ALC_Q1, ALC_1
During the past 12 months,
that is, from one year ago
to
yesterday, have you had a
drink of beer, wine, liquor
or any other alcoholic
beverage?
1 Yes
2 No
DK, RF

CHIWOS study, 2013-2015

Comparisons/categories

S6-Q1
How often in the last year
have you had a drink
containing alcohol?
Never
Monthly or less
2-4 times a month
2-3 times a week
4 or more times a week
DK
PNTA

a) Alcohol use in last
year:
Yes
No

S6Q3. Considering all types of
alcoholic beverages (e.g.,
wine, beer, etc), have you had
4 or more drinks on any one
single occasion in the past
month?
• Yes
• No

Non-binge drinkers
(monthly): those who
responded NO to S6Q3
(in CHIWOS) AND
those who responded
Never to ALC-Q3 (in
CCHS);

b) alcohol drinking
frequency
4 or more times a week
2-3 times a week
2-4 times a months
Monthly or less
None

Question identifier:
ALC_Q2, ALC_2
During the past 12 months,
how often did you drink
alcoholic
beverages?
1 Less than once a month
2 Once a month
3 2 to 3 times a month
4 Once a week
5 2 to 3 times a week
6 4 to 6 times a week
7 Every day
DK, RF
Variable: more than 3
times a week, 2-3 times a
week, once a week, once a
month and others (less than
once a month or never)

Binge drinking

ALC_Q3, ALC_3
How often in the past 12
months have you had
BINGE DRINK (=4 for
women) or more drinks on
one occasion?
1 Never
2 Less than once a month
3 Once a month
4 2 to 3 times a month
5 Once a week
6 More than once a week
DK, RF

S6Q4. How many times in the
past month have you had 4 or
more drinks on any one single
occasion?
Indicate number of times:
__________
0=0
1=1
2-9=2
10 - 19 = 3

Light binge drinkers
(monthly): those who
responded Yes to S6Q3
but reported 0 to S6Q4 or
reported 1 to S6Q4
(CHIWOS) AND those
who responded once a
month or less than once a
month to ALC-Q3 (in
CCHS).
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CHIWOS study, 2013-2015
20 or more = 4

Comparisons/categories
Moderate binge drinkers
(monthly): those who
reported 2-3 times per
month to S6Q4
(CHIWOS) AND those
who reported 2 to 3 times
a month to ALC-Q3 (in
CCHS).
Heavy binge drinkers
(monthly): those who
reported 4 or more times
per month to S6Q4
(CHIWOS) AND those
who reported once a
week or more than once a
week to ALC-Q3 (in
CCHS).

Smoking (SMK)
Current status of
cigarette smoking

Number of cigarette
per day or month

Question identifier:
SMK_Q202, SMK_202
At the present time, do you
smoke cigarettes every
day, occasionally or not at
all?
1: Daily
2: Occasionally
3: Not at all
8: RF
9: DK
Variable: regular users
(daily), occasional user,
other options
Question identifier:
SMK_Q204, SMK_204
How many cigarettes do
you smoke each day now?
NO: …..

S6-Q5.
What is your cigarette
(tobacco) smoking history?
I am currently a regular
smoker
I smoke occasionally
I am a former smoker
I have never been a smoker
DK
PNTA

a) smoke cigarette
currently
Yes
No

S6-Q6.
How many cigarettes do you
normally smoke?

Number of cigarettes per
day:
This will be an ordinal
variable such as:
20+ cigarette/day
16-20 cigarette/day
11-15 cigarette/day
6-10 cigarette/day
1-5 cigarette/day
None

Indicate number of cigarettes
….. per day/or per month

Variable: an ordinal
variable will be created
based on pack per day

Indicate number of packs: ….
Per day / or per moth

FSC_Q010, FSC_010
Which of the following
statements best describes
the food eaten in your
household in the past 12
months, that is, since

S1-Q22. Which of the
following statements best
describes the food eaten in
your household in the past 12
months, that is since [current
month] of last year? Select

b) Current pattern of
cigarette smoking
regular or daily
occasionally
others (never, former)

Social determinants

Food security

Q1) Last year
household food eaten
status:
Enough /the kind wanted
Enough /not kind wanted
Sometimes/often not
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CHIWOS study, 2013-2015

current month of last year?
1. You and other
household members always
had enough of the kinds of
food you wanted to eat.
2 you and other household
members had enough to
eat, but not always the
kinds of food you wanted.
3 Sometimes you and other
household member did not
have enough to eat.
4 Often you and other
household members didn’t
have enough to eat.
DK, RF

one.
- In the past 12 months, you
and other household members
always had enough of the
kinds of food you wanted to
eat
- In the past 12 months, you
and other household members
had enough to eat, but not
always the kinds of food you
want
- Sometimes you and other
household members did not
have enough to eat
- Often you and other
household members didn’t
have enough to eat
- Don't know
- Prefer not to answer
S1-Q23.
In the past 12 months, you and
other household
members worried that food
would run out before
you got money to buy more.
1 Often true
2 Sometimes true
3 Never true
PNTA

FSC_Q020, FSC_020
You and other members
worried that food would
run out before you got
money to buy more. Was
that often true, sometimes
true, or never true in the
past 12 months?
1 Often true
2 Sometimes true
3 Never true
DK, RF
FSC_Q030, FSC_030
The food that you and
other members bought just
didn’t last, and there
wasn’t any money to get
more. Was that often true,
sometimes true, or never
true in the past 12 months?
1 Often true
2 Sometimes true
3 Never true
DK, RF
FSC_Q040, FSC_040
You and other members
couldn’t afford to eat
balanced meals. In the past
12 months was that often
true, sometimes true, or
never true?
1 Often true
2 Sometimes true
3 Never true
DK, RF

Comparisons/categories
have enough
Q2-4) Description of
food situations
Often true=2, sometimes
true=1, never true =0;
Score range 0 to 6
Food secure 0-1 / food
insecure 2-6

S1-Q23.
In the past 12 months, the
food that you and other
household members bought
just didn’t last, and
there wasn’t any money to get
more.
1 Often true
2 Sometimes true
3 Never true
PNTA
S1-Q23.
In the past 12 months, you and
other household
members couldn’t afford to eat
balanced meals.
1 Often true
2 Sometimes true
3 Never true
PNTA
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Household income

Personal income

INC_Q5A
Can you estimate in which
of the following groups
your household income
falls? Was the total
household income in the
past 12 months...?
1 Less than $50,000
including income loss
2 $50,000 and more
INC_Q5B, INC_5B
Please stop me when I
have read the category
which applies to ^YOUR1
household. Was it...?
1 Less than $5,000
2 $5,000 to less than
$10,000
3 $10,000 to less than
$15,000
4 $15,000 to less than
$20,000
5 $20,000 to less than
$30,000
6 $30,000 to less than
$40,000
7 $40,000 to less than
$50,000
DK, RF
INC_Q5C, INC_5C
Please stop me when I
have read the category
which applies to your
household. Was it...?
1 $50,000 to less than less
than $60,000
2 $60,000 to less than less
than $70,000
3 $70,000 to less than less
than $80,000
4 $80,000 to less than less
than $90,000
5 $90,000 to less than less
than $100,000
6 $100,000 to less than less
than $150,000
7 $150,000 and over
DK, RF
INC_Q8B
Can you estimate in which
of the following groups
^YOUR1 personal income
falls? Was ^YOUR1 total

CHIWOS study, 2013-2015
S1-Q11a. How much does
your household make in a
year, before taxes (i.e.,
household gross yearly
income)?
Less than $10,000
$10,000 to $19,999
$20,000 to $29,999
$30,000 to $39,999
$40,000 to $49,999
$50,000 to $59,999
$60,000 to $69,999
$70,000 to $79,999
$80,000 to $99,999
$100,000 or more
Don’t know / Prefer to
estimate by month
Prefer not to answer

Comparisons/categories
Base on the definitions
used for LICO:
Less than 20,000
≥ 20,000
20,000 is not the exact
cut point, but it is the
closest cut off point. This
will be adjusted based on
the number of
dependents.

S1-Q11b. If unable to answer
gross yearly household
income, prompt for gross
monthly income: Indicate
gross monthly income in
dollars: __

S1-Q12a. How much do you
make in a year, before taxes
(i.e., personal gross yearly
income)?
Less than $10,000

Base on the definitions
used for LICO:
Less than 20,000
≥ 20,000
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personal income in the past
12 months...?
1 Less than $30,000
including income loss
2 $30,000 and more

Race and gender
discrimination

INC_Q8C, INC_8C
Please stop me when I
have read the category
which applies to you Was
it...?
1 Less than $5,000
2 $5,000 to less than
$10,000
3 $10,000 to less than
$15,000
4 $15,000 to less than
$20,000
5 $20,000 to less than
$25,000
6 $25,000 to less than
$30,000
DK, RF
INC_Q8D, INC_8D
Please stop me when I
have read the category
which applies to you Was
it...?
01 $30,000 to less than
$40,000
02 $40,000 to less than
$50,000
03 $50,000 to less than
$60,000
04 $60,000 to less than
$70,000
05 $70,000 to less than
$80,000
06 $80,000 to less than
$90,000
07 $90,000 to less than
$100,000
08 $100,000 and over
DK, RF
EDS_Q005, EDS_005
In your day-to-day life,
how often do any of the
following things happen to
you?
You are treated with less
courtesy or respect than
other people are.
1 At least once a week
2 A few times a month

CHIWOS study, 2013-2015
$10,000 to $19,999
$20,000 to $29,999
$30,000 to $39,999
$40,000 to $49,999
$50,000 to $59,999
$60,000 to $69,999
$70,000 to $79,999
$80,000 to $99,999
$100,000 or more
Don’t know / Prefer to
estimate by month
Prefer not to answer

Comparisons/categories
20,000 is not the exact
cut point, but it is the
closest cut off point

S1-Q12b. If unable to answer
gross yearly household
income, prompt for gross
monthly income: Indicate
gross monthly income in
dollars: __

S5-Q2. These next questions
ask about your experiences of
racism. Please think carefully,
and do your best to answer
each question
Q1) You are treated with less
courtesy
Q2) You are treated with less
respect
Almost everyday

We found five matched
questions on contents and
wordings. These items
will be summed up to
create a new continuous
variable. The range of
scale for CCHS will be
5-25, whereas it will be
6-30 in CHIWOS. We
will combine two items
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3 A few times a year
4 Less than once a year
5 Never
DK, RF

Frequently
Sometimes
Not that often
Almost never
Never

EDS_Q010, EDS_010
In your day-to-day life,
how often do any of the
following things happen to
you?
You receive poorer service
than other people at
restaurants or stores.
1 At least once a week
2 A few times a month
3 A few times a year
4 Less than once a year
5 Never
DK, RF
EDS_Q015, EDS_015
In your day-to-day life,
how often do any of the
following things happen to
you?
People act as if they think
you are not smart.
1 At least once a week
2 A few times a month
3 A few times a year
4 Less than once a year
5 Never
DK, RF
EDS_Q020, EDS_020
In your day-to-day life,
how often do any of the
following things happen to
you?
People act as if they are
afraid of you.
1 At least once a week
2 A few times a month
3 A few times a year
4 Less than once a year
5 Never
DK, RF
EDS_Q025, EDS_025
In your day-to-day life,
how often do any of the
following things happen to

S5-Q2. These next questions
ask about your experiences of
racism. Please think carefully,
and do your best to answer
each question
Q3) You receive poorer
service
Almost everyday
Frequently
Sometimes
Not that often
Almost never
Never

Comparisons/categories
of “not that often” and
“almost never” in
CHIWOS to create a
single item conceptually
close to the item of “less
than once a year” in
CCHS. By doing this,
both scales will have
matched ranges from 5 to
25.

S5-Q2. These next questions
ask about your experiences of
racism. Please think carefully,
and do your best to answer
each question
Q4) People act as if you are
not as smart
Almost everyday
Frequently
Sometimes
Not that often
Almost never
Never
S5-Q2. These next questions
ask about your experiences of
racism. Please think carefully,
and do your best to answer
each question
Q5) People act as if they are
afraid of you
Almost everyday
Frequently
Sometimes
Not that often
Almost never
Never
S5-Q2. These next questions
ask about your experiences of
racism. Please think carefully,
and do your best to answer
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you?
You are threatened or
harassed.
1 At least once a week
2 A few times a month
3 A few times a year
4 Less than once a year
5 Never
DK, RF

EDS_Q030 What do you
think the reasons might be
for you to have had these
experiences? Was it...
EDS_030A 01 Your race
EDS_030B 02 Your
gender
DK, RF

CHIWOS study, 2013-2015

Comparisons/categories

each question
Q6) You are threatened or
harassed
Almost everyday
Frequently
Sometimes
Not that often
Almost never
Never
Point: the questionnaire in the
CHIWOS has two more
questions in this section, but
CCHS does not. Then, We
will remove these two in the
analysis to make balance in
terms of the questions
Important point:
In the CHIWOS, participants
were explicitly asked these
questions regarding their race
discrimination and these
questions once again repeated
to sex discrimination
(assumed to be gender
discrimination). However, in
the CCHS, participants were
asked these questions first and
then were asked the reason for
such experiences that gender
and race are among those
reason. Then, these questions
will be summed to calculate
the scores for only those who
reported the reasons for race
and gender. Those who did
not report these experiences
for both race and gender
separately, we will assign the
least possible score for them.
Additionally, in CHIWOS,
trans participants were asked
questions regarding
discrimination in relation to
their gender, whereas
cisgender women were asked
about discriminating in
relation to being a woman.
This will be considered in the
analysis.

EDS_Q035, EDS_035
Of the reasons you just
mentioned, which one do
you think is the main

253

CCHS 2013-2014

CHIWOS study, 2013-2015

Comparisons/categories

a) We will sum these
four items and create a
new continuous variable.
Total score with current
version range: 4-20 (in
CHIWOS) and 4-16 (in
CCHS) obtained by
summing each item. We
will combine “most of
the time” and “some of
the time” in the
CHIWOS study and
create four-point-Likert
scale. The new construct
will have a range from 4
to 16, matched with
CCHS data.

reason?
01 Your race
02 Your gender
DK, RF
Social support
A) SSemotional/informatio
nal

SPS_Q06, SPS_06
There is a trustworthy
person I could turn to for
advice if I were having
problems.
1 Strongly agree
2 Agree
3 Disagree
4 Strongly disagree
DK, RF

S9-Q4 (1)
Someone to turn to for
suggestions about how to deal
with a personal problem
All of the time
Most of the time
Some of the time
A little of the time
None of the time
DK
PNTA

B) SS- Tangible
support

SPS_Q01, SPS_01
There are people I can
depend on to help me if I
really need it.
1 Strongly agree
2 Agree
3 Disagree
4 Strongly disagree
DK, RF

C) SS- affectionate
support

SPS_Q08, SPS_08
I feel a strong emotional
bond with at least one
other person.
1 Strongly agree
2 Agree
3 Disagree
4 Strongly disagree
DK, RF

D) SS- positive
social interaction

SPS_Q02 , SPS_02
There are people who
enjoy the same social
activities I do.
1 Strongly agree
2 Agree
3 Disagree
4 Strongly disagree
DK, RF

Housing status

SDC_Q7A, DHH_OWN
Now a question about the
dwelling in which you live.
Is this dwelling… ?
1 Owned by you or a
member of this household,

S9-Q4 (2)
Someone to help with daily
chores if you were sick
All of the time
Most of the time
Some of the time
A little of the time
None of the time
DK
PNTA
S9-Q4 (3)
Someone to love and make
you feel wanted
All of the time
Most of the time
Some of the time
A little of the time
None of the time
DK
PNTA
S9-Q4 (4)
Someone to do something
enjoyable with
All of the time
Most of the time
Some of the time
A little of the time
None of the time
DK
PNTA
S1-Q14.
Which of the following best
describes the residence in
which you currently live?
House that you own
Apartment or Condominium

Housing status
Owned a house or an
apartment
Others (rented, not
rented, under-housed,
homeless)
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Relationship
(marital) status

Education
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CHIWOS study, 2013-2015

even if it is still being paid
for
2 Rented, even if no cash
rent is paid
DK, RF

that you own
House that you rent
Floor in a house that you rent
A basement apartment that
you rent
Apartment or Condominium
that you rent
Self-contained room in a
house with other people
Self-contained room in an
apartment with other people
Self-contained room with
amenities
Self-contained room with no
amenities
An HIV care group home
where you have your own
room but share a kitchen and
bathroom and where you
receive care and support
related to HIV
A housing facility (such as a
group home) where you have
your own room but share a
kitchen and bathroom
and where you receive care
and support related to your
older age, physical health,
mental health, substance
use, disability or rehabilitation
Outdoors, on the street, parks,
or in a car
Couch Surfing
Transition house/Halfway
house/Safe House
Shelter
Jail
Other, please specify:
________________
Don’t know
Prefer not to answer
S1-Q4.
What is your current legal
relationship status?
Legally married
Common-law
In a relationship, not living
together
Single
Separated / Divorced
Widowed
Other, please specify:
Prefer not to answer
S1-Q9. What is the highest

MSNC_Q01
What is [respondent
name]’s marital status? Is
[he/she]:
INTERVIEWER: Read
categories to respondent.
1 ... married?
2 ... living common-law?
3 ... widowed?
4 ... separated?
5 ... divorced?
6 ... single, never married?
EHG2_Q01, EDU_1

Comparisons/categories

Marital status
Married/ Common-law
Others type of marital
status (separated,
divorced, widowed)
Single/never married

Educational status
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What is the highest grade
of elementary or high
school [respondent name]
has ever completed?
1 Grade 8 or lower
(Québec: Secondary II or
lower)
2 Grade 9 - 10 (Québec:
Secondary III or IV,
Newfoundland and
Labrador: 1st year
secondary)
3. Grade 11 - 13 (Québec:
Secondary V,
Newfoundland and
Labrador: 2nd to 3rd year
of secondary)

CHIWOS study, 2013-2015
level of formal education you
have completed?
Select one.
No formal education
Elementary / Grade school
High school / Secondary
GED (General Education
Diploma)
Trade or Technical training
CEGEP / College
Undergraduate university
Post-graduate education
Other, please specify
___________
Don’t know
Prefer not to answer

Comparisons/categories
Secondary and below
Above secondary

EHG2_Q02, EDU_2
Did [respondent
name]complete a high
school diploma or its
equivalent?
1 Yes
2 No
EHG2_Q03, EDU_3
Has [respondent name]
received any other
education that could be
counted towards a
certificate, diploma or
degree from an educational
institution?
1 Yes
2 No
EHG2_Q04, EDU_1
What is the highest
certificate, diploma or
degree that [respondent
name] has completed?
1 Less than high school
diploma or its equivalent
2 High school diploma or a
high school equivalency
certificate
3. Trade certificate or
diploma
4. College, CEGEP or
other non-university
certificate or diploma
(other than trades
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Comparisons/categories

certificates or diplomas)
5. University certificate or
diploma below the
bachelor's level
6. Bachelor's degree (e.g.
B.A., B.Sc., LL.B.)
7. University certificate,
diploma, degree above the
bachelor's level
EDU_Q05, SDC_8
^ARE_C ^YOU1 currently
attending a school, college,
cégep or university?
1 Yes
2 No (Go to EDU_END)
DK, RF (Go to
EDU_END)

Job status

EDU_Q06, SDC_9
^ARE_C ^YOU1 enrolled
as...?
1 A full-time student
2 A part-time student
3 Both full-time and parttime student
Have you worked at a job
or business at any time in
the past 12 months?
1 Yes
2 No

S1-Q10a. People make money
in a variety of ways; for
instance, a regular job, and
some under-the-table work.
Over the last year, what were
the different ways you’ve
made money?
Paid job, taxes paid
Paid job, taxes unpaid /
"Under-the-table work"
Social assistance
Pension
Sex work
Selling drugs / drugs
paraphernalia
Pan-handling/ 'squeegeeing' /
recycling
Worker’s compensation
(WCB)
Employment Insurance (EI)
Personal savings
Loan(s) / Student Loan(s)
Parent / friend / relative /
partner income
Honoraria (workshops,
trainings)
Other, please specify: ____

Categories:
- Yes (paid job with or
without tax)
- No (others)

257

CCHS 2013-2014
Household size
(probably useful for
income adjustments)

Hhsz

CHIWOS study, 2013-2015

Comparisons/categories

S1-Q13a. How many people
are financially dependent on
you, not including yourself?
…..

Selected list of variables available in CHIWOS for the first and second waves used in
objectives 1 and 2

Variables on substance

Wave 1

Wave 2

Variable ID, question

Variable ID, question

use
Alcohol consumption
questionnaire

Definition: A standard drink was considered to be contained 13.45 grams of pure
alcohol or the equivalent of 0.6 ounces (oz) of 100% alcohol and was defined as
341 ml (12-oz) bottle of 5% alcohol "beer, cider or cooler", 142 ml (5-oz) glass of
12% alcohol "wine", and 43 ml (1.5-oz) serving of "liquor or spirits".
S6-Q1
How often in the last year have
you had a drink containing
alcohol?
Never
Monthly or less
2-4 times a month
2-3 times a week
4 or more times a week
DK
PNTA
This item is also indicative of the
frequency measure
S6-Q2
How many drinks containing
alcohol do you have on a typical
day when you are drinking?
1 or 2
3 or 4
5 or 6
7, 8 or 9
10 or more
Don’t know
Prefer not to answer
S6-Q3.
Considering all types of alcoholic
beverages (e.g., wine, beer, etc),
have you had 4 or more drinks on
any one single occasion in the
past month?

S7-01.
How often in the last year have you had a
drink containing alcohol?
Never
Monthly or less
2-4 times a month
2-3 times a week
4 or more times a week
DK
PNTA

S7-02.
How many drinks containing alcohol do
you have on a typical day when you are
drinking?
1 or 2
3 or 4
5 or 6
7, 8 or 9
10 or more
Don’t know
Prefer not to answer
S7-03.
How often do you have six or more drinks
on one occasion?
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And

Stimulant use

Opiate/Opioids

S6-Q4.
How many times in the past
month have you had 4 or more
drinks on any one single
occasion?
S6-Q10b.
[3 months before HIV diagnose]
Within three months before your
HIV diagnosis, did you use any of
the following drugs?
- Cocaine
- Crack [crack cocaine]
- Methamphetamine,
- Speed [amphetamine/MDA]
S6-Q11b.
[3 months after HIV diagnose]
Within three months after your
HIV diagnosis, did you use any of
the following drugs?
- Cocaine
- Crack [crack cocaine]
- Methamphetamine,
- Speed [amphetamine/MDA]
S6-Q12b.
[Last three months] Over the last
three months (current), did you
use any of the following drugs?
- Cocaine
- Crack [crack cocaine]
- Methamphetamine,
- Speed [amphetamine/MDA]

S6-Q10b.
[3 months before HIV diagnose]
Within three months before your
HIV diagnosis, did you use any of
the following drugs?
- Heroin
- Speedball
- Morphine
- Methadone
- OxyContin/Oxycodone
- Codeine (t3 & T4)
- Fentanyl
- Dilaudid (hydromorphone)
- Talwin & Ritalin (T & R))
S6-Q11b.
[3 months after HIV diagnose]
Within three months after your
HIV diagnosis, did you use any of
the following drugs?
- Heroin
- Speedball

---

---

S7-11. And S7-14
Within six months before your HIV
diagnosis, did you use any of the following
drugs?
- Cocaine
- Crack [crack cocaine]
- Methamphetamine,
- Speed [amphetamine/MDA]
- Goofballs (heroin + crystal meth) (only
in w2; then, removed)
---

---
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- Morphine
- Methadone
- OxyContin/Oxycodone
- Codeine (t3 & T4)
- Fentanyl
- Dilaudid (hydromorphone)
- Talwin & Ritalin (T & R))
S6-Q12b.
[Last three months] Over the last
three months (current), did you
use any of the following drugs?
- Heroin
- Speedball
- Morphine
- Methadone
- OxyContin/Oxycodone
- Codeine (t3 & T4)
- Fentanyl
- Dilaudid (hydromorphone)
- Talwin & Ritalin (T & R))

S7-11. And S7-14
Over the last six months (current), did
you use any of the following drugs?
- Heroin
- Speedball
- Morphine
- Methadone
- OxyContin/Oxycodone
- Codeine (t3 & T4)
- Fentanyl
- Dilaudid (hydromorphone)
- Talwin & Ritalin (T & R))

Clinical outcomes
Current ART use

S2-Q8.
Are you currently taking ARVs?

S2-02d.
Are you currently taking ARVs for your
own health?

Treatment adherence
Last month

S2-Q9b.
We understand that many people
on HIV medications find it
difficult to take….

S2-06.
We understand that many people on HIV
medications find it difficult to take….

Optimal adherence:
Yes if ≥95%
No if <95%
Viral load suppression
status

S2-Q12b.
What was your most recent viral
load, undetectable or detectable?
Undetectable (i.e. below 40
copies/mL)
Detectable (i.e. over 40 copies/mL)
DK
PNTA
S2-Q12c.
Do you remember the exact
result?
Indicate result: ______ copies/mL

Other variables (social
determinants and
exploratory variables)
Age at interview

Participant’s Date of Birth

S2-11a.
What was your most recent viral load,
undetectable or detectable?

S2-11a.
Do you remember the exact result?
Indicate result: ______ copies/mL

---
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Biological sex at birth

Current gender identity

Sexual orientation

Marital status

Legal status

S1-Q1.
What was your biological sex at
birth?
Male
Female
Intersex
Undetermined
Other, please specify:
Don’t know
Prefer not to answer
S1-Q2a.
With respect to your gender, how
do you currently identify?

---

Woman
Trans Man (Female to Male)
(excluded)
Trans Woman (Male to Female)
Two-spirited
Intersex
Gender Queer
Other,
Man (excluded)
S1-Q3.
With respect to your sexual
orientation, how do you currently
identify?

Woman
Trans Man (Female to Male) (excluded)
Trans Woman (Male to Female)
Two-spirited
Intersex
Gender Queer
Other,
Man (excluded)

Heterosexual / Straight
Lesbian
Gay
Queer
Bisexual
Two-spirited
Questioning
Others
DK
PNTA
S1-Q4.
What is your current legal
relationship status?
Legally married
Common-law
In a relationship, not living
together
Single
Separated / Divorced
Widowed
Other, please specify:
Prefer not to answer
S1-Q6.
What is your current legal status
in Canada?
Canadian citizen
Landed Immigrant/Permanent
Resident

S1-01
With respect to your gender, how do you
currently identify?

S1-04.
With respect to your sexual orientation*,
how do you currently identify?

S1-05.
What is your current legal relationship
status?

S1-06.
What is your current legal status in
Canada?
Canadian citizen
Landed Immigrant/Permanent Resident
Refugee/Protected Person
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Ethno-racial

Refugee/Protected Person
Refugee claimant/Person in need of
protection
Here with Temporary Work Papers
Here with Humanitarian and
Compassionate approval
Here as a visitor
Here on a Student Visa
Undocumented/Illegal Immigrant
Other, please specify:
Don’t know
Prefer not to answer
S1-Q7.
What do you consider to be your
racial and/or ethnic background?

Refugee claimant/Person in need of
protection
Here with Temporary Work Papers
Here with Humanitarian and Compassionate
approval
Here as a visitor
Here on a Student Visa
Undocumented/Illegal Immigrant
Other, please specify:
Don’t know
Prefer not to answer
---

Many groups …
Educational attainment

Employment status

Household income

Household income

S1-Q9.
What is the highest level of
formal education you have
completed?
Many groups …
S1-Q10a.
People make money in a variety
of ways; for instance, a regular
job, and some under-the-table
work. Over the last year, what
were the different ways you’ve
made money?
Many groups …
S1-Q11a.
How much does your household
make in a year, before taxes (i.e.,
household gross yearly income)?
Less than 10,000
10,000 to 19,999
20,000 to 29,999
30,000 to 39,999
40,000 to 49,999
….
S1-Q11b.
If unable to answer gross yearly
household income, prompt for
gross monthly income:

S1-23.
What is the highest level of formal
education you have completed*?

S1-24.
Are you currently employed?

S1-27.
Considering all income sources, how
much does your household make in a
year, before taxes (i.e., household gross
yearly income*)?

---

Indicate gross monthly income in
dollars: ……….
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Personal income

Personal income

Difficulty in meeting
monthly housing costs

Number of dependents

Housing status

S1-Q12a.
How much do you make in a
year, before taxes (i.e., personal
gross yearly income)?
Less than 10,000
10,000 to 19,999
20,000 to 29,999
30,000 to 39,999
40,000 to 49,999
….
S1-Q12b.
If unable to answer gross yearly
personal income, prompt for
gross monthly income:
Indicate gross monthly income in
dollars: ……….
S1-Q18.
Given your total household
income, how difficult is it to meet
your monthly housing costs
including rent/mortgage,
property taxes, and utilities (e.g.,
heat, electricity, water and gas)?
Would you say that it is
S1-Q13a.
How many people are financially
dependent on you, not including
yourself?
Indicate the number of people:
………
S1-Q14.
Which of the following best
describes the residence in which
you currently live?
Many groups …

S1-28.
Considering all income sources, how
much do you make in a year, before taxes
(i.e., personal gross yearly income*)?

---

S1-36.
Given your total household income, how
difficult is it to meet your monthly
housing costs

---

S1-29.
Since your last visit, have you been
homeless*?

S1-30.
Do you have a regular place to stay right
now?

S1-33.
What type of place are you currently
living in?

S1-37.
My current housing situation is stable
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Geographic location

S1-Q19.
What are the first three digits of
the postal code at which you are
currently living?
Only record first three digits Postal
Code: ……

Food insecurity

S1-Q23.
Item 1
Item 2
Item 3

In past 12 months
Specific addiction
treatment enrollment

Ever status which makes it
difficult to use, but since
occur before baseline time
point, we can use it.

Addiction treatment
enrollment (overall)

Time since HIV diagnosis
(HIV duration)

S6-Q17.
Now I am going to ask you some
questions about your use of
substance related services, as they
relate to your use of drugs or
alcohol (not tobacco).
Have you ever used any of the
following substance-related
services?
S6-Q17.
Now I am going to ask you some
questions about your use of
substance related services, as they
relate to your use of drugs or
alcohol (not tobacco).
Have you ever used any of the
following substance-related
services?
S2-Q4a.
When were you diagnosed with
HIV?

S1-31.
What is the postal code for the place
where you are currently living or
regularly sleep?

---

S7-17.
Since your last CHIWOS interview, have
you used any of the following substancerelated services?

S7-17.
Since your last CHIWOS interview, have
you used any of the following substancerelated services?

---

Age at HIV diagnose

S2-Q4a.
When were you diagnosed with
HIV?

---

Time since ART
initiation

S2-Q7.
When was the first time you ever
took ARVs?

---

(duration of ART uptake)
Time for last CD4 count

Current status!

S2-Q10a.
When did you last receive your
CD4 count results?
S2-Q10b.
What was your most recent CD4
count?

Time since nadir CD4

S2-Q10c.
Are you able to estimate your
most recent CD4
count?
S2-Q11a.

Current status
CD4 count measure

S2-07.
When did you last receive your CD4
count results?
S2-08a.
What was your most recent CD4 count?
S2-08b.
Are you able to estimate your most recent
CD4 count?

---
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count
Results of nadir CD4
count

CD4 count first time
diagnosed with HIV

When did you receive your lowest
(nadir) CD4 count results?
S2-Q11b.
What was your lowest (nadir)
CD4 count?
S2-Q11c.
Are you able to estimate your
lowest (nadir) CD4 count?
---

CD4 count at time ART
initiated

---

Change ART since last
CHIWOS wave

---

Viral load last result
(time)

S2-Q12a.
When did you last receive your
HIV viral load results?
Indicate Year: …..
Indicate Month: ….

Time takes to travel to
HIV clinic [where
primarily receive HIV
medical care]

HIV medical care
satisfaction

HCV infection and
medication

Never received viral load results
DK
PNTA
S3-Q19.
How much time does it take to
travel one-way from your
residence to this clinic?
Between 0 and <30 min
Between 30 and <60 min
Between 1 and <3 hours
Between 3 and <5 hours
Five hours or more
Don't know
Prefer not to answer
S3-Q30
All 6 items

S2-Q15a.
Have you ever been told by a
doctor or nurse that you have or
had hepatitis C (Hep C)?

---

S2-09b.
Are you able to estimate your CD4 count
when you were first diagnosed with HIV?

S2-09c.
Are you able to estimate your CD4 count
when you first started taking ARVs (i.e.,
for the first time ever)?
S2-03.
Since your last CHIWOS interview, have
there been any changes in your HIV
antiretroviral therapy medications (i.e.
ARVs*)?
S2-10.
When did you receive your most recent
HIV viral load* results?
Indicate Year: …..
Indicate Month: ….
Never received viral load results
DK
PNTA
---

S3-30
All 6 items

S2-15.
Have you ever been told by a doctor or
nurse that you have hepatitis C (Hep C)?
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HBV

Quality of life
Last 4 weeks

Social support
MOS-SS scale

Resilience

S2-Q15b.
Have you ever taken medication
for hepatitis C?
S2-Q16.
Have you ever been told by a
doctor or nurse that you have
hepatitis B (Hep B)?
Using SF-12
S9-Q5. (both items)
S9-Q6. (both items)
S9-Q7. (both items)
S9-Q8.
S9-Q9. (all three items)
S9-Q10.
S9-Q11.
S9-Q4
Item 1
Item 2
Item 3
Item 4
S9-Q12
All items in this scale

S2-16
Have you ever taken medication for
hepatitis C?
S2-17
Since your last CHIWOS interview, have
you been told by a doctor or nurse that
you have hepatitis B (Hep B)?
Using SF-12
S4-04 (both items)
S4-05 (both items)
S4-06 (both items)
S4-07
S4-08 (all three items)
S4-09
S4-10
---

---

Connor-Davidson
resilience scale (CDRS)
Without time limit!
HIV stigma

S5-Q1
All items under this scale

S6-01
All items under this scale

Berger HIV stigma scale
Without time limit!
Experience of Racial
discrimination (time:
day-to-day)

S5-Q2
All items under this scale

Detroit Area study (EDS)
scale
Experience of sexism
(time: day-to-day)

S5-Q3
All items under this scale

Willingness to HIV status
disclosure

S5-Q5
All items under this scale

S6-02
All items under this scale

Depressive symptoms

S9-Q2
All items under this scale

S4-02
All items under this scale

---

S4-03
All items under this scale

CES-D 10 scale – past
week
Distress
Kessler Psychological
Distress scale (K6) –
during past 30 days
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PTSD

S9-Q3
All items under this scale

---

PTSD checklist (PCL-C)

Mental health conditions
(overall)

Specific mental health
conditions

S9-Q1b.
Which ones [mental health
conditions]?

Recent incarceration

S1-Q29.
In the last year, have you been
incarcerated, or held in custody
overnight or longer, in Canada?

S4-01
Which, if any, of the following mental
health conditions are you currently living
with? Please only include conditions that
have been diagnosed by a healthcare
provider
S4-01
Which, if any, of the following mental
health conditions are you currently living
with? Please only include conditions that
have been diagnosed by a healthcare
provider
S1-38.
Since your last CHIWOS interview, have
you been incarcerated*, or held in
custody overnight or longer, in Canada?

Any experience of
violence in the past 3
months (adulthood
violence, ≥ 16 years)

S7-Q2c.
Has this [physical violence]
happened in the last 3 months?

S8-02
In the last 3 months, has someone ever
physically hurt you?

S7-Q3c.
Has this [insulted, threatened,
screamed, or cursed] happened in
the last 3 months?

S8-08.
In the last 3 months, has someone
insulted, threatened, screamed, or cursed
at you?

Ever

S9-Q1a.
Have you ever been diagnosed
with a mental health condition by
a care provider?

S7-Q4c.
Has this [restricted your actions
by controlling] happened in the
last 3 months?
S7-Q5c.
Has this [sexually forced]
happened in the last 3 months?

Adverse childhood
experiences

S8-12.
In the last three months, has someone
restricted your actions by controlling
where you can go and what you can do?
S8-16
In the last three months, has someone
sexually forced themselves on you, or
forced you to have sex?

i) Any experience of violence in
childhood (< 16 years)
S7-Q6a. This second series of
questions are about experiences you
had as a child. For our purposes,
child is defined as less than 16
years of age. During your
childhood, did an adult ever
physically hurt you?
S7-Q8a. During your childhood, did
someone ever sexually force
themselves on you, or forced you to
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have sex?
ii) S1-Q25. Have you ever been
under the care of Child Protection
Services? Select one.
Yes
No
Don’t know
Prefer not to answer

Barriers to care scale

iii) S1-Q26. Have you ever been
in foster care? Select one.
Yes
No
Don’t know
Prefer not to answer
S3-42. Please indicate to what
extent each of the following
circumstances have made it
difficult for you to receive the
care, services, or opportunities
you wish to obtain over the past
year
1. Long distances to medical
facilities and personnel
2. Medical personnel (e.g.
physicians, nurses), who decline to
provide direct care to persons with
HIV/AIDS
3. The lack of health care
professionals who are adequately
trained and competent in HIV/ care
4. The lack of transportation to
access the services you need
5. The shortages of psychologists,
social workers and mental health
counselors who can help address
mental health issues
6. The lack of psychological
support groups for persons with
HIV/AIDS
7. The level of knowledge about
HIV/AIDS among residents in the
community
8. Community residents' stigma
against persons living with
HIV/AIDS
9. The lack of employment
opportunities for people living with
HIV/AIDS
10. The lack of supportive and
understanding work environments
for people living with HIV/AIDS
11. Your personal financial
resources
12. Lack of adequate and affordable

Please indicate to what extent each of the
following circumstances have made it
difficult for you to receive the care,
services, or opportunities you wish to
obtain over the past year
1. Long distances to medical facilities and
personnel
2. Medical personnel (e.g. physicians,
nurses), who decline to provide direct care to
persons with HIV/AIDS
3. The lack of health care professionals who
are adequately trained and competent in
HIV/AIDS care
4. The lack of transportation to access the
services you need
5. The shortages of psychologists, social
workers and mental health counselors who
can help address mental health issues
6. The lack of psychological support groups
for persons with HIV/AIDS
7. The level of knowledge about HIV/AIDS
among residents in the community
8. Community residents' stigma against
persons living with HIV/AIDS
9. The lack of employment opportunities for
people living with HIV/AIDS
10. The lack of supportive and
understanding work environments for people
living with HIV/AIDS
11. Your personal financial resources
12. Lack of adequate and affordable housing
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housing
Access to medical care

Access to medical care

S2-Q4b. After receiving your
HIV diagnosis, when did you first
access HIV medical care?
Indicate Year: …………
Indicate Month: …………
I have never accessed HIV medical
care
Don’t know
Prefer not to answer
S3-Q41a. Have you ever tried to
access HIV support services and
been unable to?
Select one.
Yes
No
Don’t know
Prefer not to answer
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